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SUMMARY
A* Regulation of calcium mobilisation in bovine aortic 
endothelial cells
1. In the presence of 1.8mM extracellular calcium,
bradykinin (0.3nM-100nM), adenosine triphosphate (ATP; 
0. 3^M-100/jM) and thrombin (0.03U ml”1-3U ml”1) each induced 
biphasic elevations of intracellular free calcium ([Ca2+]i) 
in bovine aortic endothelial cells (BAEC), consisting of a 
large, initial transient component, which peaked within 30 
seconds, followed by a lower, sustained plateau phase.
2. Platelet-activating factor (up to 120nM), histamine 
(up to 10/xM) and lipopolysaccharide (up to 10/xg ml ) each 
had no effect on [Ca2+]i in BAEC.
3. In the presence of 1.8mM extracellular calcium,
treatment of endothelial cells with the calcium influx
blocker, nickel chloride (4mM), had no effect on basal 
2+[Ca ]i or on the magnitude of the bradykinin-induced
2+ .transient elevation of [Ca ]i, but abolished the plateau 
phase.
4. When BAEC were bathed in nominally calcium-free
solution, containing 0.5mM EGTA, bradykinin and ATP each
2+ .induced only a transient elevation of [Ca ]i: the
magnitude of this component was significantly smaller than 
that obtained in the presence of extracellular calcium, and 
the plateau phase was abolished. In the continued presence 
of bradykinin or ATP, re-addition of extracellular calcium, 
to achieve a level of around 1.8mM, resulted in the 
induction of a large, initial transient component, followed 
by a lower, sustained component. Procaine (ImM) had no 
effect on the large, transient component, suggesting that 
calcium- induced calcium release is not involved in the 
generation of this component.
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in the presence of lmM extracellular calcium,
treatment with the calcium chelator, EGTA (2mM; lmin),
slightly reduced basal [Ca2+]i and significantly reduced
the magnitude of the bradykinin-induced transient elevation 
2+ .
of [Ca ]i. Increasing the exposure time to lOmin or the 
concentration of EGTA to 5mM resulted in no further 
reduction in the magnitude of the bradykinin-induced 
transient component.
6. An attempt was made to selectively inhibit release of
calcium from intracellular stores. In the presence of
1.8mM extracellular calcium, treatment of BAEC with the
putative inhibitor of intracellular calcium release, 3,4,5-
trimethoxybenzoic acid-8-(diethylamino) octyl ester (TMB-8;
O.lmM) increased basal [Ca2+]i slightly, but had no effect
on either component of the bradykinin-induced biphasic
2+elevation of [Ca ]i. To determine the effects of TMB-8 on
only the intracellular release component, BAEC were bathed
in nominally calcium-free solution, in the presence of EGTA
(0.5mM). TMB-8 (O.lmM) had no effect on basal [Ca2+]i or
2+ •the bradykinm-mduced transient elevation of [Ca ]i. 
These findings suggest that TMB-8 does not inhibit release 
of calcium from intracellular stores.
7. An attempt was made to determine whether removal of
extracellular calcium results in the depletion of
2+ .intracellular calcium stores. The elevation of [Ca ]i 
induced by caffeine (5mM) was almost completely abolished 
when BAEC were bathed in nominally calcium-free solution
containing 0.5mM EGTA, suggesting that depletion of these
stores does occur.
8. In the presence of 1.8mM extracellular calcium, 
addition of potassium chloride (KC1; 30mM and 60mM) had no 
effect on basal [Ca2+]i. However, 60mM KC1, but not 30mM 
KC1, reduced the magnitude of the initial transient 
elevation of [Ca2+]i induced by bradykinin (lOnM).
Addition of KCl(30mM) during the plateau phase of the 
increase in [Ca2"^ ]i induced by bradykinin (lOnM),
XV
thrombin (1U ml and ATP (30/uM), resulted in a fall in 
2+ .
[Ca ]i which was not well maintained. Hence, calcium 
entry in BAEC does not occur through voltage—operated 
channels, although the effects of membrane depolarisation 
on agonist-induced calcium mobilisation appear to be 
complex.
9. It has been proposed that activation of protein kinase 
C may inhibit the release of EDRF by inhibition of 
agonist-induced calcium mobilisation. Pre-treatment of 
BAEC with an activator of protein kinase C, 4B-phorbol 
12-myristate 13-acetate (PMA; lOOnM, 5min) reduced the 
magnitude of the initial transient elevation of [Ca2+]i 
induced by thrombin (1U ml 1), and by low concentrations of 
bradykinin (InM) or ATP (0.3/xM, 3/iM) , but not by higher 
concentrations of the latter two agonists. Addition of PMA 
(lOOnM) during the plateau phase of the increase in [Ca2+]i 
induced by thrombin (1U ml ), bradykinin (InM, lOnM) or 
ATP (0.3juM) resulted in a fall in [Ca2+]i. These findings 
suggest that activation of protein kinase C inhibits 
mobilisation of calcium in BAEC.
10. The inhibitory effects of PMA (lOOnM) were attenuated 
by staurosporine (lOOnM), an inhibitor of protein kinase C, 
but not mimicked by the inactive phorbol ester, 40<-phorbol
12,13 didecanoate (4 0( -PDD; lOOnM). Furthermore,
2+staurosporine (lOOnM) increased [Ca ]i when added during
2+the plateau phase of the increase m  [Ca ]i induced by
bradykinin (lOnM) or thrombin (1U ml ^). In contrast,
2+ .staurosporine (lOOnM) reduced [Ca ]i when added during the
2+ .plateau phase of the increase in [Ca ]i induced by ATP 
(30juM). These findings suggest that PMA may exert its 
actions via the activation of protein kinase C and that 
agonist-induced protein kinase C activation may modulate 
[Ca2+]i in BAEC.
2+11. The ability of manganese (Mn ) to quench the 
fluorescence of fura-2 was used as a marker for bivalent 
cation entry into endothelial cells. Using this technique,
XVI
PMA (lOOnM), but not 4 -PDD (lOOnM), was found to inhibit 
the thrombin-induced Mn^ quench of fura-2, suggesting that 
PMA inhibits calcium entry into BAEC.
12. Addition of PMA (lOOnM) during the sustained elevation
2+
of [Ca ]i induced by a low concentration of ionomycin had
2+no effect on [Ca ]i, suggesting that activation of protein 
kinase C does not promote calcium efflux in BAEC.
13. An attempt was made to determine whether cyclic AMP 
modulates calcium mobilisation in BAEC. Pre-treatment with 
forskolin (10/iM), an activator of adenylate cyclase, had no
effect on the magnitude of the initial transient elevation
2+ -1 of [Ca ]i induced by thrombin (1U ml ), bradykinin (InM,
lOnM) or ATP (30/LtM). Furthermore, Pre-treatment with
isoprenaline (10/liM) had no effect on the initial transient
• 2 +elevation of [Ca ]i induced by bradykinin (3nM). In
contrast, forskolin (10/iM) and isoprenaline (10/iM) each
2 +mduced biphasic elevations of [Ca ]i when added during
2+the plateau phase of the increase in [Ca ]i, induced by 
the three agonists. In the presence of the inhibitor of 
calcium influx, nickel chloride (4mM), these biphasic 
elevations were reduced to monophasic transient elevations.
14. Pre-treatment with forskolin (10/iM) had no effect on
the ability of PMA (lOOnM) to attenuate the
2+ .thrombin-induced plateau phase of [Ca ]i, suggesting that
2+ . . . .  forskolin does not enhance [Ca ]i by inhibiting the
actions of protein kinase C.
15. 8 bromo cyclic GMP (30/iM), a membrane-permeant
2+ .analogue of cyclic GMP, had no effect on basal [Ca ]i or 
on the magnitude of the initial transient elevation of
o  i  —
[Ca ]i induced by thrombin (1U ml ), bradykinin (lOnM) or 
ATP (30/iM). Furthermore, 8 bromo cyclic GMP (30/iM) and 
sodium nitroprusside (1/iM), an activator of soluble
guanylate cyclase, had no effect when added during the
2+plateau phase of the increase in [Ca ]i induced by each of 
the three agonists. These findings suggest that cyclic GMP
XVII
does not modulate calcium mobilisation in BAEC.
G
16. N -nitro-L-arginine (50/iM), an inhibitor of nitric 
oxide synthase, had no effect on the magnitude of the 
initial transient elevation of [Ca2+]i induced by thrombin 
(1U ml ), bradykinin (InM) or ATP (3/iM), and had no effect 
on the plateau phase of the increase in [Ca2+]i induced by 
these agents. These findings suggest that EDRF, via 
endogenously generated cyclic GMP, does not modulate 
calcium mobilisation in BAEC.
17. Pre-treatment with pertussis toxin (25ng ml-1; 20hrs) 
had no effect on mobilisation of [Ca2+]i induced by 
thrombin (1U ml""1), bradykinin (lOnM) or ATP {30(M), 
suggesting that the G proteins involved in the regulation 
of calcium mobilisation in BAEC are pertussis toxin- 
insensitive.
18. These findings suggest that, in bovine aortic
endothelial cells, the agonist-induced transient elevation 
2+ .of [Ca ]i is completely dependent upon release of calcium 
from intracellular stores and the sustained component is 
due to calcium influx. The intracellular calcium stores 
may consist of two pools, one of which is rapidly depleted 
in the absence of extracellular calcium and a second which 
is resistant to such depletion.
Furthermore, these findings suggest that activation of 
protein kinase C inhibits, elevation of cyclic AMP content 
augments and elevation of cyclic GMP has no effect on 
calcium mobilisation in bovine aortic endothelial cells.
B. Role of calcium mobilisation in the regulation of 
endothelial barrier function
1. Cultures of bovine pulmonary artery endothelial cells 
(BPAEC) were seeded and grown to confluence on Transwell 
membrane filters. These endothelial monolayers restricted
XVIII
the passage of trypan blue-labelled albumin and, thus, 
mimicked the in vivo endothelial barrier.
2. Albumin transfer across monolayers of BPAEC was 
increased by both thrombin (1U ml ^; 90min) and phorbol 
myristate acetate (PMA; 600nM; 90min), an activator of 
protein kinase C.
3. It has been proposed that elevation of cyclic AMP
content enhances endothelial barrier function in vivo. 
Co-incubation with forskolin (30/iM; 90min), an activator of 
adenylate cyclase, abolished both the thrombin (1U ml 1) 
and PMA (600nM)-induced increases in albumin transfer
across monolayers of BPAEC, suggesting that elevation of 
cyclic AMP enhances endothelial barrier function.
4. An attempt was made to determine whether elevation of
cyclic GMP content could modulate endothelial barrier
function. Co-incubation with atriopeptin II (lOOnM;
90min), an activator of particulate guanylate cyclase, or 8
bromo cyclic GMP (30/iM), a membrane permeant analogue of
cyclic GMP, had no effect on PMA (600nM)-induced albumin
-1transfer, but abolished that induced by thrombin (1U ml ). 
These findings suggest that cyclic GMP enhances endothelial 
barrier function.
5. Pre-treatment of BPAEC with PMA (lOOnM, 5min) had no
2+ . . .  . —1effect on basal [Ca ]i, but inhibited thrombin (1U ml )-
induced calcium mobilisation. These findings suggest that 
elevations of [Ca2+]i are not a pre-requisite for increased 
albumin transfer and that activation of protein kinase C 
may regulate receptor-mediated processes in these cells.
6. An attempt was made to determine whether elevation of
cyclic GMP content inhibits thrombin-induced albumin
transfer via the inhibition of calcium mobilisation.
However, pre—treatment with forskolin (30/iM; 5min) had no
-1
effect on the magnitude of the thrombin (1U ml )-induced
2 +initial transient elevation of [Ca ]i. In contrast,
XIX
addition of forskolin (30/iM), during the plateau phase of
the increase in [Ca2+]i induced by thrombin (1U ml 1),
2+ .increased [Ca ]i. These findings suggest that cyclic AMP 
does not inhibit thrombin-induced albumin transfer by 
inhibiting calcium mobilisation.
7. Pre-treatment of BPAEC with atriopeptin II (lOOnM, 5
min) or 8 bromo cyclic GMP (30/iM, 5 min) had no effect on
2+the magnitude of the initial transient elevation of [Ca ]i
induced by thrombin (1U ml ). In contrast, addition of
atriopeptin II (lOOnM) or 8 bromo cyclic GMP (30/iM) during
2+ .the thrombin-induced plateau phase of [Ca ]i resulted m  a
2+ .small increase m  [Ca ]i. These findings suggest that 
cyclic GMP does not inhibit thrombin-induced albumin 
transfer via the inhibition of calcium mobilisation.
9. These findings suggest that elevation of cyclic AMP or 
cyclic AMP content enhances endothelial barrier function. 
Cyclic AMP may inhibit the actions of protein kinase C, 
while cyclic GMP may inhibit a step proximal to the 
activation of protein kinase C.
XX
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INTRODUCTION
CHAPTER 1
1.1 Role of the endothelium in the regulation of
haemostasis and vasomotor tone
The vascular endothelium, which consists of a single layer 
of cells resting on a basement membrane in close apposition 
to the blood vessel wall, forms an interface between the 
blood and vascular smooth muscle and is, therefore, ideally 
positioned to modulate the functions of both components. 
The endothelium exerts many of its actions by secreting a 
number of physiologically important molecules. For
example, vasomotor tone may be modulated by prostacyclin 
(Moncada et al., 1976a) or endothelium-derived relaxing
factor (EDRF? Furchgott & Zawadzki, 1980), which may be 
nitric oxide (Palmer et al., 1987) or a nitric
oxide-containing substance (Myers et al., 1990). The 
abluminal release of these substances in response to a 
number of physical and chemical stimuli (e.g. shear stress, 
acetylcholine) results in vasodilation. Release of EDRF 
may be of importance in the regulation of blood flow in 
vascular beds; for example, the coronary circulation 
(Amezcua et al., 1988). The actions of EDRF and
prostacyclin may be counter-balanced by the release of the 
endothelins, a class of vasoconstrictor peptides recently 
described by Yanagisawa et al. (1988). It is likely that 
accurate, physiological regulation of blood flow requires a 
precise balance between these antagonistic systems.
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Luminal release of endothelium-derived substances is known 
to modulate haemostasis. The endothelium may inhibit 
coagulation by the production both of anticoagulant and 
fibrinolytic substances; for example, via production of 
thrombomodulin, an endothelial cell surface protein which 
binds thrombin and enhances its ability to activate protein 
C. Fibrinolysis may be promoted via two types of 
plasminogen activator, tissue plasminogen activator and 
urokinase type plasminogen activator (Levin & Loskutoff, 
1982). However, under certain conditions, the endothelium 
may express procoagulant activity; for example, thrombin 
and endotoxin may induce production of thromboplastin (Brox 
et al., 1984). Coagulation may also be accelerated by 
endothelial production of factor V (Cerveny et al., 1984) 
and plasminogen activator (Hanss & Collen, 1987).
The endothelium is normally non-thrombogenic, presumably 
due to the cell surface and to the release of EDRF and 
prostacyclin which inhibit platelet aggregation (Moncada et 
al., 1976a, b; Azuma et al., 1986; Furlong et al., 1987; 
Radomski et al., 1987a, b; Bhardwaj et al., 1988; Hogan et 
al., 1988). EDRF also inhibits platelet adhesion to the 
endothelium (Radomski et al., 1987c; Sneddon & Vane, 1988), 
although prostacyclin only inhibits the adhesion of 
activated platelets (Fry et al., 1980). Under different 
circumstances, such as during tissue injury, the 
endothelium may also promote platelet adhesion and 
aggregation via the production of collagen (Sage et al.,
1979), thrombospondin (Mosher et al., 1982), fibronectin
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(Jaffe & Mosher, 1978) and von Willebrand factor (Jaffe et 
al., 1973).
The ability of both endogenous and exogenous agents to 
control vasomotor tone and haemostasis may be regulated by 
endothelial cell metabolism. For example, the endothelial 
membrane contains angiotensin-converting enzyme, a 
carboxypeptidase which may regulate vasomotor tone by 
inactivating bradykinin, a potent vasodilator, while 
converting angiotensin I to angiotensin II, a potent 
vasoconstrictor (Fishman et al., 1974). The metabolism of 
adenine nucleotides (Pearson et al., 1980) may completely 
alter the responses produced by these mediators. For 
example, the ability of ADP, secreted from aggregating 
platelets, to induce further aggregation, may be attenuated 
by the metabolism of ADP to adenosine, an inhibitor of 
platelet aggregation.
1.2 Endothelium-derived relaxing factor (EDRF)
1.2.1 Discovery of EDRF
Furchgott and Zawadzki (1980) discovered that the relaxant 
actions of acetylcholine were dependent upon the release of 
a non-prostanoid relaxant, which was termed endothelium- 
derived relaxing factor (EDRF). A wide variety of stimuli 
has been shown to induce EDRF release, including 
bradykinin, ATP, thrombin, histamine, substance P and the 
calcium ionophore A23187 (Furchgott, 1984).
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The first bioassay for EDRF was developed by Furchgott and 
Zawadzki (1980) who used a sandwich-mount preparation of 
both an endothelium-denuded and an endothelium-intact 
rabbit aortic strip. Addition of acetycholine to this 
preparation resulted in the relaxation of the 
endothelium-denuded strip, demonstrating that EDRF is a 
diffusible substance. Griffith et al., (1984) determined 
the half-life of EDRF by examining the dilation of a 
pre-constricted rabbit coronary artery by the effluent from 
an acetylcholine-stimulated rabbit aorta. By increasing 
the transit time of the effluent to the sensor, a half-life 
of 6 seconds was calculated for EDRF. Similar values 
(6-49s) have been obtained in other studies (Forstermann et 
al., 1984? Cocks et al., 1985; Rubanyi et al., 1985; 
Gryglewski et al., 1986).
1.2.2 Nature of EDRF
Much speculation has been generated concerning the nature 
of EDRF. However, it now appears that EDRF may be nitric 
oxide, or a closely related derivative. Support for this 
proposal is provided by a strong line of evidence. For 
example, the relaxation induced by both nitric oxide and 
EDRF is associated with increased smooth muscle cyclic GMP 
content (Greutter et al., 1981? Rapoport & Murad, 1983). 
Furthermore, nitric oxide and EDRF activity is potentiated 
by superoxide dismutase (Gryglewski et al., 1986) and 
inhibited by haemoglobin (Martin et al., 1985? Furchgott et 
al., 1987). Using a chemiluminescence technique, Palmer et 
al. (1987) have demonstrated that bradykinin induces the
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concentration-dependent release of both EDRF and nitric 
oxide from cultured endothelial cells. This latter point 
has been disputed by Myers and co-workers (1989) who claim 
that the amount of EDRF released is not sufficient to 
account for relaxation induced by EDRF. Furthermore, 
differences in the comparative pharmacology of EDRF and 
nitric oxide have been described. EDRF has been proposed 
to preferentially relax vascular smooth muscle, while 
nitric oxide has a more widespread action (Shikano et al., 
1988). A difference in the chemical nature of these 
relaxants has been proposed by Cocks et al. (1988), who 
have shown that EDRF is negatively charged, while nitric 
oxide is a polar molecule. It is, therefore, possible that 
the nitric oxide released from the endothelium is derived 
from a large molecule, which has a stabilising role. As 
the incorporation of nitric oxide into a nitrosothiol group 
increases the potency and stability of this molecule, Myers 
et al. (1990) have proposed that S-nitrosocysteine or a 
similar substance may mimic the actions of EDRF more 
closely. However, the release of this compound has yet to 
be demonstrated.
1.2.3 Synthesis of nitric oxide
The vascular endothelial cell synthesizes nitric oxide from 
the terminal guanidino nitrogen of L-arginine by the action 
of nitric oxide synthase (Palmer et al., 1988a, b; Schmidt 
et al., 1988), the co-product of this reaction being 
L-citrulline which lacks vasodilating activity. The 
ability of NG-monomethyl-L-arginine (L-NMMA) to inhibit the
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enzymatic production of nitric oxide and citrulline (Palmer 
& Moncada, 1989), due to the presence of a methyl group on 
the guanidino nitrogen in L-NMMA, and the reversibility of 
the inhibitory actions of L-NMMA by L-arginine, suggests 
that L-arginine is likely to the physiological precursor 
for the production of nitric oxide/EDRF. Nitric oxide 
appears to be produced in a diverse range of cell types, in 
addition to the endothelium. For example, in smooth 
muscle, platelets, neutrophils, macrophages, liver and
neurones (Wood et al., 1990; Radomski et al., 1990; Rimele 
et al., 1988; Hibbs et al., 1988; Knowles et al., 1990;
Gillespie et al., 1990; Garthwaite et al., 1988). In some 
tissues, such as the endothelium and the brain, nitric 
oxide synthase is constitutively expressed and
calcium-calmodulin-dependent (Palmer et al., 1989; Mayer et 
al., 1989; Busse & Miilsch, 1990; Forstermann et al., 1990; 
Knowles et al., 1990). However, in other cells, including 
smooth muscle, hepatocytes and macrophages, the enzyme is 
not normally present, but may be induced by endotoxin 
(Stuehr & Marietta, 1985; Knowles et al., 1990). This
inducible form of the enzyme is calcium-independent in some 
tissues (e.g. macrophages), but calcium-dependent in others 
(e.g. neutrophils) (Hiki et al., 1991).
1.2.4 Actions of EDRF in vascular smooth muscle 
EDRF and the nitrovasodilators both relax smooth muscle and 
elevate cyclic GMP content (Katsuki et al., 1977; Rapoport 
& Murad, 1983), with the elevation of cyclic GMP content 
occurring prior to muscle relaxation. This observation,
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coupled with the relaxation of smooth muscle induced by 8 
bromo cyclic GMP, a membrane-permeant analogue of cyclic 
GMP (Collins et al., 1986), suggests increases in cyclic 
GMP levels are closely associated with relaxation. Further 
evidence is provided by the ability of haemoglobin, which 
binds EDRF, and methylene blue, which oxidizes the iron in 
the haem prosthetic group from the ferrous to the ferric 
oxidation state, to inhibit the ability of EDRF to induce 
relaxation and increase cyclic GMP (Martin et al., 1985; 
Griffith et al., 1985). Zaprinast, an inhibitor of cyclic 
GMP phosphodiesterase, potentiates the actions of EDRF, and 
further supports a role for cyclic GMP. Rapoport et al. 
(1983) demonstrated that the changes in cyclic GMP induced 
by EDRF were associated with increased protein 
phosphorylation, suggesting that EDRF may alter the 
activity of key cellular proteins.
Smooth muscle contraction is dependent upon calcium- 
calmodulin-dependent phosphorylation of myosin light- 
chains, via the enzyme myosin light-chain kinase (MLCK). 
However, in contrast to the ability of cyclic AMP-dependent 
protein kinase to inhibit the calcium sensitivity of 
purified MLCK, the enzyme activity is unaffected by cyclic 
GMP-dependent protein kinase (Hathaway et al., 1985). In 
contrast, Itoh et al. (1985) have shown that cyclic GMP 
alters the calcium sensitivity of skinned muscle fibres, 
suggesting that a key regulatory component may be absent 
from the purified MLCK.
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Cyclic GMP is thought to produce its actions predominantly 
through the inhibition of calcium mobilisation (Collins et 
al., 1986) and promotion of calcium efflux (Rashatwar et 
al., 1987). It has been suggested that cyclic GMP inhibits 
calcium influx through receptor operated channels (ROCs) to 
a greater degree than calcium influx through voltage 
operated channels (VOCs) (Collins et al., 1988). 
Inhibition of calcium influx through ROCs may result, in 
part, from the cyclic GMP-mediated inhibition of 
phosphoinositide hydrolysis (Rapoport, 1986). Hence, as 
smooth muscle contraction is dependent on 
calcium-calmodulin-induced activation of MLCK, the lowering 
of cytosolic calcium will result in relaxation.
1.2.5 Actions of EDRF in platelets
EDRF is a potent inhibitor of platelet activation. It has 
been shown to inhibit aggregation in vitro (Azuma et al., 
1986; Furlong et al., 1987) and in vivo (Bhardwaj et al., 
1988; Hogan et al., 1988) and to block platelet adhesion to 
the vascular endothelium (Radomski et al., 1987c; Sneddon & 
Vane, 1988). These luminal actions of EDRF may have a key 
role in the regulation of haemostasis. More recently, 
Radomski et al. (1990) have suggested that platelets 
themselves may contain an endogenous nitric 
oxide-L-arginine system and that this may have a negative 
feedback role in the regulation of platelet function. The 
inhibitory actions of EDRF are likely to reflect the 
ability of cyclic GMP to inhibit platelet secretion, 
phosphoinositide hydrolysis and calcium mobilisation (Takai
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et al. , 1981; MacIntyre et al., 1985b). The inhibitory
effects of EDRF on platelet aggregation are potentiated by 
prostacyclin (Radomski et al., 1987b) and, therefore, the 
basal release of both substances may be sufficient to exert 
a tonic inhibitory action.
1.3 Prostacyclin
1.3.1 Discovery and synthesis of prostacyclin 
Prostacyclin, or PGI2' originally termed PGX, was 
discovered in 1976 and found to be an unstable substance, 
produced by enzymes isolated from blood vessel walls, which 
inhibited platelet aggregation (Moncada et al., 1976a, b). 
Prostacyclin production depends upon the liberation of 
arachidonic acid from membrane phospholipids by 
phospholipase This is the calcium-dependent step in
the production of prostacyclin (Van Den Bosch, 1980). 
Arachidonic acid is then converted to prostaglandin G b y  
cyclo-oxygenase, an enzyme which cyclizes the arachidonate 
and, subsequently, adds a 15-hydroperoxy functional group. 
Prostaglandin G i s  converted to prostaglandin H v i a  a 
peroxidase reaction and the subsequent isomerization of 
prostaglandin H^r by prostacyclin synthase, yields 
prostacyclin. The half-life of prostacyclin at 
physiological pH is 3 minutes and longer than that of EDRF. 
Prostacyclin is mainly broken down by a non-enzymic 
reaction to the inactive product, 6-keto-PGF^. Cultured 
vascular endothelial cells and perfused tissues release 
prostacyclin in response to a number of stimuli, including
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thrombin, trypsin, A23187, ATP, histamine, leukotriene c , 
leukotriene D4 and bradykinin (Weksler et al., 1978; 
Pearson et al., 1983; Johnson et al., 1985; Clark et al., 
1986), suggesting that this prostanoid may play an 
important role in the regulation of vasomotor tone.
1-3.2 Actions of prostacyclin in vascular smooth muscle 
Prostacyclin exerts its physiological actions through 
binding to a membrane-associated receptor, termed the 
IP-receptor. Prostacyclin is a potent vasodilator 
(Armstrong et al., 1978) and this action is associated with 
stimulation of adenylate cyclase and elevated cyclic AMP 
content in vascular smooth muscle (Dembinska - Kiec et al.,
1980).
Cyclic AMP appears to induce relaxation by a number of 
mechanisms, all via phosphorylation by cyclic AMP-dependent 
protein kinase. For example, the phosphorylation of myosin 
light-chain kinase (MLCK) by cyclic AMP-dependent protein 
kinase (Conti & Adelstein, 1981; Hathaway et al., 1985) 
increases the calcium-calmodulin requirement for activation 
of MLCK. Consequently, at a given level of cytosolic 
calcium, MLCK-induced phosphorylation of myosin 
light-chains will be reduced. An important additional 
mechanism inducing relaxation is the lowering of cytosolic 
calcium levels. Cyclic AMP inhibits calcium influx through 
VOCs in smooth muscle (Meisheri & van Breemen, 1982). 
Furthermore, the inhibition of noradrenaline-induced 
contractions in rat aorta, by elevation of cyclic AMP
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content, suggests that calcium influx through ROCs may also 
be inhibited (Lincoln & Simpson, 1984). Elevation of 
cyclic AMP content inhibits the contraction induced by 
intracellular calcium release (van Eldere et al., 1982),
presumably by attenuation of receptor-mediated 
phosphoinositide hydrolysis (Hall et al., 1989). 
Additionally, cytoplasmic calcium levels may be lowered via 
enhanced uptake into intracellular calcium stores (Itoh et 
al., 1985), a process which may involve the endoplasmic 
reticulum protein, phospholamban (Raeymaekers & Jones,
1986). In contrast, cyclic AMP does not appear to promote 
calcium extrusion in vascular smooth muscle (Rashatwar et 
al., 1987). Cyclic AMP has been reported to interact 
synergistically with cyclic GMP to relax smooth muscle 
(Grace et al., 1988), providing the possibility that 
prostacyclin and EDRF may potentiate the actions of each 
other in the vasculature.
1.3.3 Actions of prostacyclin in platelets
Prostacyclin-mediated inhibition of platelet aggregation is 
associated with increased cyclic AMP content (Tateson et 
al., 1977). Such elevations of platelet cyclic AMP content 
have been found to inhibit calcium mobilisation, 
phosphoinositide breakdown, aggregation, shape change and 
secretion (Takai et al., 1982; Sage & Rink, 1985). The 
ability of cyclic AMP and cyclic GMP to synergistically 
inhibit platelet phosphoinositide hydrolysis and secretion 
(Takai et al., 1982) is likely to explain the potent, 
synergistic inhibition of platelet function observed with
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low concentrations of EDRF and prostacyclin (Radomski et 
al., 1987b).
1.4 Endothelial ion fluxes : regulation of vasomotor
tone
1.4.1 Endothelial cell hyperpolarisation and endothelium
-derived hyperpolarisina factor (EDHF)
It is well documented that several agents which stimulate
EDRF production, including ATP, bradykinin and A23187 also 
• 86 +increase the efflux of Rb , a marker for potassium, in
vascular endothelial cells (Gordon & Martin, 1983a). This 
• 86 +increased Rb efflux reflects the activation of 
calcium-activated potassium channels (Colden-Stanfield et 
al., 1987; Sauve et al., 1988). Endothelial
hyperpolarisation, resulting from the activation of these 
potassium channels, has also been reported following 
stimulation with acetylcholine (Olesen et al., 1988b) or 
haemodynamic shear stress (Olesen et al., 1988a) and is 
thought to be functionally important. For example, smooth 
muscle relaxation may be mediated via the gap-junctional 
coupling of endothelial cells to smooth muscle cells 
(Davies, 1986). Although electronic spread of endothelial 
hyperpolarisation may explain the ability of muscarinic 
agonists to induce smooth muscle hyperpolarisation (Bolton 
et al., 1984), an alternative proposal involves the release 
of an unidentified substance, termed endothelium-derived 
hyperpolarising factor (EDHF) (Chen et al., 1988; Huang et 
al., 1988a). The differential release of two distinct
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substances EDRF and EDHF is supported by the observations 
of Komori and Suzuki (1987) who demonstrated that 
activation of M^ and receptors was required for
production of EDHF and EDRF, respectively. In support of 
these proposals, haemoglobin, which binds and inactivates 
EDRF (Martin et al., 1985), was found to inhibit both 
acetycholine-mediated relaxation in rat aorta and the 
associated elevation of cyclic GMP content, but had no 
effect on the hyperpolarisation produced (Chen et al.,
1988). This supports the proposal that EDRF or nitric 
oxide does not mediate the hyperpolarisation. However, a 
recent study has demonstrated that nitric oxide can 
hyperpolarise vascular smooth muscle (Tare et al., 1990). 
Hence, EDRF may mediate some of its actions through 
hyperpolafisation. EDHF may exert a greater action on 
muscle membrane potential in some vascular beds, although 
it is not clear if this is a releasable factor or if it 
simply results from the electrotonic spread of current 
following receptor - or calcium - induced activation of 
potassium channels.
1.4.2 Regulation of endothelial function bv mechanical 
stimulation of ion channels or by depolarisation 
A study undertaken by Lansman et al. (1987) initially 
demonstrated the ability of mechanical stretch, presumably 
acting via mechanotransducers, to activate cation-selective 
channels in vascular endothelial cells. As EDRF and 
prostacyclin production is calcium dependent (Singer & 
Peach, 1982; Weksler et al., 1978), the increased entry of
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calcium may serve to enhance release of these two 
vasoactive substances, leading to vasodilation. This 
proposal has been supported by direct measurement of 
cytosolic calcium levels using fura-2 demonstrating that 
mechanical stimulation elevates [Ca^+ ]i by mobilisation of 
calcium from both intracellular and extracellular stores 
(Goligorsky, 1988).
In addition to the release of a vasoactive substance from 
the endothelium by mechanical stimulation, endothelial
24-membrane depolarisation has been found to reduce [Ca ]i in 
vascular smooth muscle, via the production of a diffusible 
substance (Goligorsky, 1988). However, it is not clear how 
depolarisation promotes the release of this substance as 
endothelial cells do not possess voltage-operated calcium 
channels (Hallam & Pearson, 1986) and, in fact, 
agonist-induced EDRF production is actually inhibited by 
membrane depolarisation (Ltickhoff & Busse, 1990).
1.5 Endothelium-derived constricting factors
1.5.1 The endothelins
The proposal that endothelial cells release a 
vasoconstrictor peptide (Hickey et al., 1985; Gillespie et 
al., 1986) was confirmed following the isolation of 
endothelin (now termed endothelin-1) from the culture 
supernatant of pig aortic endothelial cells (Yanagisawa et 
al., 1988). Endothelin-1, a 21 amino acid peptide, is 
synthesized from a 203 amino acid precursor by a two step
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process: the precursor is first cleaved proteolytically,
to produce big endothelin-1 (38 or 39 amino acids), and 
this is subsequently cleaved by an endoproteolytic process 
to yield endothelin-1 (Yanagisawa et al., 1988). This 
biological activity of endothelin-1 is 100 times greater 
than that of big endothelin (Yanagisawa & Masaki, 1989).
Endothelin-1 release is induced by a wide range of stimuli, 
including thrombin, A23187, angiotensin II, transforming 
growth factor J3, interleukin-1, vasopressin and hypoxia 
(Yanagisawa et al., 1988; Emori et al, 1989; Yoshizumi et 
al., 1990; Hexum et al., 1990; Hieda et al., 1990). 
Although enhancement of endothelin-1 production is a 
relatively slow process, occurring over several hours and 
requiring increased mRNA production (Yanagisawa et al.,
1988), shear stress has been proposed to induce rapid 
release of endothelin-1, within 3 minutes (Milner et al., 
1990) .
It is now known that there is a family of endothelin-like 
peptides consisting of endothelins-1, -2, -3 (ET-1, ET-2
and ET-3). Similar biological activity has been found in 
the sarafotoxins S6, a group of peptide toxins from the 
venom of the burrowing asp, Atractaspis engaddenis, 
suggesting a common evolutionary origin of these peptides. 
Three genes for endothelin have been cloned (Inoue et al.,
1989) which separately encode for ET-1, ET-2 and ET-3, 
although only ET-1 has been detected in endothelial cells.
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1-5.2 Actions of endothelins in vascular smooth muscle 
Endothelin-1 induces large, sustained contractions of 
vascular smooth muscle in a number of blood vessels and 
vascular beds (for review, Yanagisawa & Masaki, 1989). 
Although ET-1 has a half life of only 2 minutes and is 
rapidly eliminated from the circulation, the pressor 
response is much longer lasting.
Endothelin-1 stimulates phosphoinositidase C-induced 
hydrolysis of phosphatidylinositol-4, 5-bisphosphate, which 
results in the generation of inositol (1,4,5) 
trisphosphate, calcium mobilisation and activation of 
protein kinase C via diacylglycerol (Resink et al., 1988; 
Marsden et al., 1989; Griendling et al., 1989). The 
activation of protein kinase C by diacylglycerol may 
account for the sustained contraction, as activation of 
protein kinase C, via phorbol esters, induces a slow, long 
lasting contraction (Itoh et al., 1988) similar to that 
obtained with endothelin-1. Diacylglycerol accumulation 
may also occur as a result of phosphatidylcholine 
hydrolysis by endothelin (MacNulty et al., 1990). 
Originally, endothelin-1 was proposed to directly activate 
a dihydropyridine-sensitive calcium channel (Yanagisawa et 
al., 1988), although van Renterghem and co-workers (1988) 
have suggested that these calcium channels are opened 
subsequent to membrane depolarisation.
In addition to powerful vasoconstricting activity, certain 
endothelins also have vasorelaxant activity. Endothelin-1
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and endothelin-3 induce release of EDRF and prostacyclin 
from perfused vascular beds (De Nucci et al., 1988b; Warner 
et al., 1989) and this may occur as a result of endothelial 
phosphoinositide breakdown and calcium mobilisation (Emori 
et al., 1990, 1991) .
The discovery of 3 distinct endothelin peptides, as well as 
a snake venom counterpart, suggests the possible existence 
of receptor subtypes. In support of this, 2 distinct 
endothelin receptors have recently been described, in 
cardiac membranes, on the basis of differing agonist 
affinities (Watanabe et al., 1989).
1.5.3 Other endothelium-derived constricting factors 
In addition to the endothelins, other substances may be 
involved in the production of rapid, endothelium-dependent 
contractions. For example, an arachidonic acid metabolite 
may be involved in the production of endothelium-dependent 
contractions induced by agents such as acetylcholine or 
serotonin (Miller & Vanhoutte, 1985; Liischer & Vanhoutte, 
1986 a, b) . Release of this factor during hypoxia may 
contribute to hypoxia-induced vasospasm (Vanhoutte, 1988).
An alternative constricting factor may be superoxide anion. 
The endothelium can produce large quantities of superoxide 
anion (Matsubara & Ziff, 1986), but its origin is unclear. 
It may be produced, in part, by endothelial cyclo-oxygenase 
activation, as a consequence of arachidonate metabolism 
(Kontos et al., 1985). The contractile actions of
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superoxide anion are likely to be explained by its ability 
to inactivate EDRF (Rubyani & Vanhoutte, 1986; Gryglewski 
et al., 1986).
1.6 Calcium and inositol phosphates 
1-6.1 The Phosphatidylinositol pathway
The first indication that phospholipid metabolism was 
involved in cellular signalling was demonstrated by Hokin 
and Hokin (1953), who observed that acetylcholine could 
enhance phospholipid metabolism and, specifically, the 
incorporation of 32P into phosphatidylinositol (Ptdlns) and 
phosphatidic acid. Several years later, Michell (1975) 
suggested the potential importance of this signalling 
pathway by illustrating the correlation between Ptdlns 
hydrolysis by phospholipase C and calcium mobilisation. 
Recent studies have shown that several types of 
phospholipase C exist, including a Ptdlns 
specific-phospholipase C and phosphatidylcholine - specific 
phospholipase C. The former enzyme is now commonly termed 
phosphoinositidase C, and this term is used throughout the 
text. In most tissues, 80-85% of the inositol lipid is 
Ptdlns, with variable, but similar, amounts of 
phosphatidylinositol-4-phosphate (Ptdlns(4)P) and
phosphatidylinositol-4, 5-bisphosphate (PtdIns(4,5)P2). 
Sequential phosphorylation of Ptdlns on the 4- and 5- 
hydroxyl groups of inositol yields PtdIns(4)P and 
Ptdlns(4,5)P2, respectively. It is now apparent that the 
main pathway for inositol lipid metabolism involves the
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receptor-mediated hydrolysis of PtdIns(4,5)P2 to yield 
inositol - 1/4,5 - trisphosphate (Ins(l,4,5)P3) and
diacylglycerol (DAG) (Michell et al., 1981). lns(l,4,5)P
is the first metabolite to be produced upon receptor 
activation and this is followed by the production of 
inositol - 1,3,4,5 - tetrakisphosphate (Ins(l,3,4,5)P4),
inositol - 1,4 - bisphosphate (Wollheim & Biden, 1986).
Subsquent dephosphorylation of the tris and 
tetrakisphosphate isomers yields inositol bisphosphates, 
inositol monophosphates and, finally, inositol which may 
then be re-utilized in the synthesis of Ptdlns.
1.6.2 Mechanism of inositol phosphate-induced calcium 
mobilisation
The importance of calcium in the regulation of 
physiological function has long been appreciated since the 
observation made by Ringer (1883) that this ion was 
required to sustain contraction of cardiac muscle. Calcium 
exerts its action as an intracellular messenger by two 
mechanisms; it can bind directly to certain effector 
proteins, such as troponin C in skeletal muscle or, 
alternatively, it may first bind to the specific calcium 
binding protein, calmodulin (Cheung, 1980), which then 
activates specific protein kinases.
Although Ins(l,4,5)P3 and, more speculatively, 
Ins( 1,3 ,4,5)P may have a major role in the regulation of 
calcium mobilisation (Streb et al., 1983; Berridge, 1984; 
Irvine & Moor, 1986, 1987), the precise location of their
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intracellular sites of action is not entirely clear. 
Ins(1,4,5)P3 induces release of calcium from 
non-mitochondrial intracellular calcium stores in 
permeabilized cells (streb et al., 1983). Initial studies 
suggested that these calcium stores may reside in the 
endoplasmic reticulum (Streb et al., 1984). A major role 
for Ins(l,4,5)P3 is supported by the observation that the 
injection of Ins(l,4,5)P3 mimics the effects of receptor 
activation (Oron et al., 1985). However, recent studies 
have suggsted that the site of Ins(l,4,5)?3 action may not 
be the endoplasmic reticulum and the existence of a 
subcellular organelle, termed the "calciosome" has been 
proposed (Krause et al., 1989). Ins(l,4,5)P3 exerts its
actions through a specific receptor which has been cloned 
and its primary structure determined (Furuichi et al.,
1989) .
Production of lns(l,3,4,5)P^ occurs via the phosphorylation 
of Ins(l,4,5)P3 by the calcium-dependent 3-kinase (Biden & 
Wollheim, 1986). Hence, Ins(1,4,5)P3-induced calcium 
mobilisation may promote the formation of Ins(1,3,4,5)P4. 
It has also been proposed that the 3-kinase may be directly 
coupled to receptor activation in some cells (Irvine et 
al., 1988). It has been further suggested that the 
Ins(1,4,5)P3-induced release of calcium from intracellular 
pools may act in conjunction with Ins(l,3,4,5)P4 to gate 
calcium entry at the plasma membrane (Irvine & Moor, 1986, 
1987; Irvine et al., 1988). In this system, Ins
(1, 3 ,4 ,5)P. may have a permissive role in the action of
4
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Ins(l,4,5)P3 by controlling the state of the 
Ins(1,4,5)P3“sensitive intracellular calcium stores, 
through regulation of calcium entry (Figure 1.1). Recent 
work suggests that Ins(l,3,4,5)P4 may also regulate the 
movement of intracellular calcium from Ins(1,4,5)P3~ 
insensitive stores (Irvine et al., 1988). This 
Ins(1,3,4,5)P^-regulated process may require the presence 
of GTP (Irvine et al., 1988), which has been previously 
shown to regulate the formation of gap junctions between 
membranes (Mullaney et al., 1987).
In a number of cells, calcium entry may also occur in the 
absence of inositol phosphate generation, influx being 
directly coupled to receptor activation. One well studied 
example is the ATP receptor-operated channel in vascular 
smooth muscle (Benham & Tsien, 1987).
2+ .When measuring agonist-induced elevations of [Ca ]i in a
population of cells, using fluorescent indicators, a
2+ .biphasic elevation of [Ca ]i is often observed. For
example, in endothelial cells, platelets, smooth muscle and
neutrophils (Rotrosen & Gallin, 1986; Sage & Rink, 1985;
Itoh et al., 1988; McCarthy et al., 1989). However, single
2+ .cell analysis of the changes in [Ca ]i (Jacob et al.,
1988), shows that they consist of repetitive, large, 
transient elevations of [Ca2+]i spiking from either resting
o  -i- 2  H"*levels of [Ca ]i or an elevated level of [Ca ]i. It is
2+ .likely, therefore, that the biphasic elevations of [Ca ]i
2 +  •observed in populations of cells reflects the mean [Ca ]i
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Figure 1.1 Schematic diagram of proposed actions of 
Ins(l,4,5)P3 and Ins(l,3,4,5)P (reproduced and modified 
from Irvine et al., 1988). Ins(l,4,5)P3 releases calcium
from an intracellular store which may be the endoplasmic 
reticulum or a more specialised organelle, termed the 
calciosome. Ins(1,3,4,5)P4 may induce calcium
mobilisation by a number of mechanisms. These include (a) 
gating of calcium into the Ins(1,4,5)P3~sensitive store 
from the extracellular space, (b) transfer of calcium from 
the Ins(l,4,5)P3~insensitive store and (c) direct gating of 
calcium into the cytosol from the extracellular space. The 
actions of Ins(1,3,4,5)P4 may require the presence of GTP.
signal from thousands of cells which are oscillating
asynchronously.
1*6.3 Calcium oscillations
Measurement of [Ca2+]i in cells which are electrically 
inexcitable led to the discovery that stimuli which 
activate Ptdlns metabolism, often induce periodic 
oscillations of [Ca2+]i. This may allow the digital coding 
of cellular responses following exposure to external
stimuli. Several theoretical models have been proposed to 
account for these oscillations in [Ca2+]i and they all 
involve Ins(1,4,5)P3, although they differ on whether or 
not levels of Ins(l,4,5)P3 actually oscillate. These 
models have been sub-divided into those that are
receptor-controlled and those that are second-messenger 
controlled (Berridge, 1990). With receptor-controlled 
models, potential feedback mechanisms may exert their 
actions at the level of receptor-mediated Ins(l,4,5)P3 
production, resulting in oscillations in Ins(l,4,5)P3 
levels. For example, protein kinase C could exert a
negative feedback action on phosphoinositidase C activation 
by the uncoupling of receptor -G protein interactions 
(Woods et al., 1987). This would result in an inhibition 
of Ins(l,4,5)P3 generation and calcium mobilisation until 
the actions of cellular phosphatases reverse the actions of 
protein kinase C, allowing a subsquent burst of 
Ins(l,4,5)P3 generation and calcium mobilisation. An 
alternative mechanism has been proposed by Meyer and Stryer 
(1988), who suggest that Ins(1,4,5)P3-induced elevations of
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2+ .
[Ca ]i exert a positive feedback action on
phosphoinositidase C, thus enhancing both Ins(l,4,5)P3
production and calcium mobilisation. Depletion of the
Ins(1,4,5)P3~sensitive store and the sequestration of
calcium by other sites, results in a fall in [Ca2+]i and
the termination of the response. Therefore, refilling of
the Ins(l,4,5)P3-sensitive calcium stores is required
before the next burst of calcium release can be obtained
despite the continued presence of Ins(l,4,5)P3.
Second messenger-controlled models are dependent upon near
constant levels of Ins(l,4,5)P3. The model proposed by
Gray (1988) suggests that elevated [Ca2+]i inhibits the
release of calcium from intracellular stores. Recent
observations suggest that calcium may exert this negative
feedback inhibition by acting at the Ins(l,4,5)P3 receptor
(Pietri et al., 1990; Payne et al., 1990). An alternative
model depends upon the existence of two releasable stores
of calcium, an Ins(l,4,5)P3-sensitive store and an
Ins(l,4,5)P3~insensitive store (Berridge & Galione, 1988).
Ins(l,4,5)P3 induces calcium mobilisation and this calcium,
along with calcium which enters the cytosol from the
extracellular space, is taken up into Ins(l,4,5)P3
-insensitive stores. This eventually results in
overloading of these stores and the discharge of excess
calcium into the cytosol occurs. The periodic loading and
discharge of these stores is proposed to produce
2+  •oscillations in [Ca ]i.
- 23 -
1-6.4 Calcium, inositol phosphates and control of
endothelial cell function 
Direct measurement of calcium mobilisation, by the use of 
fluorescent calcium indicators, such as fura-2 or indo-1, 
and the measurement of inositol phosphate production, has 
strengthened the proposal that production of EDRF and 
prostacyclin is closely linked to the inositol phosphate/ 
calcium system. For example, agents such as bradykinin, 
ATP, thrombin and histamine, which all increase EDRF and 
prostacyclin release, have been shown to elevate [Ca2+]i 
(Ltickhoff & Busse, 1986; Rotrosen & Gallin, 1986; Hallam & 
Pearson, 1986; Jaffe et al., 1987; Colden-Stanfield et al.,
1987) and increase inositol phosphate production (Derian & 
Moskowitz, 1986; Pirotton et al, 1987; Halldorsson et al.,
1988) in the endothelium.
Calcium is an important regulator of endothelial cell
function. Sustained release of EDRF is dependent upon the 
presence of extracellular calcium (Singer & Peach, 1982; 
Long & Stone, 1985; Luckhoff et al, 1988a; White & Martin,
1989). As described in section 1.2.2, EDRF is thought to
be nitric oxide (Palmer et al., 1987) and this is produced
in the endothelium by the enzyme, nitric oxide synthase.
Activation of this enzyme occurs, concentration-
dependently, within a calcium concentration range of
2+ .30-300nM (Mayer et al., 1989). As basal levels of [Ca ]i
in endothelial cells are typically 60-100nM (Hallam &
Pearson, 1986; Colden-Stanfield et al., 1987; Hallam et
al., 1988a, b), nitric oxide synthase will be partially
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activated, even in unstimulated cells; this may account for 
the observed basal release of EDRF (Griffith et al., 1984).
The calcium-induced activation of the constitutive nitric 
oxide synthase appears to be mediated through the calcium 
binding protein, calmodulin, rather than by a direct 
calcium-enzyme interaction (Forstermann et al., 1990; Biisse 
& Mulsch, 1990).
Calcium is also an important stimulus for the production of 
prostacyclin, as demonstrated by the ability of A23187 (a 
calcium ionophore) to induce release of prostacyclin from 
endothelial cell cultures (Weksler et al., 1978; Adams 
Brotherton & Hoak, 1982; Seid et al., 1983) and the ability 
of the calmodulin antagonist, W7, to inhibit its production 
(Seid et al., 1983). The calcium-dependent step is likely 
to be the activation of phospholipase A^, the enzyme which 
produces arachidonic acid from membrane phospholipids (Van 
Den Bosch, 1980). Agonist-induced prostacyclin production 
is transient (Pearson et al., 1983; Gordon & Martin, 1983b) 
and this may reflect the dependence of prostacyclin 
production on the large, transient release of calcium from 
intracellular stores (Liickhoff et al., 1988a; Hallam et 
al., 1988a; White & Martin, 1989). This is supported by 
the ability of TMB-8, a putative intracellular calcium 
antagonist (Malagodi & Chiou, 1974), to inhibit endothelial 
prostacyclin production (Seid et al., 1983; Liickhoff et 
al., 1988a; White & Martin, 1989). Recent studies have 
suggested that elevation of [Ca ]i above a critical
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threshold of approximately 800nM may be required for 
prostacyclin production, at least in human umbilical vein 
endothelial cells (Hallam et al., 1988a; Carter et al.,
1989).
Calcium mobilisation has been shown to enhance endothelin 
production in the endothelium (Emori et al., 1989), 
although the enhanced production occurs over a period of 
hours, suggesting that calcium merely serves as a trigger 
in a complex sequence of events involving peptide 
synthesis.
1.7 Protein kinase C
1.7.1 Activation of protein kinase C
The ability of diacylglycerol (DAG) to promote activation 
of a protein kinase was first demonstrated by Nishizuka and 
co-workers (Takai et al., 1979; Kishimoto et al., 1980). 
This enzyme, termed protein kinase C, requires calcium and 
phospholipid, preferably phosphatidylserine, for its 
activation (Takai et al., 1979), and phosphorylates a wide 
range of substrates in many cell types (Nishizuka, 1986). 
The stimulatory actions of DAG on protein kinase C are 
mimicked by the tumour-promoting phorbol esters (Castagna 
et al., 1982), allowing these compounds to serve as useful 
pharmacological tools in the evaluation of the role of this 
enzyme, especially as they exert a prolonged stimulatory 
action on protein kinase C, in contrast to DAG which is 
rapidly metabolised.
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The diacylglycerol required to activate protein kinase C 
may be derived from receptor-mediated hydrolysis of 
Ptdlns(4,5)P2 by phosphoinositidase C (Berridge, 1984). 
However, hydrolysis of this inositol lipid is known to be 
relatively transient and, therefore sustained production of 
DAG may derive from an alternative source, for example, 
phosphatidylinositol. Recent evidence has suggested that 
hydrolysis of phosphatidylcholine may be a useful 
alternative source of DAG in a wide range of tissues 
(Billah & Anthes, 1990). Phosphatidylcholine hydrolysis 
may be mediated by either a phospholipase C, which yields 
DAG and phosphocholine as products, or by a phospholipase 
D, which yields choline and phosphatidic acid. 
Phosphatidic acid may subsequently be catabolised to DAG by 
the enzyme phosphatidic acid phosphohydrolase.
1.7.2 Actions of protein kinase C
Protein kinase C has been described as a bidirectional 
regulator of cell function (Drummond, 1985). This reflects 
its ability to promote cellular activation (for example, 
hormone secretion, growth, contraction or metabolism), 
while simultaneously impairing the receptor-operated 
transduction processes by which receptors mediate these 
cellular functions. Hence, by phosphorylation of 
appropriate substrates, protein kinase C may promote 
positive responses, in addition to activating negative 
feedback regulatory pathways. This dual action has been 
demonstrated in the platelet where calcium mobilisation and 
protein kinase C activation synergistically promote
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secretion (Rink et al., 1983) despite protein kinase C 
activation inhibiting inositol lipid metabolism and calcium 
mobilisation (MacIntyre et al., 1985a).
1.7.3 Protein kinase C and control of endothelial cell 
function
As with many other cell types, protein kinase C activation 
in endothelial cells may exert an inhibitory action on cell 
function or, alternatively, may promote cell activation. 
Agents, such as bradykinin, which enhance release of EDRF 
and prostacyclin, are known to generate diacylglycerol via 
hydrolysis of endothelial phosphoinositides (Derian & 
Moskowitz, 1986). This diacylglycerol may serve to 
regulate EDRF and prostacyclin production, as the 
tumour-promoting phorbol esters, which mimic the 
stimulatory action of diacylglycerol on protein kinase C 
(Castagna et al., 1982), inhibit endothelium-dependent 
relaxation induced by histamine in guinea-pig pulmonary 
artery (Weinheimer et al., 1986), acetylcholine and 
substance P in rabbit aorta (Lewis & Henderson, 1987) and 
acetylcholine in rabbit pulmonary artery (Cherry & Gillis,
1988). The inability of the phorbol esters to inhibit 
relaxations induced by nitroprusside (Lewis & Henderson,
1987), suggests that these compounds act by the inhibition 
of EDRF production and not by blockade of its actions. 
Furthermore, the inability of phorbol esters to suppress 
endothelium-dependent relaxations induced by the calcium 
ionophore, A23187, suggest that these compounds inhibit 
EDRF release via inhibition of receptor-mediated
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mobilisation of calcium (Weinheimer et al., 1986; Lewis & 
Henderson, 1987; Cherry & Gillis, 1988). The phorbol 
ester-mediated inhibition of EDRF release has also been 
observed in studies using endothelial cell cultures (De
Nucci et al., 1988a; Smith & Lang, 1990), illustrating the
validity of using these cultured cell systems in the
evaluation of endothelial cell function. However, in 
contrast to the above studies, Sakata and Karaki (1990)
have recently demonstrated that phorbol esters may promote 
EDRF release from rat aortic rings. Hence, in addition to 
the well- documented negative feedback pathway, phorbol 
esters may also promote EDRF release.
Release of prostacyclin from bovine aortic endothelial
cells can be induced either by phorbol esters or by
2+ .increasing [Ca ]i (Demolle & Boeynaems, 1988).
Simultaneous activation of both pathways results in a
highly synergistic release of prostacyclin. Recent studies
suggest that protein kinase C may enhance the calcium
sensitivity of phospholipase A2, resulting in enhanced
2+  •prostacyclin production at a given [Ca ]i (Carter et al.,
1989). However, the actions of phorbol esters on 
prostacyclin production are complex, as demonstrated by the 
ability of these agents to inhibit thrombin-induced 
prostacyclin production, perhaps by inhibition of inositol 
phosphate production (Halldorsson et al., 1988).
Phorbol esters are known to promote release of endothelin, 
by a mechanism that is highly synergistic with elevations
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2+ .
of [Ca ]i (Emori et al., 1989). However, unlike the
effects of phorbol esters on EDRF and prostacyclin, which 
occur within minutes, the effects of these agents on 
endothelin production occur over a number of hours.
1.8 Adenylate cyclase
1.8.1 Cyclic AMP
Cyclic AMP (adenosine - 3':5' cyclic monophosphate) is a 
nucleotide synthesised from adenosine triphosphate (ATP) by 
the action of adenylate cyclase, a transmembrane protein. 
A number of membrane-bound receptors are now known to exert 
their stimulatory actions on adenylate cyclase via guanine 
nucleotide regulatory proteins (G proteins) (Gilman, 1987). 
The G protein associated with stimulation of adenylate
cyclase is termed Gg and is cholera toxin-sensitive. 
Stimulation of adenylate cyclase is thought to result from 
the direct interaction of the G .subunit with the enzyme,
SO*
resulting in enhanced cyclic AMP turnover.
Activation of a number of receptors - for example,
muscarinic rceptors and 0C2-adrenoceptors - inhibits
adenylate cyclase activity, resulting in reduced cyclic AMP
production. Receptor-mediated inhibition of adenylate
cyclase arises via the action of a pertussis
toxin-sensitive, inhibitory G protein, G^ , although how
adenylate cyclase is inhibited is not entirely clear.
Inhibition may be mediated by the direct interaction of the
G. . subunit with adenylate cyclase and this may be 
1 Ps
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potentiated by the free Btf subunits of combining with 
any free subunit, thus terminating their stimulatory
actions (Katada et al., 1986). It has also been proposed 
that the By subunit may directly inhibit adenylate cyclase 
(Katada et al., 1986).
1.8.2 Mechanism of action of cyclic AMP
In mammalian cells, cyclic AMP exerts the majority of its 
biological actions through activation of a specific protein 
kinase, cyclic AMP-dependent protein kinase (protein kinase 
A). Protein kinase A exists in two major isoforms, types I 
and II, both are tetramers and are activated by cyclic AMP 
as follows:
R2C2 + 4cAMPf^R2 (cAMP)4 + 2C
where R represents the regulatory components and C 
represents the catalytic components (for review, Corbin et 
al., 1988). Binding of cyclic AMP results in the 
dissociation of the catalytic subunits, which then exert 
their actions through phosphorylation of cytosolic 
proteins. However, in some systems, for example, in 
olfactory cilia, cyclic AMP may exert a direct action on 
ion conductances, independently of protein kinase 
activation (Nakamura & Gold, 1987).
1.8.3 Degradation of cyclic AMP
Cyclic AMP degradation occurs via the action of 
phosphodiesterase enzymes which hydrolyse cyclic AMP to
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5/—adenosine monophosphate (AMP). The main subtypes 
involved are type I (Calcium - calmodulin dependent), type 
II (cyclic GMP - stimulated), type III (cyclic GMP - 
inhibited) and type IV (cyclic AMP - specific), according 
to the classification of Beavo and Reifsnyder (1990). In 
some tissues, for example, cardiac muscle, each of these 
subtypes is present, although this is not typical of all 
tissues and the distribution of the enzyme subtypes varies 
considerably.
1.8.4 Cyclic AMP and control of endothelial cell function 
Endothelial cyclic AMP levels can be elevated by a number 
of agents including prostacyclin (Dembinska-Kiec et al., 
1980; Hopkins & Gorman, 1981), B-adrenoceptor agonists 
(Buonassi & Venter, 1976; Hopkins & Gorman, 1981), 
forskolin (Adams Brotherton et al., 1982), adenosine 
(Legrand et al. , 1990) and calcitonin gene-related peptide 
(CGRP; Crossman et al., 1987). Despite this, only a small 
number of studies have attempted to relate the changes in 
endothelial cyclic AMP levels to altered cell function. 
Initial studies suggested that elevation of cyclic AMP 
content induced by prostacyclin (PGI2) served as a negative 
feedback mechanism to limit PGI2 production (Hopkins & 
Gorman, 1981; Adams Brotherton & Hoak, 1982). However, 
later studies ascribed this inhibition to the cyclic 
AMP-independent, inhibitory actions of the
phosphodiesterase inhibitor, 3-isobutyl-1-methyl xanthine, 
which was utilised during these studies (Adams Brotherton 
et al., 1982).
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The possibility that cyclic AMP regulates endothelial
production of EDRF has been investigated. Stimulation of
EDRF production, following treatment with prostacyclin and
forskolin, may result from elevation of endothelial cyclic
AMP content (Shimokawa et al., 1988). Furthermore, two
stimulants of adenylate cyclase, isoprenaline and CGRP,
induce endothelium-dependent relaxation of rat aorta (Gray
& Marshall, 1991 a, b) and this was inhibited by 
GN -nitro-L-arginine, strongly suggesting the involvement of 
EDRF. Supporting these observations, vasodilation induced 
by 62-adrenoceptor agonists, in rat perfused hindquarters, 
was attenuated by an inhibitor of EDRF production,
Q
N -nitro-L-arginine methylester (L-NAME) (Gardiner et al., 
1991). However, the inability of CGRP to enhance levels of 
cyclic GMP in co-culture systems of smooth muscle and 
endothelium, derived from bovine aorta, but to still 
increase cyclic AMP in both cell types, suggests that the 
actions of CGRP may not be endothelium-dependent in all 
cell types (Crossman et al., 1990).
1.9 Guanylate cyclase
1.9.1 Cyclic GMP
Cyclic GMP (guanosine - 3':5' cyclic monophosphate)
formation is catalysed from guanosine triphosphate by two 
different enzymes, soluble guanylate cyclase and 
particulate guanylate cyclase (for review, Tremblay et al.,
1988). Soluble guanylate cyclase is a cytosolic protein 
with a molecular weight of approximately 150kDa. Its
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activation is promoted by a number of compounds including 
nitric oxide (Mittal & Murad, 1977), which may be EDRF 
(Palmer et al., 1987), and agents which act via the release 
of nitric oxide, such as the nitrovasodilators. Craven and 
De Rubertis (1978) first described the presence of a haem 
prosthetic group in guanylate cyclase; nitric oxide is 
thought to promote enzyme activation by binding to this 
haem moeity.
Particulate guanylate cyclase is distinct from soluble 
guanylate cyclase in that it is membrane associated and is 
typically activated by extracellular peptides, such as 
enterotoxins and atrial natriuretic factors (ANF) (Tremblay 
et al., 1988). How agents, such as ANF, activate 
particulate guanylate cyclase is not fully understood, 
although the ANF receptor and catalytic subunit appear to 
be tightly coupled (Chinkers et al., 1989) and may, in 
fact, be part of the same protein. A second, more 
abundant, class of ANF receptor, the ANF -receptor, exists 
although it is not coupled to guanylate cyclase (Leitman et 
al. , 1986) and may represent a site for clearing ANF from 
the plasma.
1.9.2 Mechanism of action of cyclic GMP
Cyclic GMP exerts the majority of its actions through the 
activation of a protein kinase, termed cyclic GMP-dependent 
protein kinase. Activation of the enzyme may be 
represented by the following scheme:
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(RC)2 + 4cGMPf= (RC) 2 . (cGMP)
Unlike cyclic AMP-dependent protein kinase, the regulatory 
subunits (R) and catalytic subunits (C) of cyclic 
GMP-dependent protein kinase do not dissociate upon binding 
of cyclic GMP (for review, Corbin et al., 1988). The 
phosphorylation of cellular substrates by this kinase 
mediates many of the actions of cyclic GMP, although the 
nucleotide may also act directly in some systems. For 
example, Fesenko and co-workers (1985) demonstrated the 
opening of sodium-permeable channels in the plasma membrane 
of retinal rods, following exposure to cyclic GMP.
1.9.3 Degradation of cyclic GMP
Degradation and inactivation of cyclic GMP occurs via the 
actions of phosphodiesterase enzymes which catalyse the 
hydrolysis of cyclic GMP to 5' guanosine monophosphate 
(GMP). The subtypes of phosphodiesterase which catalyse 
cyclic GMP hydrolysis are type I (calcium-calmodulin- 
stimulated) and type V (cyclic GMP-specific) (Beavo & 
Reifsnyder, 1990).
1.9.4 Cyclic GMP and control of endothelial cell function 
Vascular endothelial cyclic GMP content can be elevated in 
response to both endogenously produced EDRF (Martin et al.,
1988) and exogenously applied atrial natriuretic peptides 
(Leitman & Murad, 1986; Martin et al., 1988). However, 
whether or not cyclic GMP modulates endothelial cell
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function is a subject of debate. The ability of 8 bromo
cyclic GMP (Evans et al., 1988) and atrial natriuretic
peptides (Hogan et al., 1989) to inhibit release of EDRF 
has lead to the proposal that elevation of endothelial 
cyclic GMP may serve as a negative feedback mechanism
regulating EDRF production. However, this proposal is not 
supported by the recent work of Kuhn and co-workers (1991) 
who found that elevation of cyclic GMP content did not 
inhibit EDRF release from bovine aortic endothelial cells.
Doni and co-workers (1988) have proposed that nitric oxide 
may exert an inhibitory action on prostacyclin production 
in bovine aortic endothelial cells. This action is thought 
to be related to the ability of nitric oxide to elevate 
cyclic GMP, as the inhibitory effect was potentiated by
zaprinast, a selective inhibitor of cyclic GMP 
phosphodiesterase (Doni et al., 1988). However, in 
previous studies, elevation of cyclic GMP, induced by 
atriopeptin II, 8 bromo cyclic GMP and sodium 
nitroprusside, appeared unable to modulate release of 
prostacyclin from either pig aortic endothelial cells 
(Martin et al., 1989) or human umbilical vein endothelial 
cells (Adams Brotherton, 1986).
In addition to possibly modulating release of EDRF and 
prostacyclin, elevation of cyclic GMP content, stimulated 
by atrial natriuretic peptides or nitrovasodilators, 
appears to inhibit both basal and thrombin—stimulated 
release of endothelin from human umbilical vein endothelial
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cells (Saijonmaa et al., 1990). These findings are 
supported by the observations that N^-nitro-L-arginine, an 
inhibitor of EDRF production, enhances endothelin 
production, while superoxide dismutase, which prolongs the 
half-life of EDRF, inhibits endothelin production from the 
endothelium of pig aorta (Boulanger and Luscher, 1990). As 
endothelin is a potent vasoconstrictor, this action of 
cyclic GMP may represent an important mechanism by which 
EDRF, nitrovasodilators and atrial natriuretic peptides 
regulate vasoactive tone, in addition to their direct, 
inhibitory actions on blood vessels.
1.10 Interactive regulation of intracellular messenger 
systems and control of endothelial cell function
Little is known of the interactions which occur between 
second messenger pathways in the endothelial cell or how 
these interactions modify endothelial cell functions. 
Functional studies suggest that calcium acts as an 
important primary messenger in mediating certain rapid, 
cellular responses to extracellular stimuli. For example, 
the stimulated production both of EDRF and prostacyclin 
probably reflects the calcium-dependence of nitric oxide 
synthase (Meyer et al., 1989) and phospholipase A  ^ (Van Den 
Bosch, 1980), respectively.
Evidence from other cell types indicates that other 
intracellular messengers, including protein kinase C, 
cyclic AMP and cyclic GMP, often exert their actions 
through the modulation of calcium mobilisation. For
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example, calcium is the primary stimulus for contraction of 
smooth muscle (Bolzer, 1969) and for secretion and 
aggregation of platelets (Knight et al., 1982). Therefore, 
as agents which activate protein kinase C, or elevate 
cyclic nucleotide levels in these cells, have been found to 
inhibit calcium mobilisation (Meisheri & van Breemen, 1982; 
MacIntyre et al., 1985b; Collins et al., 1986; Itoh et al.,
1988), this may represent the mechanism by which the second 
messengers affect cell function. Intracellular messengers 
may also augment calcium mobilisation. For example, cyclic 
AMP enhances calcium entry in several cell types, including 
hepatocytes (Poggioli et al., 1986), cardiac myocytes 
(Cachelin et al., 1983) and a pituitary cell line (Luini et 
al., 1985), while cyclic GMP also promotes calcium influx 
in pancreatic acinar cells (Pandol & Schoeffield-Payne,
1990). Hence, it is clear that cellular functions may be 
modulated by interactions between a number of second 
messengers, although the regulation of calcium mobilisation 
is likely to be the primary mechanism by which endothelial 
production of EDRF and prostacyclin is controlled. For 
example, tumour-promoting phorbol esters activate protein 
kinase C and have been shown to inhibit receptor-mediated 
production of EDRF, while having no effect on that induced 
by the calcium ionophore, A23187 (Weinheimer et al, 1986; 
Lewis & Henderson, 1987; Cherry & Gillis, 1988). This 
suggests that protein kinase C activation may inhibit EDRF 
release by inhibition of receptor-mediated mobilisation of 
calcium, the primary stimulus for EDRF production. 
Inhibition of EDRF and prostacyclin production by cyclic
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GMP (Evans et al. , 1988; Doni et al., 1988; Hogan et al.,
1989) may also occur via the inhibition of calcium
mobilisation. Therefore, by investigating how
intracellular messengers, including protein kinase C, 
cyclic AMP and cyclic GMP, can control endothelial calcium 
mobilisation, we may gain a deeper insight into how these 
second messengers regulate endothelial cell function.
l.ll Scope of this investigation
24-In this study, endothelial [Ca ]i was measured using the
fluorescent probe, fura-2. The contributions made by
intracellular and extracellular calcium pools to
2+agonist-induced elevations of [Ca ]i were assessed. 
Properties of the intracellular calcium stores, and how 
they are functionally linked to calcium in the
extracellular fluid, were also investigated. Finally, the 
effects of protein kinase C stimulation and of elevation of 
cyclic AMP and cyclic GMP content were examined on 
agonist-induced mobilisation of intracellular and 
extracellular calcium.
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CHAPTER 2
2.1 Role of the endothelial barrier
The endothelium and its underlying basement membrane 
constitutes an important barrier between the components of 
the blood and the tissues of the body. Although the 
endothelium allows the passage of small, non-polar 
molecules through the cell, it restricts the passage of 
charged molecules and high molecular weight solutes. 
Macromolecules must traverse the endothelial barrier by 
alternative pathways: for example, via inter-endothelial
gaps, through the cells via transcellular pores or, in 
certain cases, by receptor-mediated endocytosis (Renkin,
1985). Alterations in the properties of this barrier are 
necessary for normal homeostasis but also underl/e the 
development of pathological processes, such as inflammation 
and atherosclerosis.
Atherosclerosis is a pathological condition associated with 
smooth muscle proliferation, lipid disposition in the 
arterial wall and with the progressive narrowing of the 
vessel lumen. The processes underlying the development of 
this condition are complex and have been reviewed by Ross 
(1986) and by Munro and Cotran (1988). Endothelial 
dysfunction is believed to play a major role in the 
development of atherosclerosis and may occur as a result of 
injurious stimuli. These include elevated plasma levels of 
low density lipoprotein (LDL) or homocysteine, mechanical 
stress, cigarette smoke or, possibly, viral infection.
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These stimuli are thought to reduce endothelial barrier 
function, facilitating entry of LDL into the blood vessel 
wall. LDL has been shown to promote monocyte adhesion to 
the endothelium, both in vivo and in vitro (Faggiato et 
a-L • r 1984; Alderson et al., 1986). Release of the 
monocyte-derived cytokine, interleukin-1, may further 
compromise endothelial barrier function by both a direct 
action on the endothelium (Royall et al., 1989) and by 
enhancing monocyte adhesion to the endothelium, through 
stimulated expression of adhesion molecules (Bevilacqua et 
al., 1985). Endothelium dysfunction may also result in 
inhibition of EDRF and prostacyclin production, thus 
facilitating the adhesion of platelets and monocytes 
(Radomski et al., 1987c; Bath et al., 1991). Release of 
growth factors from endothelial cells, platelets and 
monocytes contributes to hypertrophy of smooth muscle in 
the blood vessel wall. When this occurs, at the sites of 
lipid deposition, the characteristic fibrous plaques of 
atherosclerosis are observed. Further development of these 
plaques, along with increased smooth muscle growth, leads 
to the narrowing of the blood vessel lumen which is 
associated with atherosclerosis.
Alterations in endothelial barrier function are of 
importance during the development of the inflammatory 
response, which may be defined as a coordinated response to 
local injury, consisting of blood vessel dilatation, 
invasion of tissues by leucocytes and the passage of blood 
proteins through post-capillary venule walls. Normally,
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access of leucocytes and proteins to the tissue is 
restricted by the endothelial barrier, but permeability 
increases following the actions of a number of mediators, 
including histamine, kinins, prostaglandins and cytokines, 
leading to inflammatory oedema. In contrast to the slow 
alterations in endothelial barrier function which develop 
during atherosclerosis, those taking place during 
inflammation occur within minutes or hours and may, 
therefore, be more susceptible to modulation by rapid 
changes in the levels of endothelial intracellular 
messengers.
2.2 Development of inflammation
2.2.1 Role of haemodynamic changes in inflammation 
Haemodynamic changes are perhaps the first observable 
occurrences during the development of inflammation and 
arise as a consequence of a marked increase in blood flow 
to the site of injury. This local increase in blood flow 
increases hydrostatic pressure, which forces fluid into the 
tissues and also allows for increased delivery of 
leucocytes to the site of injury. The importance of this 
increased blood flow in enhancing vascular permeability is 
illustrated by the ability of vasodilators, such as 
prostacyclin, to markedly enhance leakage induced by 
chemoattractants (Rampart & Williams, 1986). The rapid 
vasodilation induced during an inflammatory response may be 
modulated by the release of EDRF (Chander et al., 1988; 
Hughes et al., 1990) and may enhance oedema formation, as
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inhibitors of EDRF production were found to inhibit 
substance P-induced oedema formation (Hughes et al., 1990). 
Calcitonin gene-related peptide and substance P, which are 
co-located in sensory nerves, may also be released during 
inflammation, resulting in vasodilation (Brain & Williams,
1989).
2.2.2 Role of the endothelial barrier in inflammation 
The endothelium and its underlying basement membrane 
normally provides the major barrier to movement of blood 
components into the surrounding tissues. However, during 
the inflammatory response, changes occur in endothelial 
barrier function; these changes involve endothelial cell 
contraction, cytoskeletal re-organisation and, possibly, 
endothelial damage. The major site of the inflammatory 
response is the post-capillary venule (Majno et al., 1961; 
Svensjo et al., 1979). A number of inflammatory agents, 
such as serotonin, bradykinin and histamine, have been 
found to induce endothelial cell contraction (Majno et al., 
1969), perhaps by a mechanism involving calcium, calmodulin 
and myosin light-chain kinase (Wysolmerski et al., 1990), 
although activation of protein kinase C may also be 
important (Antonov et al., 1986). The endothelial shape 
change and contraction results in rapid formation of 
inter-endothelial gaps (Majno et al., 1969) and the 
movement of fluid and plasma proteins into the 
extravascular space. Increased vascular permeability may 
also be promoted by cytokines, such as tumour necrosis 
factor, although these changes are much slower in onset
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than those of the classical inf laminatory mediators and 
occur over a number of hours (Stolpen et al., 1986). The 
endothelial barrier function may be further diminished by 
injury - via the dual actions of oxygen-derived free 
radicals and proteolytic enzymes released from neutrophils 
(Wedmore & Williams, 1981). Injured endothelial cells may 
retract or lyse, resulting in enhanced vascular leakage. 
This may result in enhanced blood stasis and, therefore, 
potentially greater leucocyte adhesion and migration.
2.2.3 Role of the endothelium in leucocyte adhesion and 
migration during inflammation 
Endothelial-leucocyte adhesion is followed by diapedesis of 
the white blood cells across the endothelial barrier. 
Adhesion of neutrophils to endothelial cells occurs 
rapidly, in response to agents which raise endothelial 
cytosolic calcium, for example, thrombin and histamine, and 
may be associated with the translocation of the adhesion 
molecule, GMP-140, from the Weibel-Palade bodies to the 
plasma membrane (Hattori et al., 1989). Neutrophil 
adherence is facilitated by the endothelial production of 
platelet activating factor (PAF; Prescott et al., 1984). 
It is likely, that PAF facilitates neutrophil binding by 
inducing the up—regulation of neutrophil adhesion 
molecules, particularly members of the CD18 family 
(Tonnesen et al., 1989). Subsequent prolonged attachment 
of neutrophils to the endothelium may require interaction 
of these adhesion molecules with the endothelial adhesion 
molecules, ICAM-1 and ECAM-1 (Vevilaqua et al. , 1987).
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Expression of ECAM-1 appears to be optimal after 4 hours 
exposure to cytokines, such as interleukin-1 and TNF, and 
will bind both neutrophils and monocytes. These cytokines 
also promote the synthesis of interleukin-8, a low 
molecular weight cytokine, in a number of cell types. 
Interleukin-8 is chemotactic towards neutrophils and may 
also induce their degranulation (Matsushima & Oppenheim,
1989). It is likely that interleukin-8 is identical to the 
leucocyte adhesion inhibitor described by Gimbrone and 
co-workers (1989), which may switch neutrophil binding to a 
lower affinity adhesion molecule (for example, ICAM-1), 
thus aiding the diapedesis of the cells across the venule 
wall.
2.3 Endothelial barrier function - role of intracellular 
messenger systems
2.3.1 Calcium and inositol phosphates
Calcium mobilisation, resulting from the actions of 
inositol phosphates, may modulate both endothelial 
contraction and secretion and, therefore, regulate 
endothelial function during development of inflammation. A 
number of inflammatory mediators, including histamine, 
bradykinin and thrombin, inhibit endothelial barrier 
function in vivo (Majno & Palade, 1961; Marciniak et al., 
1978? Svensjo et al, 1979) or in vitro (Killackey et al., 
1986; Rotrosen & Gallin, 1986), probably via endothelial 
cell contraction (Majno et al., 1969; Laposata et al., 
1983; Killackey et al., 1986).
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Using an in vitro model in which human umbilical vein
endothelial cells were grown on porous membranes, Rotrosen
and Gallin (1986) demonstrated that histamine increases
albumin transfer across endothelial monolayers with a
similar concentration-dependence to the mobilisation of
calcium. On the basis of this, they suggested that
endothelial shape change or contraction may be dependent on
2+ .changes m  [Ca ]i. This proposal is supported by the 
observations that calcium chelators inhibit
histamine-induced vascular leakage (Liddell et al., 1981) 
in vitro and that A23187, a calcium ionophore, enhances 
albumin transfer across cultured endothelial monolayers 
(Shasby et al., 1985; Gudgeon & Martin, 1989). Thrombin- 
and platelet activating factor(PAF)-induced endothelial
shape change (Laposata et al., 1983; Killackey et al., 
1986; Garcia et al., 1986; Grigorian & Ryan, 1987) may also 
reflect the ability of these agents to increase endothelial 
[Ca2+]i (Brock & Gimbrone, 1986; Jaffe et al., 1987).
In smooth muscle, calcium is the primary stimulus for 
induction of contraction (Bolzer, 1969), exerting its 
actions via the calcium-calmodulin activation of myosin 
light-chain kinase (MLCK). MLCK subsequently
phosphorylates the 20kDa regulatory light chain subunit of 
myosin, resulting in smooth muscle contraction (Kamm & 
Stull, 1985). The presence of myosin and actin filaments 
has been demonstrated in the vascular endothelium (Becker & 
Nachman, 1973; Drenckhahn, 1983) and, therefore, a similar 
process may be involved in the development of endothelial
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cell shape change and contraction. Furthermore, as 
endothelial levels of F-actin are reduced in response to 
calcium-mobilising agents (Rotrosen & Gallin, 1986), 
calcium may modulate endothelial cytoskeletal function by 
altering the activity of the F-actin fragmenting protein, 
gelsolin (Yin & Stossel, 1979).
Regulation of endothelial secretion by cytosolic calcium 
may also modulate induction of the inflammatory response. 
As described earlier, production of EDRF and prostacyclin 
is highly calcium-dependent (Singer & Peach, 1982; Long &
Stone, 1985; Jaffe et al., 1987; Hallam et al., 1988a).
2+Rapid elevation of [Ca ]i results in the rapid release of 
these mediators and a rapidly developing vasodilation 
during the initial stages of the inflammatory response.
Endothelial production of PAF is highly dependent on 
calcium influx, which probably exerts a regulatory action 
on the synthetic enzyme, phospholipase A2 (Whatley et al.,
1989). Hence, inflammatory agents may exert indirect 
actions on neutrophil activation and adhesion via the 
production of endothelium-derived PAF.
2.3.2 Protein kinase C
Protein kinase C activation results in the slow development 
of a long-lasting contraction in vascular smooth muscle, by 
a mechanism which is thought to involve enhanced calcium 
sensitivity of muscle contractile filaments (Itoh et al., 
1988). Activation of protein kinase C may similarly induce
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endothelial cell contraction and shape change, resulting in 
increased vascular leakage. In vitro studies have 
demonstrated that 48-phorbol 12-myristate 13-acetate (PMA), 
an activator of protein kinase C, induces shape change in 
human umbilical vein endothelial cells (Antonov et al., 
1986) and bovine pulmonary artery endothelial cells 
(Grigorian & Ryan, 1987), and increases albumin transfer 
across monolayers of pig aortic endothelial cells (Gudgeon 
& Martin, 1989), although Olesen (1987) found no effect of 
PMA on vascular leakage from frog brain venules in vivo.
Activation of protein kinase C may further potentiate the 
inflammatory response by enhancing endothelial production 
of PAF (Whatley et al., 1989) thus facilitating neutrophil 
activation and adhesion to endothelial membranes.
2.3.3 Cyclic AMP
B -adrenoceptor agonists inhibit bradykinin - and 
histamine-induced vascular leakage from post-capillary 
venules (Svensjo et al., 1977, 1979; Marciniak et al.,
1978). These inhibitory actions are likely to be due to a 
cyclic AMP-induced enhancement of barrier function. 
Evidence for this has been obtained in a number of in vitro 
studies which have demonstrated the ability of cyclic AMP 
elevating agents, such as isoprenaline and prostacyclin, to 
inhibit either endothelial albumin transfer or 
inter—endothelial gap formation (Laposata et al., 1983; 
Killackey et al., 1986; Mizuno-Yagya et al., 1987; Gudgeon 
& Martin, 1989). This action of the cyclic AMP-elevating
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agents was associated with enhanced cell flattening and 
greater cell-to-cell contact (Bensch et al., 1983). In 
contrast to the above studies, adenylate cyclase activation 
has been shown to promote endothelial shape change and 
inter-endothelial gap formation in cultures of human 
umbilical vein endothelial cells (Antonov et al., 1986). 
However, as other studies have shown that cyclic AMP 
inhibits gap formation in these cells (Laposata et al., 
1983; Killackey et al., 1986), the reasons for these
differences are not apparent.
2.3.4 Cyclic GMP
Release of EDRF can enhance vascular leakage induced by
inflammatory agents, such as substance P and histamine, 
although this action probably results indirectly from an 
increase in local blood flow (Chander et al., 1988; Hughes 
et al., 1990). It is not yet known whether changes in
endothelial barrier function can be produced by EDRF by a 
direct effect on the endothelial cell during an
inflammatory response. As described earlier, endothelial 
cyclic GMP content increases in response both to 
endogenously produced EDRF (Martin et al., 1988) and atrial 
natriuretic peptides (Leitman & Murad, 1986; Martin et al.,
1988). By analogy with vascular smooth muscle where cyclic 
GMP and cyclic AMP induce relaxation (Itoh et al., 1985), 
it is possible that cyclic GMP, like cyclic AMP (Laposata 
et al., 1983; Bensch et al., 1983; Killackey et al., 1986), 
may induce endothelial cell relaxation and so enhance 
barrier function. However, it should be noted that
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elevation of cyclic AMP, but not cyclic GMP, content 
enhances the integrity of gallbladder epithelial tight 
junctions (Duffey et al., 1981).
2.4 Role of intracellular messenger interactions in the 
regulation of endothelial barrier function
Progression of inflammatory oedema may be controlled by 
functional regulation at a number of different sites. For 
example, changes in blood flow will alter hydrostatic 
pressure and, therefore, alter vascular leakage. However, 
direct alterations in post-capillary endothelial barrier 
function may be one of the major mechanisms by which 
vascular leakage and, therefore, development of the 
inflammatory response may be modulated (Majno et al., 1961; 
Svensjo et al, 1979).
By comparison with other biological systems, alterations in 
endothelial barrier function are likely to be regulated by 
both synergistic and antagonistic interactions between 
intracellular messenger systems. However, it is not 
entirely clear where regulation occurs and how these 
interactions correlate with changes in endothelial barrier 
function. As described in section 2.3.1, elevations of 
[Ca2+]i could be an important trigger for the development 
of endothelial contraction and the formation of 
inter-endothelial cell gaps. Agents which increase 
endothelial [Ca2+]i may also increase endothelial 
hydrolysis of phosphoinositides (Derian & Moskowitz, 1986; 
Halldorsson et al, 1988), resulting in the concomitant
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production of diacylglycerol. Diacylglycerol can directly 
activate protein kinase C and this enzyme may inhibit 
endothelial barrier function either alone or via the 
synergistic interaction with calcium which has been 
described in other cell systems (Nishizuka, 1986).
Several intracellular messenger pathways may be involved in 
the enhancement of endothelial barrier function and, as 
described in sections2.3.3 and2.3.4, cyclic AMP and cyclic 
GMP may have key roles in the regulation of this aspect of 
endothelial cell function. As both cyclic nucleotides 
inhibit smooth muscle contraction (Itoh et al., 1985), via 
a mechanism that involves inhibition of calcium 
mobilisation (Meisheri & van Breemen, 1982; Collins et al.,
1986), it is important to determine whether they may exert 
similar actions on calcium mobilisation in the endothelium 
and whether these actions relate to their functional 
effects in the endothelium. Alternatively, cyclic AMP and 
cyclic GMP may exert their functional actions via a 
different mechanism - for example, via inhibition of the 
actions of protein kinase C (Rasmussen et al., 1984).
2.5 Scope of this investigation
In this study, an in vitro model of endothelial barrier 
function was established, using bovine pulmonary artery 
endothelial cells, and the effects of activating several 
intracellular messenger pathways examined. Specifically, 
the second messenger pathways considered were calcium, 
protein kinase C, cyclic AMP and cyclic GMP. The
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mechanisms underlying the alterations in endothelial 
barrier function were examined. Specifically, the effects 
of the cyclic nucleotides, cyclic AMP and cyclic GMP, and 
of stimulation of protein kinase C on agonist-induced 
calcium mobilisation were examined.
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METHODS
CHAPTER 3
3.1 Isolation of Primary Cultures of Endothelial Cells
3.1.1 Isolation of bovine aortic endothelial cells (BAEC)
At a local abattoir, bovine thoracic aortae were removed
shortly after death (approximately 5 minutes) and flushed
with sterile saline containing benzyl penicillin (100U 
—1ml ) and streptomycin (100/ig ml ). The end of each 
vessel, originally proximal to the aortic arch, was ligated 
and the distal end subsequently cannulated with a 60ml 
syringe and adaptor containing the same sterile saline. 
This saline was then infused into the lumen of the aorta 
and the vessel transported to the laboratory.
At the laboratory, all subsequent work was undertaken in a 
laminar flow hood (Flow laboratories). The aortic 
intercostal arteries were cleared of adhering fat and 
ligated with surgical thread. 20ml of a sterile 
collagenase solution (Type II, Sigma; 0.1% in Dulbecco's 
modification of Eagle's medium (DMEM) ) was then infused 
into the lumen. The vessel was then incubated at 37 C in 
an atmosphere of 5% 00^/95% air for 25 min. At the end of 
this incubation period, the aorta was gently massaged and 
the resulting cell suspension collected. To collect any 
remaining cells, sterile saline (20ml) was infused into the 
lumen and then removed. The resulting cell suspensions 
were centrifuged (200g; 4 min; 10 C). The supernatants
were decanted and the cell pellets resuspended in DMEM
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containing foetal calf serum (10%), newborn calf serum
(10%), glutamine (4mM), benzyl penicillin (200U ml”1) and
streptomycin (200/ig ml 1) (referred to as complete medium
throughout the rest of the text). These suspensions of
BAEC from each aorta were combined and centrifuged again
(200g; 4 min; 10 C). The resulting cell pellet was
resuspended in 50ml of complete medium and seeded into 2 or 
2
3 80cm culture flasks (Gibco). The flasks were then 
placed in an incubator (Flow laboratories) at 37°C in an 
atmosphere of 5% C02 and 95% air. The culture medium was 
changed the day following the initial isolation and every
2-3 days subsequently. Figures 3.1.a and 3.1.b show light 
micrographs of BAEC one day after isolation and at 
confluence (3 days), respectively. The cells demonstrated 
the characteristic endothelial "cobblestone" morphology.
3.1.2 Isolation of bovine pulmonary artery endothelial 
cells (BPAEC)
At a local abattoir, bovine pulmonary arteries were removed
and flushed with sterile saline containing benzyl
-1 -1 penicillin (100U ml ) and streptomycin (lOOfiq ml ). The
artery was then transferred to a plastic container which
had been sterilised using 100% ethanol the previous day and
which contained the above sterile saline. The container
was then transferred to the laboratory and subsequent
procedures undertaken in a laminar flow hood (Flow
laboratories). The end of the artery, which was originally
proximal to the heart, was ligated and, at the other end,
one of the two branches of the artery was clamped with 2
- 54 -
V ' ,
Figure 3.1 Differential interference contrast micrographs 
of primary cultures of bovine aortic endothelial cells, 
isolated by collagenase treatment. The cells are isolated 
as clumps, and adhere to the underlying substrate within 24 
hours (a). They subsequently divide and multiply to form a 
strict monolayer which displays the characteristic 
cobblestone appearance of the vascular endothelium. A 
confluent monolayer obtained 3 days after isolation is 
shown (b).
artery forceps. The second branch was then cannulated with 
a syringe and adaptor containing 10ml of sterile 
collagenase solution (type II, sigma; 0.1% in DMEM). The 
collagenase solution was infused into the lumen and the 
vessel incubated at 37 C for 25 minutes in an atmosphere of 
5% C02/95% air. At the end of this incubation period the 
artery was gently massaged and the resulting cell 
suspension collected. Sterile saline (10ml) was then 
infused into the vessel lumen and the remaining cells 
harvested. Following centrifugation (200g; 4 min; 10°C), 
the resulting cell pellet was resuspended in 50ml of
complete medium and the cell suspension was seeded into 2
2 . .or 3 80cm culture flasks (Gibco). With BPAEC, thymidine
-5(10 M) was included m  the complete medium, as this 
supplement was found to aid healthy cellular growth. Use 
of this supplement has also been proposed by Laskey and 
co-workers (1990). The flasks were then placed in an 
incubator (Flow laboratories) in an atmosphere of 5% CC>2 
and 95% air. The medium was changed the day after 
isolation and every 2-3 days subsequently. Confluence was 
reached after 3-6 days. The cells displayed the 
characteristic endothelial "cobblestone" morphology.
3.2 Measurement of Calcium Using Fur a-2
3.2.1 Principles of measuring calcium concentrations 
( rca2+l) using quin 2 and fura-2 
Development of the fluorescent calcium indicator, quin 2 
(Figure 3.2), by Tsien and co-workers (1982a, b) allowed
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Figure 3.2 Structure of quin 2 acid.
the first measurement of cytoplasmic calcium concentration 
2+ .
([Ca ]i) m  populations of small mammalian cells. Quin-2
has calcium-binding properties, as its structure is derived
from EGTA, a calcium chelator, and fluorescence properties,
due to attached fluorophores. The suitability of quin 2 to
act as a calcium indicator stems from its ability to sense
2+changes m  [Ca ]i in the physiological range (nM-/xM).
Although quin 2 itself cannot enter cells, it may be loaded
into cells using a membrane-permeant ester derivative.
This is hydrolyzed by cystosolic esterases to the
membrane-impermeant quin 2 anion, thus leaving the
2+fluorescent dye trapped m  the cystosol. [Ca ]i may be
evaluated by excitation at a wavelength of 339nm with
fluorescence emission collected at 492nm, with increases in
2+ .fluorescence being proportional to increases in [Ca ]i.
Although the development of quin 2 was a major step
forward, its use has several limitations. For example,
quin 2 does not undergo much of a shift in excitation
(Figure 3.3) or emission wavelength upon the binding of
2+  •calcium. Hence, as measurement of [Ca ]i with quin 2 is 
wholly dependent on absolute fluorescence changes, errors 
may arise due to changes in fluorescence which are 
independent of changes in [Ca^+]i. These variable factors 
include cellular concentrations of quin 2, cell thickness 
in the beam pathway, photobleaching and the intensity and 
stability of the illumination source. Furthermore, the 
extinction coefficient and quantum yield of quin 2 are low 
and this necessitates a high cytosolic dye concentration,
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Figure 3.3 Excitation spectrum illustrating the spectral 
characteristics of quin 2 acid in the presence of ImM 
calcium (solid line) and in the absence of calcium (broken 
line). Emission was collected at 492nm.
which may result in the buffering of calcium transients. 
The high affinity of quin 2 for calcium allows accurate 
measurement of [Ca2+]i near resting levels of lOOnM but, at 
near micromolar levels, the dye approaches saturation and 
resolution of the signal is lost.
More recently, the development of a new class of calcium 
indicators, including fura-2, has overcome some of the 
problems associated with quin 2 (Grynkiewicz et al., 1985). 
In this study, measurement of calcium was routinely 
undertaken using the fluorescent probe, fura-2. Fura-2, 
like quin 2, has the ion binding properties of bivalent ion 
chelators (e.g. EGTA) in addition to attached fluorophores. 
The structure of fura -2 is illustrated in Figure 3.4. The 
improved ability of fura-2 over quin 2 depends upon its 
ability to alter its special properties and to increase in 
fluorescence emission upon calcium binding. Like quin 2, 
fura-2 is a charged molecule at physiological pH and does 
not readily pass through the cell membrane. However, the 
incorporation of five acetoxymethylester (AM) groups onto 
the carboxylate functional groups of fura-2 produces a 
molecule which will readily diffuse across the cell 
membrane; the structure of fura-2/AM is illustrated in 
Figure 3.5. The hydrolysis of the AM functional groups 
leads to the cytosolic production of calcium—sensitive 
fura—2. This process is illustrated schematically in 
Figure 3.6. In the absence of calcium, fura-2 fluorescence 
emission (measured at 509nm) consists of a large, 
featureless band with peak fluorescence produced at an
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Figure 3.4 Structure of fura-2 acid.
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Figure 3.5 Structure of fura-2 penta-acetoxymethylester 
(fura-2/AM)
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Figure 3.6 Diagrammatic representation of the cellular
loading of fura-2. The membrane-permeant fura-2 pentac- 
acetoxymethylester (fura-2/AM) enters the cytoplasm and is 
hydrolysed by cytosolic esterases to yield the calcium- 
sensitive form of the indicator, fura-2 acid, which is 
trapped within the cells.
excitation wavelength of 360-370nm (Figure 3.7). Binding 
of calcium shifts the peak wavelength of the fura-2 
excitation spectrum to 340-350nm (Figure 3.7). Saturation 
of the dye with calcium results in a 3-fold rise in 
fluorescence emission excitation at 340nm and a 10-fold 
fall in fluorescence emission following excitation at 
380nm. The calcium concentration is defined absolutely by 
the ratio of emissions obtained following excitation at 
340nm (F34g) anc* 380nm (F3go^* These changes provide the 
basis for the measurement of calcium using ratio mode
(Grynkiewicz et al., 1985). Using this procedure, as the
2+calcium concentration ([Ca ]) increases, the ratio (R) of 
the dye's fluorescence intensities, F0/ir. and Foork, alsoJ 4 U JoU
increases. The experimental ratio (R) is independent of 
potentially variable factors such as the degree of dye 
loading or instrumental factors, changes in cell thickness 
and photobleaching.
Experimentally derived ratios (R) may then be inserted into 
the equation derived by Grynkiewicz et al. (1985):
Equation 1: [Ca2+] = ^^min^ (sf2)
' (R^=R) ' (Sb2)
2+
Where K n is the dissociation constant for the Ca — fura—2 
d
complex; Rmax is the maximal ratio (F340 : F380^ obtained
in saturating levels of calcium; Fmj[n the minimal ratio
( f f ) obtained in zero calcium, Sf2 is the
k 340 • 380
fluorescence emission measured at an excitation wavelength
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Figure 3.7 Excitation spectrum of fura-2 acid in the 
presence of saturating levels of calcium. HEPES 
(lOmM)-buffered Krebs containing 0.25/iM fura-2 acid and ImM 
calcium was placed in a quartz cuvette. This level of 
calcium saturated the fura-2 calcium binding sites and the 
resultant excitation spectrum is shown by the solid line. 
Fluorescence emission was collected at 509nm. Subsequent 
addition of EGTA (40mM) chelated calcium and converted 
fura-2 to the calcium-free form. The resultant excitation 
spectrum is shown by the broken line. Fluorescence 
emission was again collected at 509nm.
of 380nm in the absence of calcium and Sb2 is the 
fluorescence emission measured at an excitation wavelength 
of 380nm in the presence of saturating calcium. When these 
calibration values are required for either fura-2 in 
solution or for fura-2-loaded cells, it is desirable to 
experimentally calculate these parameters for a given 
fluorimeter, due to possible instrumental variability.
To calculate these parameters, Krebs containing (mM) : NaCl 
118, KCL 4.8, MgSO. 1, NaHCO. 2.4, glucose 11, HEPES 10, 
CaCl2 1 and fura-2 0.00025 was added to a quartz cuvette 
and placed in a Perkin-Elmer LS-3B fluorimeter. The 
cuvette was thermostatically controlled at 37°C and the 
solution was stirred continuously. Data was collected and 
processed via an IBM-PCAT and fluorescence emission was 
measured at 509nm at all times. A diagrammatic 
representation of the experimental set-up is illustrated in 
Figure 3.8. At this calcium concentration (ImM), the 
fura-2 dye was saturated with calcium and Rmax (the F34Q : 
Foon, in saturating calcium) was obtained. Figure 3.7
J o U
illustrates the excitation spectrum of fura-2 obtained 
experimentally, in buffer containing ImM calcium. Addition 
of EGTA (40mM) chelates calcium and therefore removes 
calcium from the fura-2 binding sites. The excitation 
spectrum in calcium-free conditions is illustrated in 
Figure 3.7, and from this, Rm^n (^340 : F380 zero Ca2  ^
was obtained. These derived values for Rmax anc* Rmin 
require to be corrected as they include a contribution from 
auto-fluorescence, a background fluorescence derived from
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Figure 3.8 Diagrammatic representation of the
experimental apparatus for measuring [Ca] in solution or
2+  •[Ca ]i m  the endothelium. The cuvettes are
interchangeable as denoted by the double-headed arrow.
2 +When endothelial [Ca ]i was measured, fura-2-loaded 
monolayers of endothelial cells were suspended in a quartz 
cuvette containing HEPES (lOmM)-buffered Krebs and 
maintained at 37°C in a Perkin-Elmer LS-3B fluorimeter. 
The excitation monochromator was under computer control 
(IBM-PCAT) and was driven between 34Onm and 38Onm every 
3.8s. Fluorescence emission data was collected at 509nm 
and stored in the computer. At the end of the experiment, 
[Ca2+]i was calculated from the fluorescence data.
the cuvette, buffer solutions and fluorimeter optics.
Cells, if included, will also contribute to
auto-fluorescence. To obtain correct values for R andmax
Rmin' ^  imPortant to calculate this auto-fluorescence. 
This can be done utilising the ability of manganese (Mn2+) 
to quench fura-2 fluorescence (Grynkiewicz et al., 1985). 
Therefore, at the end of each calibration, Mn2+ (200mM) is 
added to the fura-2/EGTA containing buffer to quench fura-2
fluorescence. AF and AF , the resultant
j 4 U JoO
auto-fluorescence values at 340nm and 380nm, respectively, 
were then subtracted from the raw F_.. and F00_ data and
j4U jou
the corrected ratios for ILr and R . subsequentlywax m m  ^
calculated. Using this procesure, the following 
experimentally-derived values were obtained. Rmax was I5*3 
+ 0.1 (n=4) and R . was 0.73 + 0.01 (n=4). Sf2/Sb2 is the_ \ I min _ \ /
ratio of the corrected Foor. in zero calcium to theJoU
corrected Foon in saturating calcium and was 5.65 ± 0.06
joU
(n=4).
3.2.2 Calculation of fCa2+l in experimental buffers 
Certain experimental protocols required the use of buffers 
containing low concentrations of calcium and it was
important to determine precisely the free calcium 
concentrations ([Ca2+]) present. The calcium contents of 
these buffers were (a) nominally calcium—free, (b) 
nominally calcium-free, plus 0.5mM EGTA, (c) ImM calcium 
plus 2mM EGTA and (d) ImM calcium plus 5mM EGTA. Fura-2 is 
able to detect changes in [Ca2+] in the range lOnM - 3/iM 
(Grynkiewicz et al., 1985) and was therefore used to
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2+calculate [Ca ] in these situations. In each case, the
Krebs buffer contained the following (mM) : NaCl 118, KCL
4.8, NaHC03 2.4, MgSC>4 1, glucose 11 and HEPES 10. Each
Krebs solution was placed in a quartz cuvette, maintained
at 37°C, and stirred continuously. Fura-2 acid (0.25/xM)
was then introduced into the cuvette and uncorrected F-.^ ,340
and F38q values were obtained. This fluorescence data was 
stored in the computer (IBM-PCAT). Subsequent addition of 
manganese chloride (40mM) quenched the fura-2 fluorescence 
leaving the auto-fluorescence. These values (AF..., AFoor.)
J 4U J o u
were then subtracted from the F and F values obtained
J 4 U  j o U
for the experimental ratio, to provide a corrected ratio
(R). The values for R , R . and Sf2/Sb2 (as determinedv ' max' m m  ' '
in section 3.2.1) were substituted into equation 1 (K^ was 
assumed to be 224nM at 37°C [Grynkiewicz et al., 1985]). 
An accurate estimate of the actual calcium concentration 
present in each of the Krebs buffers could then be
calculated, using the corrected f 34q :F380 rat:*-os *
2+[Ca ]
Added
Nominally "Ca^-free" 
Nominally "Ca -free" 
ImM Ca^
ImM Ca
Actual
[EGTA] [Ca ]
Added present
659 ± 3nM (n=4)
0.5mM 12 ± InM (n=4)
2mM 506 ± 30nM (n=4)
5mM 101 ± 2nM (n=4)
3.2.3 Preparation of endothelial cells for fura-2— loading
Upon attaining confluence (3-5 days after initial
isolation, primary cultures of BAEC or BPAEC were passaged,
2
i.e. the culture medium was decanted and the flask (80cm ) 
of endothelial cells was rinsed twice with 20ml of sterile
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saline. 10ml of an isotonic solution of trypsin (0.05%) 
and EDTA (0.02%) (Flow laboratories) was introduced into 
the flask and the cells incubated at 37°C until all of the 
cells had detached (usually 2-4 min). The cell suspension 
was combined with 2ml of newborn calf serum (NBCS, Gibco) 
to neutralise the action of the trypsin and the suspension 
washed by spinning twice at 200g for 4 min (10°C) followed 
by suspension in whole medium. Cells were finally 
resuspended in 10ml of complete medium. As stated 
previously (section 3.1.2), thymidine (10~5M) was included 
in the culture medium for BPAEC. Volumes of 0.5ml of the 
cell suspension were seeded onto sterile glass coverslips 
(11x42mm; No.2) which were placed in individual petri 
dishes (60x15mm? Gibco). After 60 min, the cells had 
attached to the coverslip and 5ml of complete medium was 
added to each petri dish. This medium was replaced every 3 
days. Figures 3.9a and 3.9b illustrate the cell density of 
BAEC 1 day and 3 days after seeding, respectively. The 
cells were used upon reaching confluence, typically after 
3-4 days.
3.2.4 Loading of endothelial cells with fura-2 and
2+  •measurement of TCa li 
Confluent endothelial monolayers, grown on coverslips as 
indicated above 3.2.3 were placed in a petri dish 
containing 4ml of HEPES(2OmM)-buffered DMEM (Northumbria 
Biologicals, Cramlington, UK) containing 1% bovine serum 
albumin (BSA; Fraction V, Sigma) and 2/xM fura-2/AM and 
incubated at 37°C for 45 min. Placing the petri dish on an
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Figure 3 . 9 Differential interference contrast micrographs 
of first passage bovine aortic endothelial cells, cultured 
on the glass coverslips used for fluorescence studies. The 
micrographs illustrate (a) cells at low density, 24 hours 
after passaging and (b) a confluent monolayer of cells, 3 
days after passaging.
orbital shaker (Luckham), at a low speed setting, ensured 
that the medium was mixed continuously. At the end of this 
loading period, the cells were transferred to 
HEPES-buffered Krebs containing (mM) :NaCl 118, KCL 4.8, 
NaHC03 2.4, MgSC>4 1, HEPES 10 and glucose 11. CaCl^ was 
added at the concentrations indicated in the Results. In 
experiments where nickel chloride (NiCl ) was used, NaHCOZ J
was omitted and MgSC>4 replaced with MgCl2 (ImM) to avoid 
the precipitation of these salts with nickel. The cells 
remained in the HEPES(lOmM) -buffered Krebs for 20 min at 
room temperature? this allowed extracellular fura-2/AM to 
be washed from the cells and for intracellular fura-2/AM to 
be hydrolyzed to the calcium-sensitive fura-2 acid. 
Fura-2-loaded endothelial monolayers were suspended across 
the diagonal of a quartz cuvette containing 4ml of the same 
HEPES(lOmM)-buffered Krebs. The cuvette was transferred to 
a Perkin-Elmer LS-3B fluorimeter and the coverslip 
positioned at an angle of 30° to the excitation beam. This 
angle minimises the scattering of incident light towards 
the emission monochromator. The cuvette was maintained at 
37°C and stirred continuously throughout the experiment. 
The excitation monochromator was computer-driven (IBM-PCAT) 
and alternated between 340nm and 380nm every 3.8s. 
Fluorescence emission was collected at 509nm. Drugs were 
added to the cuvette in small volumes (typically 4-8/il). 
Data collection was stopped immediately before and directly 
after addition of drugs, so as to reduce artefacts 
associated with exposing the emission monochromator to 
ambient light. At the end of each experimental run,
- 63 -
background auto-fluorescence was obtained by the method of 
Hallam et al. (1988a), which requires the addition of 
ionomycin (1/xM) to permeabilise the cells to divalent 
cations and the subsequent addition of MnCl2 (2mM) to 
quench intracellular fura-2 fluorescence. The corrected 
fura-2 fluorescence values obtained at 340nm were divided 
by those obtained at 380nm, giving a corrected ratio (R), 
as indicated in section 3.2.1.
3.2.5 Calibration of endothelial fCa2+li
2+Havmg obtained corrected values for the ratio (R), [Ca ]i 
was then calculated by the computer using the equation of 
Grynkiewicz et al. (1985):
It was important to experimentally obtain values for Rmax* 
R . , Sf2 and Sb2 in fura-2-loaded endothelial cells, asm i n f
the spectral characteristics of the dye in the cytoplasm 
may differ from those obtained in a simple buffer solution.
The fluorescence properties of fura-2 were determined in 
endothelial cell suspension rather than in cells on 
coverslips as the low calcium concentrations required to 
obtain would have resulted in detachment of cells.
Cell suspensions were obtained by treating a flask of 
confluent BAEC with 10ml of an isotonic solution of trypsin 
(0.05%) and EDTA (0.02%) (Flow laboratories, Irvine, UK).
Equation 1: [Ca2+]i = min
max
. J.11 • _____
-R) (Sb2)
i J  (sf2>
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Following detachment of the endothelial cells, typically 
after 2-4 minutes, the effects of trypsin were neutralised 
by the addition of 2ml of NBCS. After twice spinning
(200g; 4 min; 10 C) the cells and resuspending in whole
medium, one guarter of the cell suspension (approximately 3
g
x 10 cells) was spun again and resuspended in 1ml of
HEPES (20mM) -DMEM containing 1% BSA and 2juM fura-2/AM.
After incubation at 37°C for 45 min, the cell suspension
was diluted ten-fold with HEPES (2 OmM)-DMEM and, after
spinning (200g; 4 min; 10°C), the cells were resuspended in
10ml of Krebs containing (mM) : NaCl 118, KC1 4.8, MgSO 1,
NaHCC>3 2.4, glucose 11, HEPES 10 and CaCl2 1.8. Following
incubation of the fura-2-loaded cell suspension for 20 min
at room temperature, the cells were spun again (200g; 4
min; 10°C) to remove any extracellular fura-2, resuspended
in 2ml of the same HEPES (1 OmM)-buffered Krebs and
transferred to a quartz cuvette. The cuvette was
maintained at 37 °C in the fluorimeter and stirred
continuously. The trace from a typical experimental
calibration run is shown in Figure 3.10. The excitation
wavelength was alternated between 340nm and 380nm every 3.8
seconds and fluorescence emission collected at 509nm.
Addition of ATP(30/zM), a receptor-mediated agonist,
increased fluorescence following excitation at 340nm ( F ^ q )
and reduced fluorescence following excitation at 380nm
(F ). Ionomycin (8/iM), a bivalent cation ionophore which 
380
translocates calcium across the cell membrane leading to 
saturation of the fura-2 with calcium, increased F34Q bo a 
maximum value and reduced F38q bo a minimal value. After
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Figure 3^ _10 Experimental trace illustrating the
fluorescence changes which occur during an experimental 
calibration. Approximately 3xl06 BAEC were loaded with 
fura-2, suspended in 2ml of HEPES (1 OmM)-buffered Krebs in 
a quartz cuvette and maintained at 37°C in a Perkin-Elmer 
LS-3B fluorimeter. The excitation wavelength was 
alternated between 340nm and 380nm every 3.8s and 
fluorescence emission was collected at 509nm. Addition of 
ATP (30 /iM) increased fluorescence following excitation at 
340nm(F34Q) and reduced fluorescence following excitation 
at 380nm (F_on). Ionomycin (SjuM), a divalent cation
j o U
ionophore, increased F34Q to a maximum level and reduced 
F to a minimum level. At this point, the ratio
j o u
F^,:F,nn yielded the R for fura-2. Addition of EGTA 340 380 J max
(40mM) stripped calcium from fura-2 binding sites, 
resulting in F34Q falling to a minimum level and F38Q 
rising to a maximum level. At this point, the ratio
F340:F380 yielded the Rmin for fura“2* Addition of 
manganese chloride (Mn^+; 200mM) quenched fura-2
fluorescence leaving only background auto-fluorescence. 
This could then be subtracted from the F34Q and F38Q values 
to obtain a corrected ratio (R) for each experimental 
time-point.
the subtraction of auto-fluorescence, the ratio F340:F380'
at this time point, yields Rmax- Addition of EGTA (40mM)
chelated extracellular calcium and stripped intracellular
calcium from fura-2 binding sites. F34Q fell to a minimal
value while F380 rose to a maximum value. After
subtraction of auto-fluorescence, the ratio at340 380
this point yielded R . . The EGTA stock solution alsom m
contained sodium hydroxide (2M) to ensure that the final pH
of the HEPES(1OmM)-buffered Krebs was greater than 8.3.
This high pH aids the dissociation of calcium ions from
intracellular fura-2 binding sites. MnCl2 (200mM) was then
added to quench fura-2 fluorescence and yield
auto-fluorescence values at 340nm and 380nm; these were
then subtracted from the raw fluorescence data to yield
corrected R , R . , Sf2 and Sb2 values. The following max' min'
values were obtained: R 16.3 + 1.2 (n=4), R ._ 0.81 ±max — v m m
0.05 (n=4) and Sf2/Sb2 7.3 ± 0.6 (n=4). These calibration 
parameters are similar to those obtained by Hallam and 
Pearson (1986) and were used in all subsequent experiments.
3.3 Endothelial Barrier Function
3.3.1 Evaluation of endothelial barrier function 
The vascular endothelium acts as a barrier to the passage 
of high molecular weight molecules. Barrier function was 
investigated using an in vitro model, represented 
diagrammatically in Figure 3.11, in which endothelial cells 
were grown on Costar Transwells. This is a two chamber 
model, consisting of an upper and a lower chamber,
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Figure 3.11 Diagrammatic representation of a transwell 
filter unit. First passage bovine pulmonary artery 
endothelial cells were cultured on polycarbonate membrane 
filters (pore size 3/jlM) for 3 days. At the end of this 
period, the lower chamber was filled with physiological 
salt solution (PSS), typically HEPES (5mM)-buffered Krebs, 
and the upper chamber with the same buffer but containing 
trypan blue-labelled albumin (4%). Volumes were chosen 
which avoided the formation of a hydrostatic gradient and 
drugs were added to both the upper and lower chambers. The 
transwells were then agitated on an orbital shaker for 
90min and, at the end of this period, a sample was removed 
from the lower chamber and the transfer of trypan 
blue-labelled albumin assessed colourimetrically at 590nm.
representing the luminal and abluminal sides of the blood 
vessel, respectively. Endothelial cells grown on the 
polycarbonate membrane filter (pore size 3/iM; diameter of 
filter area 6.5mm) restrict the movement of high molecular 
weight markers from the upper to the lower compartment. 
Trypan-blue labelled albumin was used as the high molecular
weight marker, although others, such as dextran or
125I-labelled albumin, have also been used by other 
workers. (Minnear et al., 1989; Stelzner et al., 1989)
3.3.2 Preparation of BPAEC monolayers for permeability 
studies
2
Upon reaching confluence, 2 flasks (80cm ) of BPAEC were 
washed twice with 20ml of sterile saline and each flask 
incubated with 10ml of a solution of trypsin (0.05%) and 
EDTA (0.02%) (Flow laboratories), usually for 2-4 minutes, 
until all cells had detached. The resultant cell 
suspension was combined with 2ml of newborn calf serum to 
inhibit the trypsin. After the cells had been twice spun 
down (200g; 4 min; 10°C) and washed in 10ml of complete
medium, the cells were resuspended in 5ml of complete 
medium. lml of complete medium was added to the lower 
chamber of each transwell and the accompanying 
polycarbonate filter placed on top. 100/zl of the 
suspension of BPAEC was then added to the upper chamber of 
each transwell (48 filter units in total). The BPAEC were 
then incubated for 3 days at 37°C in an atmosphere of 95-s
air/5% CO . At the end of this period, endothelial barrier
2
function was assessed.
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3-3.3 Preparation..of trypan-blue labelled albumin complex 
Trypan blue (180mg) and bovine serum albumin (4g) were
dissolved in 100ml of Krebs containing (mM) : NaCl 118, KC1
4.8, MgSC>4 1, KH2P04 1.2, NaHCO^ 2.4, glucose 11 and HEPES 
5. This yielded a stable complex with an absorption 
maximum at 590nm (>99% of the trypan-blue was protein
bound, as determined by precipitation with 6%
trichloroacetic acid).
3.3.4 Assessment of albumin diffusion across endothelial 
monolayers
BPAEC monolayers grown on Costar Transwells were washed 
gently in HEPES(5mM)-buffered Krebs (as used for the 
preparation of trypan-blue labelled albumin) at 37°C. The 
monolayers were transferred to a 24 well plate, 600jtfl of 
HEPES (5mM)-buffered Krebs was placed in the lower chamber 
and lOOjul of the trypan-blue labelled albumin (4%) complex 
in the upper chamber. These volumes were chosen to avoid 
producing a hydrostatic gradient. Drug additions were made
to both the lower and upper chambers. The plate was then
incubated at 37 °C in air and continuously agitated on an 
orbital shaker (Luckham) for 90min. At the end of this 
period, lOOjul aliquots were sampled from the lower chamber 
and transferred to plastic cuvettes.
3.3.5 Quantification of albumin diffusion.
On completion of an experiment, the 100/il lower chamber 
samples were combined with 900/zl of HEPES (5mM) -buffered 
Krebs. The passage of trypan-blue labelled albumin into
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the lower chamber was assessed colourimetrically in a dual 
beam spectrophotometer (Shimadzu) at 590nm and expressed as 
a percentage of the value that would have been obtained if 
full equilibration had occurred. lml of HEPES-buffered 
Krebs was used as the reference sample (0% standard), the 
100% equilibration standard was prepared by adding 14.3/xl 
of trypan-blue labelled albumin (4%) to 985.7/il of 
HEPES(5mM)-buffered Krebs.
3.4 Materials
3.4.1 Tissue culture reagents and materials 
DMEM, foetal calf serum, newborn calf serum, glutamine and 
penicillin/streptomycin were all obtained from Gibco, 
Paisley, UK. HEPES (2OmM)-buffered DMEM was obtained from 
Northumbria Biologicals, Cramlington, UK. Trypsin/EDTA was 
obtained from Flow laboratories, Irvine, UK., bovine serum 
albumin (BSA), collagenase (type II) and thymidine were 
obtained from Sigma, Poole, UK. Collagenase was dissolved 
in DMEM, yielding a 0.1% solution, and sterilised by 
filtration through millipore filters (0.2/iM; Flow 
laboratories) .
A stock solution of thymidine (10 M^) was prepared in 
distilled water and sterilised by filtration through 
millipore filters (0.2juM; Flow laboratories). Tissue 
culture flasks and petri dishes were obtained from life 
technologies, Uxbridge, UK. Costar Transwells were 
obtained from Northumbria Biologicals, Cramlington, UK.
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Sterile centrifuge tubes (15ml and 50ml) were obtained from 
Falcon (UK). Sterile saline (0.9% w/v) was obtained from 
Baxter Health Care, Thetford, UK. Cylinders of 5% C02/95% 
air were obtained from B.O.C., Ltd. (UK).
3.4.2 Drugs
Adenosine triphosphate (ATP? sodium salt), atriopeptin II, 
bradykinin triacetate, 8 bromo cyclic 3Ai57 guanosine 
monophosphate, caffeine, ethylene glycol (B-aminoethyl 
ethane) N, N, N', N' - tetracetic acid (EGTA), histamine 
diphosphate, (±) isoprenaline hemisulphate, lipopoly- 
saccharide (E.coli 055:B5), NG-nitro-L-arginine, 4 o< - 
phorbol 12, 13 didecanoate (4o(- PDD), 4B - phorbol 12 -
myristate 13 - acetate (PMA), sodium nitroprusside,
thrombin (bovine) and 3, 4, 5 - trimethoxybenzoic acid 8 - 
diethylamino acetyl ester (TMB-8) were all obtained from 
Sigma, Poole, Dorset, UK. Forskolin, fura-2 acid, fura-2 
penta-acetoxymethylester (fura-2/AM), ionomycin, pertussis 
toxin, platelet activating factor and staurosporine were 
all obtained from Novabiochem, Cambridge, UK. All other 
reagents were of analytical grade. Stock solution of all 
drugs were made in distilled water, except for forskolin, 
fura-2/AM, ionomycin and staurosporine which were dissolved 
in dimethylsulphoxide (DMSO), 4®(- PDD, PMA and TMB-8 which 
were dissolved in 100% ethanol and caffeine was dissolved 
in HEPES (1 OmM)-buffered Krebs. EGTA was dissolved in 
distilled water, but 2M sodium hydroxide solution was added 
to raise the pH for use in some experimental calibrations.
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In experiments in which [Ca^ ]i was measured, in cells, 
final cuvette concentrations of ethanol and DMSO did not 
exceed 0.1%. In experiments in which endothelial barrier 
function was measured, dilutions of stock solutions were 
made in HEPES (5mM)-buffered Krebs such that final 
concentrations of ethanol and DMSO did not exceed 0.06% and 
0.1%/ respectively.
3.5 Statistical Analysis of Results
Results are expressed as the mean ± s.e. mean and 
comparisons were made by Student's t-test or by the 
Mann-Whitney test when there was unequal variance in the 
samples. A probability of 0.05 or less was considered 
significant.
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RESULTS
CHAPTER A
4.1 Calcium Mobilisation in the Endothelium
4.1.1 Agonist-induced elevations of rca2+li in bovine 
aortic endothelial cells (BAEC’i
The ability of the vascular endothelium to play a major
role in the regulation of blood vessel tone depends, to a
considerable extent, on the release of potent vasodilators
such as prostacyclin (Moncada et al., 1976a) and
endothelium-derived relaxing factor (EDRF; Furchgott &
Zawadzki, 1980). EDRF release is promoted by a diverse
range of mediators, including bradykinin, A23187, substance
P, ATP, histamine and thrombin (Furchgott, 1984). As the
release of both EDRF and prostacyclin appears to be
calcium-dependent (Weksler et al., 1978; Singer & Peach,
1982; Long & Stone, 1985), it is important to consider how
endothelial calcium mobilisation may be modulated by
intracellular messengers. Consequently, the object of this
2+ . ■section was to determine which mediators elevate [Ca ]i in 
cultures of bovine aortic endothelial cells (BAEC) and, 
subsequently, investigate how other second messenger 
systems modulate calcium mobilisation.
4.1.2 Effects of bradvkinin on fCa2+1i in BAEC
In the presence of 1.8mM extracellular calcium, the basal
level of [Ca2+]i in first passage BAEC was 102±3nM (n=89).
2+ •
Bradykinin induced a biphasic elevation of [Ca ]i,
2+ •
consisting of a large, transient elevation of [Ca ]i which
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peaked within 30s, followed by a second component which was
relatively well maintained. This latter component will be
termed the plateau phase of the increase in [Ca2"^"]i (Figure
4.1). The peak of the initial transient elevation of 
2 "t"[Ca ]i and the plateau phase of the increase in [Ca2+]i
reached maximum levels of 917±127nM (n=29) and 230±25nM
(n=29), respectively. Both components were
concentration-dependent between 0.3nM and lOOnM (EC_ =2nM50
for each of the components).
2+ .The elevations of [Ca ]i induced by bradykinin were, in
general, of a biphasic nature; however, in a limited number
of experiments (2 out of 400), bradykinin (0.3nM) induced
2+oscillations of [Ca ]i (Figure 4.2). This observation was 
only made at the lowest concentration of bradykinin 
examined (0.3nM).
The elevation of [Ca2+]i in response to bradykinin (lOOnM) 
was maximal as a second addition of bradykinin (lOOnM) 
produced no further elevation of [Ca2+]i (Figure 4.3).
Addition of bradykinin (lOnM), to fura-2 loaded BAEC, 
resulted in an increase in fluorescence following 
excitation at 340nm, but not at the calcium-insensitive, 
isobestic wavelength of 360nm (Figure 4.4).
4.1.3 Effects of ATP on TCa2+1i in BAEC
In the presence of 1.8mM extracellular calcium, the basal 
level of [Ca2+]i in BAEC, in this set of experiments, was
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Figure 4. ] Bradykinin (BK, 0.3-100nM) induced a
2+ • *concentration-dependent elevation of [Ca ]i in bovine 
aortic endothelial cells, in the presence of 1.8mM 
extracellular calcium. (a) Individual traces showing the 
biphasic nature of the response to bradykinin : a large,
initial transient elevation followed by a lower, more 
sustained component. (b) Concentration-effeet curves show
r r-% 2+ i  •the magnitude of the initial transient increase m  [Ca ]i 
(circles) and the sustained phase (triangles) measured 5min 
after addition of bradykinin. Individual points represent 
the mean of 8-29 observations and vertical bars indicate 
the s.e. mean. Where error bars are not seen, they are 
encompassed within the size of symbols.
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Figure 4.2 At the lowest concentration of bradykinin 
(BK) examined (0.3nM), a small number of monolay 
developed oscillations of [Ca2+]i subsequent to the 
addition of bradykinin. The above trace illustrate 
characteristic oscillations which were observed in 
monolayers of cells.
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Figure 4,  ^ In the presence of 1.8mM extracellular
calcium, bradykinin (BK; lOOnM) induced a biphasic
elevation of [Ca2+]i. During the plateau phase of the
increase in [Ca2+]i, a subsequent addition of bradykinin
2+ •
(lOOnM) had no further effect on [Ca ]i.
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Figure 4.4 Fura-2 loaded bovine aortic endothelial cells 
were excited alternately at 340nm and 360nm and the 
resultant fluorescence collected at 509nm. The 
experimental trace illustrates the change in fluorescence 
emission following excitation at 340nm (solid line), 
with addition of bradykinin (BK; lOnM) resulting in an 
increase in fluorescence emission. In contrast, following 
excitation at 360nm (broken line) (the isobestic 
wavelength), addition of bradykinin (lOnM) resulted in no 
change in fluorescence, demonstrating that changes in 
fluorescence induced by BK only occur at calcium-sensitive 
wavelengths.
98±3nM (n 120). ATP induced a biphasic elevation of 
[Ca2 ]i consisting of a large, initial transient component, 
which peaked within 30s, followed by a well-maintained
plateau phase of [Ca ]i. The peak of the initial
transient elevation of [Ca2+]i and the plateau phase of the
2+mcrease m  [Ca ] reached maximum levels of 959±2nM (n=44) 
and 368+16nM (n=44), respectively. Both components were
concentration-dependent between 0.3juM and 100/xM (Figure
4.5); the EC5Q for the initial, transient component was 
10/iM, while the EC5Q for the plateau phase of the increase 
in [Ca2+]i was 6/xM.
4.1.4 Effects of thrombin on TCa2+li in BAEC
In the presence of 1.8mM extracellular calcium, the basal
2+level of [Ca ]i in BAEC, m  this set of experiments, was
91+5nM (n=38). Thrombin induced a biphasic elevation of
[Ca2+]i consisting of a large, initial transient component, 
which peaked within 30s, followed by a well-maintained
plateau phase of [Ca2+]i (Figure 4.6). The peak of the 
initial transient elevation of [Ca2+]i and the plateau 
phase of the increase in [Ca2+]i reached maximum levels of 
291+30nM (n=20) and 180±13nM (n=20), respectively (Figure
4.6). Both components were concentration-dependent between
0.03U ml”1 and 3U ml”1 (Figure 4.6); the EC5Q for each
-1
component was 0.4U ml
2+ •4.1.5 Effects of lipopolvsaccharide on \Ca ]i m  BAEC
Lipopolysaccharide (LPS) has been shown to induce the 
release of EDRF from BAEC (Salvemini et al., 1989).
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Figure_____4.5 ATP (0. 3juM-100#iM) induced a
2+ f 4 ,
concentration—dependent elevation of [Ca ]i in bovine 
aortic endothelial cells, in the presence of 1.8mM 
extracellular calcium. (a) Individual traces show the 
biphasic nature of the response to ATP : a large, initial
transient elevation followed by a lower, more sustained 
component. (b) Concentration-effeet curves showing the 
magnitude of the initial transient increase in [Ca ]i 
(circles) and the sustained phase (triangles) measured 5min 
after the addition of ATP. Individual points represent the 
mean of 5-42 observations and vertical bars indicate the 
s.e. mean. Where error bars are not seen, they are 
encompassed within the size of the symbols.
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Figure 4.6 Thrombin (THR, 0.03-3U ml"1) induced a
2+ •concentration-dependent elevation of [Ca ]i m  bovine 
aortic endothelial cells, in the presence of 1. 8mM 
extracellular calcium. (a) Individual traces showing the 
biphasic nature of the response to thrombin : a large,
initial transient elevation followed by a lower, more 
sustained component. (b) Concentration-effeet curves 
showing the magnitude of the initial transient increase in 
[Ca2+]i (circles) and the sustained phase (triangles) 
measured 5min after addition of thrombin. Individual 
points represent the mean of 4-20 observations and vertical 
bars indicate the s.e. mean. Where error bars are not 
seen, they are encompassed within the size of the symbols.
Addition of LPS (10/ig ml”1) to BAEC had no effect on 
[Ca ] i in the presence of 1.8mM extracellular calcium 
(n—2) (Figure 4.7). Cellular responsiveness was confirmed 
by the addition of thrombin (1U ml ^) which induced a 
biphasic elevation of [Ca2+]i.
4.1.6 Effects of histamine on fCa2+li in BAEC 
Histamine (IO/liM) had no effect on [Ca2+]i in BAEC (n=2) 
(Figure 4.8). Cellular responsiveness was confirmed by the 
addition of ATP (30/zM) which induced a biphasic elevation 
of [Ca2+]i.
4.1.7 Effects of platelet activating factor fPAF^ on 
rCa2+li in BAEC
PAF (120nM) had no effect on [Ca2+]i in BAEC in the 
presence of l.8mM extracellular calcium (n=l) (Figure 4.9). 
Cellular responsiveness was confirmed by the addition of 
bradykinin (3nM) which induced a biphasic elevation of 
[Ca2+]i.
4.1.8 Effects of ionomvcin on fCa2+1i in BAEC
Ionomycin (IONO; lOnM), a divalent cation ionophore (Liu &
2+ •
Herman, 1978), induced a sustained elevation of [Ca ]i in 
the presence of 1.8mM extracellular calcium (n=3) (Figure 
4.10a). At a higher concentration (8/iM), ionomycin 
increased [Ca2+]i to levels beyond the upper range of 
measurement with fura-2 (approximately 3/zM) (Figure 4.10b).
4.2 Calcium Mobilisation from Intracellular and
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Figure 4.7 Addition of lipopolysaccharide (LPS; 10/zg ml )
to bovine aortic endothelial cells, in the presence of
2+ .
1.8mM extracellular calcium, had no effect on [Ca ]i. 
Cellular responsiveness was confirmed by the addition of 
thrombin (THR; 1U ml*”1), which induced a large, biphasic 
elevation of [Ca2+]i. The lack of effect of LPS on 
[Ca2+]i, illustrated in the above trace, was obtained in 2 
separate experiments.
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Figure* 4.8 Addition of histamine (HIST; 10/M) to bovine
aortic endothelial cells, in the presence of
2 4"
extracellular calcium, had no effect on [Ca ]i- Ce 
responsiveness was confirmed by the addition of ATP (30/xM)
which induced a large, biphasic elevation of [C ]*
. . • rra2+li illustrated in thelack of effect of histamine on [Ca Ji
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Figure 4.Q Addition of platelet activating factor (PAF;
120nM) to bovine aortic endothelial cells, in the presence
2+ ■
of 1.8inM extracellular calcium, had no effect on [Ca ]i. 
Cellular responsiveness was confirmed by the addition of 
bradykinin (BK; 3nM), which induced a large biphasic 
elevation of [Ca2+]i. The effects of PAF were examined 
only once.
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Figure 4.10 Individual traces illustrating the effects of
ionomycin (IONO) on [Ca2+]i in bovine aortic endothelial
cells. Traces (a) and (b) illustrate the effects of
2+ •ionomycin (10nM and 8/iM, respectively) on [Ca ]i in the 
presence of 1.8mM extracellular calcium. In trace (b), the 
concentration of ionomycin (8ptM) added is sufficient to 
saturate the intracellular fura-2 and, therefore, peak 
[Ca2+]i is denoted as infinity. Traces (a) and (b) are 
each representative of 3 and 4 individual experiments,
respectively.
Extracellular Pools
4.2.1 Agonist-induced elevations of fca2+ii in BAEC - 
role—of—intracellular and extracellular calcium 
pools
Agonist-induced elevations of [Ca2+]i may be derived from 2 
calcium pools - the intracellular and the extracellular 
calcium pools. To distinguish between the release of 
calcium from intracellular stores and calcium influx from 
an extracellular pool, two main strategies may be employed? 
firstly, removal of extracellular calcium or chelation of
extracellular calcium using EGTA or, secondly, blockade of
. 2+calcium influx using nickel (Ni ; Hallam et al., 1988b). 
Endothelial cells have no voltage-operated calcium channels 
(Hallam & Pearson, 1986; Colden - Stanfield et al., 1987) 
and, therefore, calcium influx cannot be blocked using 
organic calcium antagonists.
4.2.2 Effects of nickel on bradvkinin-induced elevations 
of rca2+1i in BAEC
• 2+
In human umbilical vein endothelial cells, nickel (Ni ) 
has been previously shown to block calcium influx (Hallam 
et al., 1988b). The use of Ni2+, therefore, enables the 
relative contribution of mobilisation from intracellular 
and extracellular calcium pools to be assessed.
In the presence of 1.8mM extracellular calcium, treatment 
with nickel chloride (4mM, 2min) had no effect on basal 
[Ca2+]i or on the magnitude of the initial transient
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elevation of [Ca ]i induced by bradykinin (0.3nM, lOnM)
but abolished the plateau phase of the increase in [Ca2*^"]i
induced by bradykinin (Figure 4.11). Addition of the
nickel chloride (4mM) during the plateau phase of the
2+ .
increase in [Ca ]i induced by bradykinin (lOnM) resulted 
in the abolition of this component, with [Ca2+]i falling 
rapidly to the original basal level (Figure 4.12).
4.2.3 Effects of lowering extracellular calcium
2+concentration on TCa li in BAEC 
Incubation of BAEC in nominally calcium-free HEPES 
(lOmM)-buffered Krebs for 25 min, followed by addition of 
EGTA (0.5mM) for 5 min, reduced extracellular calcium to 
12+lnM (n=4) and basal levels of [Ca2+]i from 88±6nM (n=ll) 
to 57±8nM (n=16). Re-addition of calcium (2.3mM) restored 
[Ca2+]i to 98±5nM (n=5). Figure 4.13 illustrates a typical 
example of the change in basal [Ca2+]i obtained upon 
addition of EGTA and the re-addition of extracellular 
calcium.
In nominally calcium-free Krebs, in the presence of EGTA
(0.5mM), the magnitude of the initial transient elevation
of [Ca2+]i induced by bradykinin (lOnM) was reduced and the
2+ (
plateau phase of the increase in [Ca ]i was abolished 
(Figure 4.14). In the continued presence of bradykinin, 
the re-addition of extracellular calcium (2.3mM) induced a 
biphasic elevation of [Ca2+]i consisting of a large, 
transient component, followed by a lower, sustained 
component (Figure 4.14).
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Figure 4.11 Individual traces (a) and a histogram (b)
showing basal and bradykinin (BK; 0.3nM and lOnM)
stimulated levels of [Ca2+]i in bovine aortic endothelial
cells, in the presence of 1.8mM extracellular calcium (open
• 24-columns) and following pre-treatment with nickel (Ni ; 
4mM, 2min, solid columns). In the histogram, basal levels 
and the magnitude of the initial transient elevations of 
[Ca2+]i are given as the mean of 4-19 observations and 
vertical bars indicate the s.e. mean.
BK 
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Figure 4-1? in the presence of l.SmH extracellular
calcium, bradykinin (BK; 10nH) induced a biphasic elev
of [Ca2+]i, consisting of a large, initial transxent
elevation of [Ca2+]i, followed by a more sustaxned
2+ •
component (the plateau phase of the increase in [
Addition of nickel (Ni2+; 4mM) during the plateau phase^of 
the increase in [Ca2+]i resulted in a rapid fall m  [Ca ]i 
to near basal levels.
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Figure 4.13 Bovine aortic endothelial cells were
incubated in nominally calcium-free HEPES (lOmM)-buffered 
Krebs for 25 min, followed by addition of EGTA (0.5mM) for 
5 min. The subsequent addition of extracellular calcium
(2. 3mM) resulted in [Ca2+]i rising to a new, sustained
level. The above experimental trace is typical of that
obtained in 5 separate experiments.
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Figure 4.14 Individual traces (a) and a histogram (b)
illustrating the effects of bradykinin (BK; lOnM) on
[Ca2+] i in bovine aortic endothelial cells, in the presence
of 1. 8mM calcium (open column), and following the removal
of extracellular calcium and addition of EGTA (0.5mM, 5min,
2+
solid column) . The effect of re-addition of calcium (Ca ; 
2.3mM) in the continued presence of bradykinin is shown in 
the cross-hatched columns. In the histogram, the magnitude 
of the initial transient elevation of [Ca2+]i is the mean 
of 6 observations and vertical bars indicate the s.e. mean. 
*p<0.05, indicates a significant difference from the 
response to bradykinin in the presence of calcium.
Incubation of BAEC in nominally calcium-free Krebs
containing EGTA (0.5mM) almost completely abolished the
initial transient elevation of [Ca2+]i induced by
bradykinin (InM) and abolished the plateau phase of the
2+ .
increase m  [Ca ]i (Figure 4.15). Subsequent re-addition
of extracellular calcium (2.3mM) induced a biphasic
2+ .elevation of [Ca ]i, the magnitude of both components
being similar to those induced by bradykinin (InM) in the 
presence of 1.8mM extracellular calcium (Figure 4.15).
Incubation of BAEC in nominally calcium-free Krebs
containing EGTA (0.5mM) attenuated the magnitude of the
2+initial transient elevation of [Ca ]i induced by ATP
(100/iM) and abolished the plateau phase of the increase in 
2+ .[Ca ]i (Figure 4.16). In the continued presence of ATP
(100/iM), re-addition of extracellular calcium (2.3mM)
2+induced a biphasic elevation of [Ca ]i, consisting of a 
large, transient component followed by a lower, more 
sustained component (Figure 4.16).
In an attempt to determine the kinetics of the loss of the
2+ .bradykinin-induced transient elevation of [Ca ]i in BAEC,
which occurs in the absence of extracellular calcium, we
examined the effects of the acute addition of EGTA for
different times and at different concentrations. All
experiments were carried out in HEPES (lOmM)-buffered Krebs
containing ImM calcium chloride. In this buffer,
2+ •
bradykinin (lOnM) induced similar elevations of [Ca ]i to 
those obtained in 1.8mM calcium (Figures 4.1 and 4.17). In
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Figure 4.15 Individual traces (a) and histogram (b)
2+ •
illustrating the effects of bradykinin (BK; InM) on [Ca ]i 
in bovine aortic endothelial cells, in the presence of 
1.8mM calcium (open columns) and following the removal of 
extracellular calcium and addition of EGTA (0.5mM, 5min, 
solid column) . The effect of re-addition of calcium 
(Ca2+; 2.3mM) in the continued presence of bradykinin is
shown in the cross-hatched column. In the histogram, the
2+ •
magnitudes of the initial transient elevation of [Ca ]i 
are the mean of 5—7 observations and vertical bars indicate 
the s.e. mean. **p<0.01, indicates a significant 
difference from the response to bradykinin in the presence 
of calcium.
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Figure 4.16 Individual traces (a) and histogram (b)
2+illustrating the effect of ATP (100/iM) on [Ca ]i m  bovine 
aortic endothelial cells, in the presence of 1.8mM calcium 
(open column) and following the removal of extracellular 
calcium and addition of EGTA (0.5mM, 5min, solid column). 
The effect of re-addition of calcium (Ca ; 2.3mM) in the 
continued presence of ATP is shown in the cross-hatched 
column. In the histogram, the magnitudes of the initial 
transient elevation of [Ca2+]i are the mean of 6 
observations and vertical bars indicate the s.e. mean. 
**P<0.01, indicates a significant difference from the 
response to ATP in the presence of calcium.
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Figure 4.17 Individual traces (a) and histogram (b) 
showing the effects of pre-treatment with EGTA (2mM and 
5mM) for 1 min or 10 min on basal and bradykinin (lOnM) - 
stimulated levels of [Ca^+]i in bovine aortic endothelial 
cells, in the presence of ImM extracellular calcium. In 
the histogram, basal levels and the magnitudes of the 
initial transient elevation are given as the mean of 4-16 
observations and vertical bars indicate the s.e. mean. 
*p<0.05 indicates a significant difference from values 
obtained in the presence of ImM extracellular calcium.
the presence of litiM extracellular calcium, addition of EGTA 
(2mM) for 1 min lowered extracellular calcium to 560±30nM, 
slightly reduced basal [Ca2+]i (although not
significantly), reduced the magnitude of the initial
• • 2+transient elevation of [Ca ]i induced by bradykinin (lOnM)
and abolished the plateau phase of the increase in [Ca2+]i 
(Figure 4.17). Exposure of BAEC to EGTA (2mM) for 10 min 
had no effect on resting [Ca2+]i and produced no further
reduction in the magnitude of the bradykinin (lOnM)-induced
2+transient elevation of [Ca ]i than that obtained after 1
min exposure (Figure 4.17). Exposure to a higher
concentration of EGTA (5mM) for 1 min lowered extracellular
calcium to 101+2nM (n=4) and induced a small, but
2+ .significant, fall m  basal [Ca ]i (Figure 4.17). However, 
this higher concentration of EGTA produced no further 
reduction in the magnitude of the bradykinin (lOnM)-induced 
transient elevation of [Ca2+]i than that obtained with a 
concentration of 2mM (Figure 4.17). The effects of higher 
concentrations of EGTA could not be examined since this 
treatment leads to significant detachment of cells from the 
coverslip.
In BAEC bathed in HEPES( lOmM)-buffered Krebs containing
CaCl (ImM) and EGTA (2mM), bradykinin (lOnM) induced a
transient elevation of [Ca2+]i, which returned to basal
levels within 100s (Figure 4.18). Subsequent addition of
2+ •
ionomycin (1/xM) induced a transient elevation of [Ca ]i 
which returned to near basal levels within 200s (Figure
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Figure 4.18 An individual trace showing the effects of
2+ .bradykinin (BK; lOnM) and ionomycin (IONO; 1/zM) on [Ca ]i
in bovine aortic endothelial cells, in the absence of
extracellular calcium. Chelation of extracellular calcium
2+ .with EGTA (2mM) resulted in a small fall in basal [Ca ]i. 
Addition of bradykinin (lOnM) induced a transient elevation 
of [Ca2+]i which returned to basal levels within 100s. 
Subsequent addition of ionomycin (1/iM) induced a transient 
elevation of [Ca2+]i which returned to basal values within 
200s. This trace is representative of 2 experimental 
traces.
4.18). Therefore, ionomycin may release calcium from 
intracellular as well as extracellular stores.
4.2.4 Effects of caffeine on rca2+~|j in BAF.c
The possibility that removal of extracellular calcium
depleted intracellular stores of calcium was tested further
by examining the effects of caffeine, which is known to
promote the release of calcium from these stores (Weber &
Herz, 1968). In the presence of 1.8mM extracellular
calcium, caffeine (5mM) induced a small elevation of
[Ca2+]i (Figure 4.19). Following incubation in nominally
calcium-free Krebs for 25 min, followed by the addition of
EGTA (0.5mM) for 5 min, basal [Ca2+]i was reduced
significantly and the ability of caffeine (5mM) to elevate 
2+ .[Ca ]i was abolished (Figure 4.19).
4.2.5 Effects of TMB-8 on bradvkinin-induced elevations 
of r Ca2+1i in BAEC
In the presence of 1.8mM extracellular calcium, treatment
with TMB-8 (O.lmM), a putative inhibitor of intracellular
calcium release (Malagodi & Chiou, 1974), induced a small
elevation of [Ca2+]i (58±6nM; n=4), but had no effect on
2+  •
the magnitude of the initial transient elevation of [Ca ]i 
induced by bradykinin (3nM) (Figure 4.20).
A more careful analysis of the effects of TMB-8 on the 
release of calcium from intracellular stores was performed 
in nominally calcium-free HEPES(lOmM) -buffered Krebs 
containing EGTA (0.5mM), so as to remove the calcium influx
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Figure 4.1Q Individual traces (a) and histogram (b)
showing the effects of removal of extracellular calcium and
addition of EGTA (0.5mM, 5min) on caffeine-stimulated
levels of [Ca2+]i in bovine aortic endothelial cells. In
2+  •
the histogram, the magnitude of the elevations of [Ca ]i 
induced by caffeine in the absence and presence of 1. 8mM 
extracellular calcium are the mean of 5-7 observations and 
vertical bars indicate the s.e. mean. *p<0.05 indicates a 
significant difference between groups joined by a bracket.
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Figure 4.20 Individual traces (a and b) and a histogram
(c) showing basal and bradykinin (BK; 3nM) - stimulated
levels of [Ca2+]i in bovine aortic endothelial cells, in
the presence of 1.8mM extracellular calcium (open columns)
and following treatment with 3,4,5-trimethoxybenzoic acid
8-(diethylamino) octyl ester (TMB-8; O.lmM, 15min, solid
columns). in the histogram, basal levels and the
2+  •
magnitude of the initial transient elevations of [Ca ]i 
are the mean of 4-8 observations and vertical bars indicate 
the s.e. mean.
component. Even under these conditions, TMB-8 (O.lmM,
3min) had no effect on the transient elevation of [Ca2+]i
induced by bradykinin (lOnM) (Figure 4.21). In the
continued presence of bradykinin (10nM), re-addition of
extracellular calcium (2.3mM) induced a biphasic elevation 
2+of [Ca ]i and this was also completely unaffected in the 
presence of TMB-8 (Figure 4.21).
4.2.6 Effects of procaine on bradykinin-induced
2+mobilisation of TCa 1i
Following incubation in nominally calcium-free HEPES
(lOmM)-buffered Krebs for 25 min, followed by EGTA (0.5mM)
for 5 min, bradykinin (lOnM) induced a transient elevation 
2+ .of [Ca ]i which returned close to basal levels within 90s
(Figure 4.22). Subsequent addition of procaine (ImM), an
inhibitor of calcium-induced calcium release (Weber & Herz,
1968; Saida & van Breemen, 1984), induced an apparent fall
in [Ca2+]i (Figure 4.22). However, procaine (ImM) was
found to reduce fura-2 fluorescence between excitation
wavelengths of 300nm and 350nm (Figure 4.23); this
selective reduction in fluorescence at 340nm, but not
380nm, is likely to account for the apparent fall in
[Ca2+]i. in the continued presence of bradykinin (lOnM)
and procaine (ImM), re-addition of extracellular calcium
2+
(2.3mM) yielded a biphasic elevation of [Ca ]i. The 
inability of procaine to abolish the transient elevation 
obtained upon re-addition of extracellular calcium, 
suggests that this component is not dependent upon 
calcium-induced calcium release.
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Figure 4.21 Bovine aortic endothelial cells were 
incubated in nominally calcium-free Krebs for 25 min 
followed by EGTA (0.5mM) for a further 5 min. The 
individual traces (a) and histogram (b) illustrate the 
effects of pre-treatment with TMB-8 (O.lmM, 3min) on the 
transient elevation of [Ca2+]i induced by bradykinin (BK; 
lOnM) and the magnitude of the initial transient elevation 
of [Ca2+]i obtained upon subsequent re-addition of
extracellular calcium (2.3mM), in the continued presence of
2 +
bradykinin. In the histogram, levels of [Ca ]i in control 
cells (open columns) and in TMB-8 cells (cross-hatched 
columns) are the mean of 4-10 observations and vertical 
bars indicate the s.e. mean.
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Figure A. 7.7. Monolayers of bovine aortic endothelial cells
were incubated in nominally calcium-free HEPES-buf fered
Krebs for 25 min and EGTA (0.5mM) was then added for 5 min.
Addition of bradykinin (BK; lOnM) then induced a transient
elevation of [Ca2+]i and subsequent addition of procaine
2+ •
(PROC; ImM) resulted in an apparent fall in [Ca ]i. In 
the continued presence of bradykinin and procaine, addition 
of extracellular calcium (2.3mM) induced a biphasic 
elevation of [Ca2+]i.
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Figure 4.23 Excitation spectra of fura-2 (0.25/iM) 
HEPES-buffered Krebs containing 1.8mM calcium chloride, 
the presence (broken line) and absence (solid line)
procaine (ImM).
4.3 Effects of Membrane Depolarisation
4.3.1 Effects of membrane depolarisation nn rca2+li in 
BAEC
In both vascular and non—vascular smooth muscle, membrane
depolarisation, induced by high potassium-containing
solutions, results in increased calcium entry via voltage —
operated channels (VOCs) and the subsequent generation of
muscle contraction (Bolton, 1979). As already discussed,
calcium entry in endothelial cells does not occur via VOCs
(Hallam & Pearson, 1986), but more recent studies have
suggested that changes in membrane potential may modulate 
2+ .[Ca ]i m  atrial endocardial endothelial cells (Laskey et
al., 1990). To determine if changes in membrane potential
2+could modulate mobilisation of [Ca ]i in bovine aortic 
endothelial cells, we examined the effects of solutions
containing high concentrations of potassium on basal and
2+ .bradykinin-simulated levels of [Ca ]i.
2+ •4.3.2 Effects of potassium chloride on TCa ]l in BAEC
In the presence of 1.8mM extracellular calcium, addition of
potassium chloride (KC1; 30mM or 60mM, 1 min) to normal,
2+ •isotonic Krebs had no effect on basal [Ca ]i in BAEC
(Figures 4.24 and 4.25). Furthermore, pre-treatment with
KC1 (30mM, 1 min) had no effect on the magnitude of the
2+
bradykinin (lOnM)-induced elevation of [Ca ]i (Figure
4.24). in contrast, pre-treatment with KCl (60mM, 1 min)
significantly inhibited the magnitude of the bradykinin
2+
(10nM)-induced transient elevation of [Ca ]i (Figure
4.25).
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Figure 4.24 Individual traces (a) and a histogram (b)
illustrating the effects of pre-treatment with potassium
2-|-
chloride (KCI; 30mM, lmin) on basal levels of [Ca ]i and 
the magnitude of the initial transient elevation of [ ] ’
induced by bradykinin (BK; lOnM) in bovine
endothelial cells, in the presence of 1.8mM extracellular 
calcium. In the histogram, basal and bradykinin-mduced 
elevations of [Ca2 + ]i in control cells (open columns) and 
in potassium chloride-treated cells (cross-hatched columns) 
are the mean of 5-11 observations and vertical bars
indicate the s.e. mean.
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Figure 4 .7.5 Individual traces (a) and a histogram (b)
illustrating the effects of pre-treatment with potassium
2 4 -
chloride (KCI; 60mM, lmin) on basal levels of [Ca ]i and
2+
the magnitude of the initial transient elevation of [Ca ]i 
induced by bradykinin (BK; lOnM) in bovine aortic 
endothelial cells, in the presence of 1.8mM extracellular 
calcium. In the histogram, basal and bradykinin-induced 
elevations of [Ca2+]i in control cells (open columns) and 
potassium chloride-treated cells (cross-hatched columns) 
are the mean of 4-8 observations and vertical bars indicate 
the s.e. mean. *p<0.05 indicates a significant difference 
between groups joined by a bracket.
Addition of KCI (30mM) during the plateau phase of the 
increase in [Ca Ji induced by bradykinin (lOnM), thrombin 
(1U ml ) and ATP (30/1M) resulted in a transient fall in 
[Ca2 ]i; [Ca ]i returned to pre-KCl levels after 
approximately 90s (Figure 4.26). it is clear from this 
study, that the effects of KCI on calcium mobilisation in 
BAEC are complex.
4.4 Protein Kinase C
4.4.1 Effects of protein kinase C stimulation on [Ca2+li 
in BAEC
The tumour-promoting phorbol esters exert their actions via 
the activation of protein kinase C (Castagna et al., 1982). 
Several studies have demonstrated the ability of phorbol 
esters to inhibit endothelium-dependent relaxation 
(Weinheimer et al., 1986; Lewis & Henderson, 1987; Cherry & 
Gillis, 1988). The inability of the phorbol esters to 
inhibit sodium nitroprusside-induced relaxations (Lewis & 
Henderson, 1987) suggests that these compounds inhibit the 
production, but not the action of endothelial-derived 
relaxing factor (EDRF). Furthermore, the finding that 
endothelium-dependent relaxation induced by the calcium 
ionophore, A23187, is unaffected by phorbol esters 
(Weinheimer et al., 1986; Lewis & Henderson, 1987; Cherry & 
Gillis, 1988) strongly suggests they inhibit EDRF 
production by blocking receptor-mediated calcium 
mobilisation. In this study, the calcium sensitive 
fluorescent probe, fura-2, was used to assess directly
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Figure 4.26 Individual traces illustrating the effects of 
addition of potassium chloride (KCI; 30mM) during the 
plateau phase of the increase in [Ca2+]i induced by 
thrombin (a; THR; 1U ml""1), bradykinin (b; BK; lOnM) and 
ATP (c; 100fiM) in bovine aortic endothelial cells, in the
presence of l.8mM extracellular calcium. Each experiment 
was undertaken on a single occasion.
whether or not phorbol esters could inhibit agonist-induced 
mobilisation of [Ca ]i in bovine aortic endothelial cells.
4.4.2 Effects_._of 46-phorbol 12-mvristate 11-acetate on
thrombin-induced elevations of rca2+li in BAEC
In the presence of 1.8mM extracellular calcium, the basal 
2+ .level of [Ca ]i m  BAEC, in this set of experiments, was
88±5nM (n=37). Pre-treatment with 4B-phorbol 12-myristate
13-acetate (PMA? lOOnM, 5min), an activator of protein
kinase C, had no effect on basal [Ca2+]i (Figure 4.27;
Table 4.1). It did, however, significantly reduce the
2+ .magnitude of the initial transient elevation of [Ca ]i
_ i
induced by thrombin (1U ml ; Figure 4.27; Table 4.1).
Furthermore, addition of PMA (lOOnM) during the plateau
2+phase of the increase in [Ca ]i induced by thrombin (1U 
ml 1) induced a fall in [Ca2+]i of 89±26nM (n=4) (Figure 
4.28) .
4.4.3 Effects of 4B-phorbol 12-mvristate 13-acetate .on
2+ •bradykinin-induced elevations of TCa— ] l in BAEC
In the presence of 1.8mM extracellular calcium,
pre-treatment of BAEC with PMA (lOOnM, 5min) inhibited the
2+ •
magnitude of the initial transient elevation of [Ca ]i 
induced by bradykinin (BK; lnM), but not that induced by 
higher concentrations of bradykinin (3nM and lOnM) (Figures 
4.29 and 4.30).
Addition of PMA (lOOnM) during the plateau phase of the 
increase in [Ca2+]i induced by bradykinin (lnM and lOnM)
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Figure 4.2 7 Individual traces illustrating the effects of 
pre-treatment with 46-phorbol 12-myristate 13-acetate (b; 
PMA; lOOnM, 5min) and 4o<-phorbol 12,13 didecanoate (c; 
4o< -PDD; lOOnM, 5min) on the magnitude of the initial 
transient elevation of [Ca2+]i induced by thrombin (a; THR; 
1U ml"1) in bovine aortic endothelial cells, in the 
presence of 1.8mM extracellular calcium. Traces (a), (b)
and (c) are representative of 20, 10 and 6 experiments,
respectively.
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Figure 4.28 Individual traces (a,b,c) and a histogram (d)
illustrating the effects of pre-treatment with 413-phorbol
12-myristate 13-acetate (PMA; lOOnM) and 4o<-phorbol 12,13
didecanoate (4<<-PDD; lOOnM) and staurosporine on the
2 +plateau phase of the increase in [Ca ]i induced by 
thrombin (THR; 1U ml-1) in bovine aortic endothelial cells,
in the presence of 1.8mM extracellular calcium. In the
2+ •
histogram, a positive value illustrates a rise in [Ca ]i
2+
and a negative value represents a fall in [Ca ]i. The 
results shown are the mean of 4-5 observations, vertical 
bars indicating s.e. mean. *p<0.05 denotes a significant 
difference between groups joined by a bracket.
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Figure 4.29 Concentration-effect curves showing the
2+ .magnitude of the initial transient elevation of [Ca ]i 
induced by bradykinin (BK) and adenosine triphosphate (ATP) 
in bovine aortic endothelial cells in the absence (squares) 
and presence (triangles) of 46-phorbol 12-myristate
13-acetate (PMA; lOOnM, 5min). All experiments were 
undertaken in the presence of 1.8mM extracellular calcium. 
Individual points represent the mean of 4-10 observations 
and vertical bars represent the s.e. mean. Where the error 
bars are not seen, they are encompassed within the symbols. 
*p<0.05, **p<0.01, indicates a significant difference from
the response obtained in the absence of PMA.
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Figure d.3 0 Individual traces illustrating the effects of
pre-treatment with 46-phorbol 12-myristate 13-acetate (PMA, 
lOOnM, 5min) on the magnitude of the initial transient 
elevation of [Ca2+]i induced by bradykinin (BK; lnM, 3nM, 
lOnM) in bovine aortic endothelial cells, in the presence 
of 1.8mM extracellular calcium.
Table 4.1
Stimulus Pre-treatment [Ca2+]i n
None (Control) None 88+5nM 37
None PMA(lOOnM) 97±9nM 10
None STSP(lOOnM) 102±7nM 13
None PMA( lOOnM)
+STSP(lOOnM) 122±4nM # 7
THR(1U ml”1)(Control) None 3 3 3±29nM - * 14
THR(1U ml”1) PMA(lOOnM) 191±20nM —
** 10
THR(1U ml”1) STSP(lOOnM) 274±34nM 6
THR(1U ml”1) PMA(lOOnM)
*
+STSP(lOOnM) 274±24nM — 9
Bovine aortic endothelial cells were pre-treated with 
either 4B-phorbol 12-myristate 13-acetate (PMA; lOOnM, 
5min), staurosporine (STSP; lOOnM, 5min) or with a
combination of STSP (lOOnM, lOmin) and PMA (lOOnM, 5min).
2+ •
The effects of these pre-treatments on both basal [Ca ]i 
and the magnitude of the initial transient elevation 
[Ca2+]i induced by thrombin (THR; 1U ml'1) are shown. 
Values are the mean ± s.e.mean. *p<0.05; ***p<0.01 denotes 
a significant difference from the control or a difference 
between groups joined by a bracket.
induced falls in [Ca ]i of 37+4nM (n=6) and 35+l4nM (n=4)/ 
respectively (Figure 4.31).
4-4.4 Effects of 4B-phorbol 12-myristate 13-acetate on 
ATP-induced elevations of rca2+)i in BAEC 
In the presence of 1.8raM extracellular calcium, 
pre-treatment of BAEC with PMA (lOOnM, 5min) inhibited the 
magnitude of the initial transient elevation of [Ca2+]i 
induced by ATP (0.3/iM and 3/zM), but not those induced by 
higher concentrations of ATP (30/jM and 100/iM) (Figures 4.29 
and 4.32).
Addition of PMA (lOOnM) during the plateau phase of the 
2+ . .increase m  [Ca ]i induced by ATP (0.3/xM and 30/4M) induced 
falls in [Ca2+]i of 71±14nM (n=4) and 161+29nM (n=4),
respectively (Figure 4.33).
4.4.5 Effects of staurosporine on fCa2+li in BAEC
Staurosporine, an inhibitor of protein kinase C (Tamaoki et
al., 1986) was used to determine whether PMA exerts its
actions via protein kinase C and whether agonist-induced
2+ •protein kinase C activation may modulate [Ca ]i in BAEC.
In the presence of 1.8mM extracellular calcium, treatment 
with staurosporine (lOOnM, 5min) had no effect on basal
levels of [Ca2+]i or on the magnitude of the thrombin-
2+
induced initial transient elevation of [Ca ]i (Table 4.1). 
Staurosporine (lOOnM, lOmin) did, however, inhibit the 
ability of PMA (lOOnM, 5min) to attenuate the thrombin- 
induced transient elevation of [Ca ]i (Table 4.1).
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Figure 4.31 Individual traces illustrating the effects of
46-phorbol 12-myristate 13-acetate (PMA; lOOnM) on the
24" •plateau phase of the increase in [Ca ]i induced by 
bradykinin (BK; lOnM, lnM) in bovine aortic endothelial 
cells, in the presence of 1.8mM extracellular calcium. 
Traces (a) and (b) are typical examples of the action of 
PMA and were obtained with 6 and 4 batches of cells, 
respectively.
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Figure 4.3 2 Individual traces illustrating the effects of 
pre-treatment with 4J3-phorbol 12-myristate 13-acetate (PMA; 
lOOnM, 5min) on the magnitude of the initial transient 
elevation of [Ca2+Ji induced by ATP (0.3/iM, 3/xM and 3 0/iM) 
in bovine aortic endothelial cells, in the presence of 
1.8mM extracellular calcium.
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£iqure 4.3 3 Individual traces illustrating the effects of 
46-phorbol 12-myristate 13-acetate (PMA; lOOnM) on the 
plateau phase of the increase in [Ca2+]i induced by ATP 
(30/iM and 0.3/zM) in bovine aortic endothelial cells, in the 
presence of 1.8itiM extracellular calcium. Traces (a) and 
(b) are typical examples of the actions of PMA obtained 
with 4 batches of cells at each concentration of ATP.
In a second series of experiments, staurosporine (lOOnM, 
5i"in) had no effect on basal [Ca2+]i or on the magnitude of 
the initial transient elevation of [Ca2+]i induced by 
bradykinin (lnM) (Figure 4.34).
Staurosporine (lOOnM) added during the plateau phase of the
24- . iincrease m  [Ca ]i induced by thrombin (1U ml”1) and
bradykinin (lOnM) resulted in increases in [Ca2+]i of
10+3nM (n=13) and 43±12nM (n=4), respectively (Figure
4.35). In contrast, staurosporine (lOOnM), induced a fall 
2+ .m  [Ca ]i of 76±14nM (n=4) when added during the plateau
24-phase of the increase in [Ca ]i induced by ATP (30/zM)
(Figure 4.35). Furthermore, staurosporine, when added
24- .during the plateau phase of the increase in [Ca ]i induced 
by thrombin (1U ml”1), reduced the PMA (lOOnM)-induced fall 
in [Ca2+]i to 19±3nM (n=4; Figure 4.28).
From these findings, it is likely that PMA mediates its 
actions through the activation of protein kinase C and that 
agonist-induced activation of protein kinase C may regulate 
[Ca2+]i in BAEC.
4.4.6 Effects of 4Q(-phorbol 12. 13-didecanoate. on
24- •thrombin-induced elevations of [Ca— ] l in BAEC 
4tf-phorbol 12, 13-didecanoate (4«(-PDD) is a phorbol ester 
which does not activate protein kinase C (Castagna et al., 
1982). Consequently, it can be used to determine if the 
actions of PMA are mediated through activation of protein 
kinase C.
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Figure 4.3 4 Individual traces (a) and a histogram (b)
showing the effects of pre-treatment with staurosporine
(STSP; lOOnM, 5 min) on the magnitude of the initial
transient elevation of [Ca^+]i induced by bradykinin in
bovine aortic endothelial cells, in the presence of 1.8mM
extracellular calcium. In the histogram, basal levels and
2+ •
bradykinin (BK; lnM)-induced elevations of [Ca ]i in 
control cells (open column) and staurosporine-treated cells 
(hatched column) are the mean of 4-8 observations and 
vertical bars indicate the s.e. mean.
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Figure 4.35 Individual traces (a,b and c) and a histogram 
(d) illustrating the changes in [Ca2+Ji observed when 
staurosporine (STSP; lOOnM) was added during the plateau 
phase of the increase in [Ca2+]i induced by bradykinin 
(10nM), thrombin (1U ml"1) and ATP (30juM) in bovine aortic 
endothelial cells, in the presence of 1.8mM extracellular 
calcium. In the histogram, results are given as the mean
of 4-13 observations and vertical bars indicate the s.e.
2 +
mean, a positive value indicates a rise in [Ca ]i while a
2+ •
negative value indicates a fall m  [Ca ji.
in the presence of 1.8mM extracellular calcium, treatment
with 4C(-PDD (lOOnM, 5min) had no effect on basal levels of
[Ca ]i or on the magnitude of the actual transient 
• 2+
elevation of [Ca ]i induced by thrombin (1U ml”1) (Figures 
4.27 and 4.36).
Addition of 4fl(—PDD (lOOnM) during the plateau phase of the
2+ . .increase in [Ca ]i induced by thrombin (1U ml" ) had no 
effect on [Ca2+]i (Figure 4.28).
From these findings, it appears that PMA exerts its action 
on calcium mobilisation via activation of protein kinase C.
4.4.7 Effects of 40(-phorbol 12. 13-didecanoate f4C(-PDD^
and 46-phorbol 12-myristate 13-acetate fPMA’I on the 
thrombin-induced manganese quench of fura-2 
Agonist-induced elevations of [Ca2+]i result from both 
mobilisation of intracellular calcium pools and from 
calcium influx across the cell membrane. The ability of 
receptor-mediated agonists to promote entry of divalent 
cations has been demonstrated in human umbilical vein 
endothelial cells by Hallam et al. (1988b). The procedure 
used to demonstrate entry of divalent cations depends on 
the ability of endothelial cells to permit entry of 
manganese (Mn2+) through the same channels which allow the 
entry of calcium. Entry of Mn2+ results in the quenching 
of intracellular fura-2. Although fura-2 responds to 
changes in calcium at most excitation wavelengths, no 
change in fluorescence is observed at an excitation
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Figure 4.36 Effects of pre-treatment with 4o<-phorbol
12,13 didecanoate (40C-PDD; lOOnM, 5min) on basal levels of
[Ca2+]i and on the magnitude of the initial transient
"~1
elevation of [Ca2+]i induced by thrombin (THR; 1U ml ) in 
bovine aortic endothelial cells, in the presence of 1.8mM 
extracellular calcium. In the histogram, basal levels of 
[Ca2+]i and the magnitude of the initial transient 
elevations of [Ca2+]i induced by thrombin in control cells 
(open columns) and in 4o(. -PDD-treated cells (hatched 
columns) are given as the mean of 6-12 observations.
wavelength of 360nm, i.e., the isobestic wavelength.
Therefore, the ability of Mn2+ to quench fura-2
fluorescence, following excitation at 360nm, provides a
measure of divalent cation entry and, by implication,
calcium entry. An attempt was made to use this technique 
to determine whether or not PMA could be shown to inhibit 
thrombin-induced divalent cation entry into BAEC.
BAEC were incubated in nominally calcium-free
HEPES(lOmM)-buffered Krebs. Following alternate excitation
at 340nM and 360nM, fura-2 fluorescence was collected at
509nm. Addition of the inactive phorbol ester, 4e(-PDD
(lOOnM), had no effect on fura-2 fluorescence (Figure
2+4.37). Addition of Mn (25juM) resulted in an increase in 
the rate of fall of the fluorescence signal produced by
excitation at both 340nm and 360nm (Figure 4.37),
reflecting Mn2+ entry, and quenching of fura-2 
fluorescence. At an excitation wavelength of 360nm, the 
quenching of fura-2 fluorescence was further accelerated by 
the addition of thrombin (1U ml 1; Figure 4.37). In 
contrast, at an excitation wavelength of 340nm, a transient
increase in fluorescence was obtained upon addition of
thrombin, followed by an increased quenching of 
fluorescence (Figure 4.37).
In a separate series of experiments, the addition of PMA 
(lOOnM) had no effect on fura-2 fluorescence (Figure 4.37). 
Addition of Mn2+ (25/iM) resulted in an increase in the rate 
of fall of the fluorescence signals induced by excitation
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Figure 4^3 7 Individual traces illustrating the effects of 
4*-phorbol 12,13 - didecanoate (4 0<-pdd; lOOnM) and
4J3-phorbol 12-myristate 13-acetate (PMA; lOOnM) on thrombin
—  1 , 2+
(1U ml )-stimulated manganese (Mn ) quenching of fura-2
in bovine aortic endothelial cells, in nominally
calcium-free buffer. The fura-2-loaded endothelial cells
were alternately excitated at 340nm and 360nm and the
resultant fluorescence emission collected at 509nm. The
2+ability of Mn to quench fura-2 fluorescence following
excitation at 360nm, the isobestic wavelength for fura-2,
2 +was used as a marker for Mn entry into the cytosol.
Addition of Mn2+ (25/uM; traces a and b) accelerated the
rate decay of the fura-2 signal at 360nm, as a result of
Mn2+ quenching of cytosolic fura-2. Following
pre-treatment with 4^-PDD (lOOnM, 5min), thrombin (1U ml )
2 +
enhanced the rate of quenching of fura-2 by Mn . In
contrast, pre-treatment with PMA (lOOnM, 5min) almost
completely abolished the ability of thrombin to enhance
2+Mn quenching of fura-2.
at 340nm and 360nm (Figure 3.47). At an excitation
wavelength of 360nm, the rate of guenching of fura-2
24-
fluorescence by Mn was almost unaffected by the addition 
of thrombin (1U ml-1; Figure 4.37). At an excitation 
wavelength of 340nm, a transient increase in fluorescence 
was obtained upon addition of thrombin (Figure 4.37).
These findings suggest that PMA, but not 4oC-PDD, inhibits 
thrombin-induced calcium influx in BAEC.
4.4.8 Effects of 4B-phorbol 12-myristate 13-acetate on
2+ . .lonomycin-mduced elevations of TCa 11 m  BAEC 
In some cell types (for example, neutrophils), phorbol
24-
esters may activate the plasma membrane Ca -ATPase (Lagast 
et al., 1984). Experimentally, this may be demonstrated by 
the ability of phorbol esters to inhibit calcium 
mobilisation induced by a calcium ionophore (McCarthy et 
al., 1989). Therefore, we wished to determine if promotion 
of calcium efflux could be observed in BAEC.
In the presence of 1.8mM extracellular calcium, PMA (lOOnM) 
has no effect on the ionomycin (lOnM) -induced sustained 
elevation of [Ca2+]i (Figure 4.38). Therefore, it is 
unlikely that phorbol esters activate the plasma membrane 
Ca2+-ATPase in BAEC.
4.5 Cyclic AMP
24- .
4.5.1 Effects of cyclic amp in the regulation of \Ca— lA
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figure 4.3« Individual trace illustrating the effects of 
48-phorbol 12-myristate 13-acetate (PMA; lOOnM) on the 
sustained elevation of [Ca2+]i induced by ionomycin (IONO; 
10nM), in the presence of 1.8mM extracellular calcium. 
This trace is representative of 2 separate experiments.
in BAEC
Cyclic AMP is known to regulate cell function via the 
modulation of calcium mobilisation in a number of cell 
types. For example, elevation of cyclic AMP has been shown 
to inhibit calcium mobilisation in vascular smooth muscle 
(Meisheri & van Breemen, 1982) and in platelets (MacIntyre 
et al. , 1985b), but to enhance calcium mobilisation in
other cell types, such as hepatocytes (Poggioli et al., 
1986), T-lymphocytes (Kelley et al., 1990) and cardiac 
myocytes (Cachelin et al., 1983). Endothelial cyclic AMP 
levels can be elevated by several agents, including 
prostacyclin (Dembinska - Kiec et al., 1980? Hopkins & 
Gorman, 1981), isoprenaline (Buonassi & Venter, 1976; 
Hopkins & Gorman, 1981) and forskolin (Adams Brotherton et 
al., 1982). Little is known about how these changes in 
cyclic AMP levels modulate either endothelial intracellular 
signalling or endothelial cell function. In this section, 
the effects of elevating cyclic AMP levels on endothelial 
calcium mobilisation were investigated.
4.5.2 Effects of forskolin and isoprenaline on thrombin- 
induced elevations of TCa2+1i in BAEC 
Forskolin is a diterpene which has been shown to directly 
activate the catalytic subunit of adenylate cyclase (Seamon 
et al., 1981). In the presence of 1.8mM extracellular 
calcium, pre-treatment with forskolin (10/zM, 5min) had no 
effect on basal levels of [Ca^+]i or on the magnitude of 
the initial transient elevation of [Ca ]i induced by 
thrombin (1U ml”1; Figure 4.39). Addition of forskolin
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Figure 4.3 9 Individual traces (a) and a histogram (b)
illustrating the effects of pre-treatment with forskolin
(FOR; 10/iM, 5min) on the magnitude of the initial transient
elevation of [Ca ]i induced by thrombin (THR; 1U ml ) in
bovine aortic endothelial cells, in the presence of 1.8mM
extracellular calcium. In the histogram, basal levels and
2+ •
the magnitude of the initial transient elevation of [Ca ]i 
in control cells (open columns) and forskolin-treated cells 
(filled columns) are given as the mean of 9-20 
observations; the vertical bars indicate the s.e. mean.
(10/iM) during the plateau phase of the increase in [Ca2+]i
induced by thrombin (lu ml-1) resulted in a biphasic
2+
elevation of [Ca ]i : the maximum increase was 66±8nM
(n=9) and this decayed to 41+6nM after 5 min (Figure 4.40).
Isoprenaline (10/iM), a S-adrenoceptor agonist, induced a
similar biphasic elevation of [Ca2 "^]i when added during the
plateau phase of the increase in [Ca2+]i induced by 
-1thrombin (1U ml ; Figure 4.40) : the maximum increase was 
61±6nM (n=6) and this decayed to 25±6nM after 5 min.
Following simulation with thrombin (1U ml”1) and the
addition of nickel (4mM), which blocks calcium influx,
forskolin (10/iM) and isoprenaline (10/iM) both induced only
2+monophasic elevations of [Ca ]i and the plateau phase was 
abolished (Figure 4.41). As nickel blocks calcium influx, 
then this demonstrates the ability of forskolin and 
isoprenaline to enhance calcium mobilisation from 
intracellular stores.
4.5.3 Effects of staurosporine on forskolin-induced
augmentations of thrombin-induced elevations of 
rca2+1i in BAEC 
It has been proposed that staurosporine may inhibit cyclic 
AMP-dependent protein kinase, in addition to inhibiting 
protein kinase C and, therefore, its actions are relatively 
non-selective (Davis et al., 1989). We therefore wished to 
determine whether staurosporine, at a concentration which 
inhibits activation of protein kinase C (Section 4.4.5), 
was able to inhibit the forskolin-induced augmentation of 
[Ca2+]i in BAEC.
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Figure 4.40 Individual traces (a,b) and a histogram (c)
illustrating the effects of the addition of forskolin
(10/iM) and isoprenaline (10/iM) during the plateau phase of
the increase in [Ca2+]i induced by thrombin (THR; 1U ml-1)
in bovine aortic endothelial cells, in the presence of
1.8mM extracellular calcium. In the histogram, the peak
elevation of [Ca ]i represents the maximum increase in 
2+[Ca ]i induced by forskolin and isoprenaline, while the 
plateau elevation of [Ca2+]i indicates the magnitude of the 
increase in [Ca2+]i, 5 min after the addition of forskolin 
and isoprenaline. Results are presented as the mean of 6-9 
observations and a vertical bar indicates the s.e. mean.
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Figure 4.41 Individual traces illustrating the effects of
forskolin (FOR; 10/iM) and isoprenaline (ISO; 10/liM) on
— 1 2 +thrombin (THR; 1U ml )-induced mobilisation of [Ca ]i in
presence of nickel (Ni2+; 4mM). The traces shown are each
typical of 2 separate experiments.
In the presence of 1.8mM extracellular calcium, the
addition of forskolin (10/zM), 700s after addition of 
* —
thrombin (1U ml ) induced a biphasic elevation of [Ca2+]i
: the maximum increase was 79+12nM (n=8). Addition of
staurosporine (lOOnM), 400s after thrombin (1U ml-1),
induced a small elevation of [Ca2+] of 8±3nM (n=8).
Addition of forskolin (lOnM), 300s after staurosporine,
increased [Ca2+]i by 53+7nM (n=8). Although apparently
slightly smaller than that obtained in cells which did not
receive staurosporine, the difference between the forskolin
responses was not significant. The small, apparent
reduction in the increase in [Ca2+]i, in the presence of
staurosporine, may be accounted for by the observation that
2+staurosporine itself induced a small elevation of [Ca ]i.
2+The total increase in [Ca ]i induced by staurosporine and 
forskolin together was 61±9nM (n=8) which was also not
significantly different from that induced by forskolin in 
cells not receiving staurosporine. Therefore, it appears 
that the concentration of staurosporine used in this study 
does not modulate cyclic AMP-mediated responses.
4.5.4 Effects of forskolin and isoprenaline on bradvkinin- 
induced elevations of rca2+li in BAE.C 
In the presence of 1.8mM extracellular calcium, 
pre-treatment with forskolin (10/iM, 5min) had no effect on 
basal [Ca2+]i or the magnitude of the initial transient 
elevation of [Ca2+]i induced by bradykinin (InM and lOnM; 
Figure 4.42). Pre-treatment with isoprenaline (10/iM, 5min) 
also had no effect on basal [Ca2+]i (Figure 4.43) or on the
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Figure 4.42 Individual traces (a) and a histogram (b) 
illustrating the effects of pre-treatment with forskolin 
(FOR; 10/iM, 5min) on the magnitude of the initial transient 
elevation of [Ca2+]i induced by bradykinin (BK; InM and 
lOnM) in bovine aortic endothelial cells, in the presence 
of 1.8mM extracellular calcium. In the histogram, basal 
levels and the magnitude of the initial transient elevation 
of [Ca2+]i in control cells (open columns) and 
forskolin—treated cells (hatched columns) are given as the 
mean of 4—23 observations; the vertical bars indicate s.e. 
mean.
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Figure 4.43 Individual trace illustrating the lack of 
effect of isoprenaline (ISO; 10/iM) on [Ca ]i in bovine 
aortic endothelial cells/ in the presence of 1.8mM 
extracellular calcium. The trace shown is representative 
of 4 separate experiments.
magnitude of the initial transient elevation of [Ca2"^ ]i 
induced by bradykinin (3nM; Figure 4.44).
Addition of forskolin (10/iM) induced a biphasic elevation 
2+ .
of [Ca ]i when added during the plateau phase of the
2+ .increase m  [Ca ]i induced by bradykinin (lOnM? Figure 
4.45) : the maximum increase was 101±8nM (n=4) and this
decayed to 35+8nM after 5 min. Isoprenaline (10/iM) induced 
a similar biphasic elevation of [Ca2+]i when added during 
the plateau phase of the increase in [Ca2+]i induced by 
bradykinin (lOnM; Figure 4,45) : the maximum increase was
130+18nM (n=4) and this decayed to 16+8nM after 5 min.
In the presence of nickel (4mM), which blocks calcium
influx, the forskolin (10/iM) - and isoprenaline
2+(10/iM)-induced elevations of [Ca ]i became monophasic, le, 
the plateau phase was abolished (Figure 4.46). These 
actions of nickel suggest that the biphasic response is 
derived from both intracellular and extracellular calcium 
pools.
4.5.5 Effects of forskolin and isoprenaline on ATP-induced 
elevations of TCa2+li in BAEC 
In the presence of 1.8mM extracellular calcium, 
pre-treatment with forskolin (10/iM, 5min) had no effect on 
basal [Ca2+]i or on the magnitude of the initial transient 
elevation of [Ca2+]i induced by ATP (30/iM? Figure 4.47).
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Figure 4.44 Histogram illustrating the effects of 
pre-treatment with isoprenaline (ISO; 10/xM, 5min) on basal 
[Ca2+]i and the magnitude of the initial transient 
elevation of [Ca2+]i induced by bradykinin (3nM) in bovine 
aortic endothelial cells, in the presence of 1.8mM 
extracellular calcium.
800 -> 1200
10004
600 4
8004
400 H 6004
4004
2004
200- J
°J ,o-J I—I 
1 minBK
10nM
FOR10p.M
160 -t Forskolin Isoprenaline!
120 A
C
+0403
o
80 A
<
40 A
Peak Plateau Peak Plateau
Figure 4.45 Individual traces (a,b) and a histogram (c)
illustrating the effects of the addition of forskolin
(10/iM) and isoprenaline (10/iM) during the plateau phase of
2 +the increase in [Ca ]i induced by bradykinin (BK; lOnM) 
in bovine aortic endothelial cells, in the presence of 
1. 8mM extracellular calcium. In the histogram, the peak 
elevation of [Ca2+]i represents the maximum increase in 
[Ca ] i induced by forskolin and isoprenaline, while the 
plateau elevation of [Ca2+]i indicates the magnitude of the 
increase in [Ca2+]i, 5 min after the addition of forskolin
and isoprenaline. Results are presented as the mean of 4 
observations and a vertical bar indicates the s.e. mean.
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Figure 4.46 Individual traces illustrating the effects of 
forskolin (FOR? 10/zM) and isoprenaline (ISO; IOjxM) on
o !
bradykinin (BK; lOnM) - induced mobilisation of [Ca ]i in
-L.
the presence of nickel (Ni ; 4mM) . The traces shown are 
each typical of 2 separate experiments.
03O
1200 
1000 H  
800 
600 
400 -  
200 -  
0 -
ATP
30(iM
t  t
FOR a t p
(10|jlM) (30|iM)
1 min
1400 -i ATP (30uM)
1200-
1000 -
800-
600-
400-
Basal200-
C FOR FOR
(IOjllM) (10)iM)
Figure 4.47 Individual traces (a) and a histogram (b) 
illustrating the effects of pre-treatment with forskolin
(IOjuM; 5min) on the magnitude of the initial transient
2 +
elevation of [Ca ]i induced by ATP (30/iM) in bovine aortic 
endothelial cells, in the presence of 1.8mM extracellular
calcium. In the histogram, basal levels and the magnitude
2+ .of the initial transient elevation of [Ca ]i m  control 
cells (open columns) and forskolin-treated cells (hatched 
columns) are given as the mean of 4-8 observations; the 
vertical bars indicate s.e. mean.
Addition of forskolin (IOjzM) during the plateau phase of
2+the increase m  [Ca ]i induced by ATP (3/iM) resulted in a 
biphasic elevation of [Ca2+]i (Figure 4.48) : the maximum
increase was 74±13nM (n=7) and this decayed to 26±7nM
within 5 min. Addition of isoprenaline (10/uM) during the 
plateau phase of the increase in [Ca2+]i induced by ATP 
(3/iM) similarly resulted in a biphasic elevation of [Ca2+]i 
(n=l? Figure 4.48).
4.5.6 Effects of forskolin on the ability of PMA to 
inhibit thrombin-induced calcium mobilisation
As elevation of cyclic AMP has previously been shown to
inhibit the actions of protein kinase C in the endothelium
(Gudgeon & Martin, 1989) and protein kinase C has been
shown to inhibit calcium mobilisation (section 4.4), we
wished to determine whether the ability of forskolin to
enhance calcium mobilisation derived from the cyclic
AMP-mediated inhibition of protein kinase C activity.
However, pre-treatment with forskolin (10/iM; 5min) did not
affect the ability of PMA (lOOnM) to induce a fall in the
2+plateau phase of the increase in [Ca ]i induced by 
thrombin (Figure 4.49) : the falls induced by PMA in
untreated cells and forskolin-treated cells were 88±8nM 
(n=5) and 114±18 (n=5), respectively.
4.6 Cyclic GMP
2+ *
4.6.1 Effects of cyclic GMP in the regulation of— LCa— |A 
in BAEC
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Figure 4.48 Individual traces illustrating the effects of 
forskolin (FOR; 10/iM) and isoprenaline (ISO; 10/iM) on 
[Ca2+]i when added during the plateau phase of the increase 
in [Ca2+]i induced by ATP (3/iM) in bovine aortic 
endothelial cells, in the presence of 1.8mM extracellular 
calcium. The forskolin experiment is typical of 7 separate 
experiments while the effects of isoprenaline were only 
examined once.
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Figure 4.49 Trace (a) illustrates the effects of
4B-phorbol 12-myristate 13-acetate (PMA; lOOnM) when added
2+ •during the plateau phase of the increase in [Ca ]i induced 
by thrombin (THR; 1U ml-1) in bovine aortic endothelial 
cells, in the presence of 1.8mM extracellular calcium. 
Trace (b) illustrates the effects of pre-treatment with 
forskolin (FOR; 10/iM, 5min before thrombin addition) on the 
PMA-induced fall in [Ca2+]i. Traces (a) and (b) are each 
representative of 5 individual experiments.
Endothelial cyclic GMP levels rise as a consequence of the 
EDRF that they produce (Martin et al., 1988) as well as to 
exogenously added atrial natriuretic factors (Leitman & 
Murad, 1986; Martin et al., 1988). It has been proposed 
that the resulting elevations of endothelial cyclic GMP 
levels inhibit EDRF production (Evans et al., 1988; Hogan 
et al., 1989). Although the thrombin-induced production of 
inositol 1, 4, 5-trisphosphate in pig aortic endothelial
cells is inhibited by the elevation of cyclic GMP (Lang & 
Lewis, 1991a), it is not clear whether endothelial calcium 
mobilisation is inhibited. Therefore, an attempt was made 
to determine whether or not elevation of cyclic GMP levels 
modulates calcium mobilisation.
4.6.2 Effects of 8 bromo cyclic GMP and sodium
nitroprusside on thrombin-induced elevations of 
rca2+li in BAEC 
In the presence of 1.8mM extracellular calcium, 
pre-treatment with 8 bromo cyclic GMP (30/xM, 5min), a 
membrane-permeant analogue of cyclic GMP, had no effect on 
basal [Ca2+]i or on the magnitude of the initial transient
n  i ( 1 ■
elevation of [Ca ]i induced by thrombin (1U ml ; Figure 
4.50).
Neither 8 bromo cyclic GMP (30/zM) nor sodium nitroprusside
(1/iM), an activator of soluble guanylate cyclase, had any
2+ •
effect on the plateau phase of the increase in [Ca ]i 
induced by thrombin (1U ml 1) (n=3 for each; Figure 4.51).
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Figure 4.50 Individual traces (a) and a histogram (b) 
illustrating the effects of pre-treatment with 8 bromo 
cyclic GMP (8BrcGMP; 30/iM, 5min) on basal levels of [Ca2+]i
and on the magnitude of the initial transient elevation of
2+ —1 [Ca ]i induced by thrombin (THR; 1U ml ) in bovine aortic
endothelial cells, in the presence of 1.8mM extracellular
calcium. In the histogram, basal levels and the magnitude
2+ .
of the thrombin-induced transient elevations of [Ca ]i are 
presented as the mean of 6-15 observations and vertical 
bars indicate s.e. mean.
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Figure 4.51 Individual traces illustrating the effects of 
8 bromo cyclic GMP (a; 8BrcGMP; 30^M) and sodium 
nitroprusside (b; SNP; 1/xM) on the plateau phase of the 
increase in [Ca2+]i induced by thrombin (THR; 1U ml in 
bovine aortic endothelial cells, in the presence of 1.8mM 
extracellular calcium. Traces (a) and (b) are each 
representative of 3 separate experiments.
4.6.3 Effects of 8 bromo cyclic GMP and sodium nitro­
prusside on bradvkinin-induced elevations of
T Ca2+1i in BAEC 
In the presence of 1.8mM extracellular calcium, 
pre-treatment with 8 bromo cyclic GMP (30/iM, 5min) had no 
effect on basal [Ca2+]i or on the magnitude of the initial 
transient elevation of [Ca2+]i induced by bradykinin (lOnM? 
Figure 4.52).
Neither 8 bromo cyclic GMP (30/iM) nor sodium nitroprusside
(1/iM) had any effect on the plateau phase of the increase 
2+ .m  [Ca ]i induced by bradykinin (lOnM) (n=5 and n=2,
respectively; Figure 4.53).
4.6.4 Effects of 8 bromo cyclic GMP and sodium nitro-
2+ . .prusside on ATP-induced elevations of fCa li in
BAEC
In the presence of 1.8mM extracellular calcium,
pre-treatment with 8 bromo cyclic GMP (30/iM, 5min) had no 
effect on basal [Ca2+]i or the magnitude of the initial 
transient elevation of [Ca2+]i induced by ATP (3/iM; Figure 
4.54) .
Neither 8 bromo cyclic GMP (30/iM) nor sodium nitroprusside 
(1/iM) had any effect when added during the plateau phase of 
the increase in [Ca2+]i induced by ATP (30/iM) (n=2 for
each; Figure 4.55).
2+
4.6.5 Effects on N -nitro-L-arcrinine on I Ca— ]i in BAEC
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Figure 4.52 Individual traces (a) and a histogram (b)
illustrating the effects of pre-treatment with 8 bromo
2+ •cyclic GMP (SBrcGMP; 30/iM, 5min) on basal levels of [Ca ]i
and on the magnitude of the initial transient elevation of
[Ca2+]i induced by bradykinin (BK; lOnM) in bovine aortic
endothelial cells, in the presence of 1.8mM extracellular
calcium. In the histogram, basal levels and the magnitude
2+ .
of the bradykinin-induced transient elevation of [Ca ]i 
are presented as the mean of 4-12 observations and vertical 
bars indicate s.e. mean.
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Figure 4.53 Individual traces illustrating the effects of 
8 bromo cyclic GMP (a; SBrcGMP; 30/iM) and sodium 
nitroprusside (b; SNP; 1/iM) on the plateau phase of the 
increase in [Ca2+]i induced by bradykinin (BK; lOnM) in 
bovine aortic endothelial cells, in the presence of 1.8mM 
extracellular calcium. Traces (a) and (b) are 
representative of 5 and 2 separate experiments, 
respectively.
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Figure 4.54 Individual traces (a) and a histogram (b)
illustrating the effects of pre-treatment with 8 bromo
cyclic GMP (SBrcGMP; 30/iM, 5min) on basal levels of [Ca2+]i
and on the magnitude of the initial transient elevation of 
2+[Ca ]i induced by ATP (3/uM) in bovine aortic endothelial 
cells, in the presence of 1.8mM extracellular calcium. In 
the histogram, basal levels and the magnitude of the 
ATP-induced transient elevation of [Ca2+]i are presented as 
the mean of 4-9 observations and vertical bars indicate the 
s.e. mean.
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Figure 4.55 Individual traces illustrating the effects of
8 bromo cyclic GMP (a; 8BrcGMP; 30/iM) and sodium
nitroprusside (b; SNP; 1/iM) on the plateau phase of the
7 +increase in [Ca ]i induced by ATP (30fj,M) m  bovine aortic 
endothelial cells, in the presence of 1.8mM extracellular 
calcium. Traces (a) and (b) are each representative of 2 
separate experiments.
Endothelial cyclic GMP content may be elevated in response 
to agonist-induced production of EDRF (Martin et al., 
1988). Therefore, it is possible that endogenously 
generated cyclic GMP had maximally affected endothelial 
calcium mobilisation such that further modulation by 
exogenously added 8 bromo cyclic GMP was not possible. To 
examine this possibility, endothelial cells were treated
rj
with N -nitro-L-arginine (L-NOARG), an inhibitor of EDRF 
production (Moore et al., 1990), and the effect on 
endothelial calcium mobilisation determined.
In the presence of 1.8mM extracellular calcium, L-NOARG
2+(50/iM) had no effect on basal levels of [Ca ]i or the
2+ .magnitude of the initial transient elevations of [Ca ]i
-linduced by thrombin (1U ml ), bradykinin (InM) or ATP 
(3/iM) (Figures 4.56, 4.57 and 4.58). Furthermore, L-NOARG 
(50/iM) had no effect when added during the plateau phase of 
the increase in [Ca2+]i induced by thrombin (1U ml 1; n=3), 
bradykinin (lOnM; n=4) or ATP (30/iM? n=l) (Figure 4.59).
4.7 Guanine Nucleotide-Dependent Regulatory Proteins 
(G proteins)
2+ •4.7.1 Role of G-proteins in the regulation of fCa li
in BAEC
Evidence that membrane receptors and intracellular 
signalling pathways may communicate through a family of 
transducing proteins, termed guanine nucleotide—dependent 
regulatory proteins or G—proteins, was first provided by
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Figure 4.56 Histogram illustrating the effects of
Gpre-treatment with N -nitro-L-arginine (L-NOARG; 50fiM,
2+ .5mm) on basal [Ca ]i and the magnitude of the peak 
elevation of [Ca2+]i induced by bradykinin (BK; InM), ATP
(3/iM) and thrombin (THR; 1U ml-1) in bovine aortic
endothelial cells, in the presence of 1.8mM extracellular
calcium. Basal levels and the magnitude of the initial
2+transient elevation of [Ca ]i are given as the mean of
6-36 observations and “vertical bars indicate s.e. mean.
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Figure 4.57 Individual traces illustrating the effects of
pre-treatment with N -nitro-L-arginine (L-NOARG; 50/iM,
2+5mm) on basal levels of [Ca ]i and on the magnitude of
2+ .the initial transient elevations of [Ca ]i induced by 
thrombin (THR; 1U ml-1) in bovine aortic endothelial cells, 
in the presence of 1.8mM extracellular calcium.
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Figure 4.58 Individual traces illustrating the effects of
Q
pre-treatment with N -nitro-L-arginine (L-NOARG; 50/iM,
2+ .5mm) on basal levels of [Ca ]i and on the magnitude of the
2+ .initial transient elevations of [Ca ]i induced by 
bradykinin (a; BK; InM) and ATP (b; 3/iM) in bovine aortic 
endothelial cells, in the presence of 1.8mM extracellular 
calcium.
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Figure 4.59 Individual traces illustrating the effects of
addition of NG-nitro-L-arginine (L-NOARG; 50/jM) during the
2+ .plateau phase of the increase m  [Ca ]i induced by
bradykinin (BK; lOnM), ATP (30/iM) and thrombin (THR; 1U 
—1ml ) in bovine aortic endothelial cells, m  the presence 
of 1.8mM extracellular calcium. The traces (a), (b) and
(c) are representative of 4, 1 and 3 experiments,
respectively.
Rodbell et al. (1971). Recent studies suggest that the 
phosphoinositidase C-mediated hydrolysis of
phosphatidylinositol 4, 5 - bisphosphate (PtdIns(4,5)P )
may be regulated via a G protein (Cockcroft & Stutchfield 
1988). Furthermore, it has been proposed that the 
ATP-induced hydrolysis of PtdIns(4,5)P2 and subsequent 
mobilisation of calcium in bovine aortic endothelial cells 
is regulated by a G-protein (Brock et al., 1988). 
G-proteins are often inhibited by bacterial toxins (for 
example, pertussis toxin), although susceptibility to the 
actions of these toxins may even vary between different 
agonists in a single cell type, as observed by Brass et al. 
(1987) in the platelet. We wished to determine whether 
calcium mobilisation induced by thrombin, bradykinin and 
ATP in bovine aortic endothelial cells is under the 
influence of pertussis toxin-sensitive G proteins.
2+ . .4.7.2 Effects of pertussis toxin on [Ca 1i m  BAEC
Monolayers of BAEC were incubated for 20hrs in complete
—1medium containing pertussis toxin (25ng ml ). Control 
monolayers were transferred to fresh medium for an 
identical period. At the end of this period, endothelial 
monolayers were loaded with fura-2 followed by measurement 
of [Ca2+]i.
Generally, treatment with pertussis toxin had no effect on
basal levels of [Ca2+]i in BAEC (Figures 4.60 and 4.62),
2+ .
although in some batches of cells, basal levels of [Ca ]i
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Figure 4.60 Individual traces (a) and a histogram (b) 
illustrating the effects of pre-treatment with pertussis
toxin (PT; 25ng ml 1, 20hr) on basal and thrombin (THR; 1U
—1 • 2+  ml ) - stimulated levels of [Ca ]i in bovine aortic
endothelial cells, in the presence of 1.8mM extracellular
calcium. In the histogram, basal levels and the magnitude
2+  •of the initial transient elevation of [Ca ]i m  control 
cells (open columns) and pertussis toxin treated cells 
(cross-hatched columns) are given as the mean of the 4 
observations and vertical bars indicate the s.e. mean.
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Figure 4.61 Individual traces (a) and a histogram (b)
illustrating the effects of pre-treatment with pertussis
toxin (PT; 25ng ml 1 , 20hr) on basal and bradykinin (BK;
2+lOnM) - stimulated levels of [Ca ]i m  bovine aortic
endothelial cells, in the presence of 1.8mM extracellular
calcium. In the histogram, basal levels and the magnitude
2+ .of the initial transient elevation of [Ca ]i m  control 
cells (open columns) and pertussis toxin-treated cells 
(cross-hatched columns) are given as the mean of 4 
observations and vertical bars indicate the s.e. mean. 
*p<0.05 indicates a significant difference between groups 
joined by a bracket.
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Figure 4.62 Individual traces (a) and a histogram (b) 
illustrating the effects of pre-treatment with pertussis
toxin (PT; 25ng ml 1, 20hr) on basal and ATP (30/iM)
2+stimulated levels of [Ca ]i in bovine aortic endothelial 
cells, in the presence of 1.8mM extracellular calcium. In
the histogram, basal levels and the magnitude of the
2+ .initial transient elevation of [Ca ]i m  control cells 
(open columns) and pertussis toxin-treated cells 
(cross-hatched columns) are given as the mean of 8 
observations and vertical bars illustrate the s.e. mean.
were found to be slightly, but significantly, reduced 
(Figure 4.61).
However, treatment with pertussis toxin had no effect on
either the initial transient or the plateau phase of the
2+ . . -1 increases in [Ca ]i induced by thrombin (1U ml ; Figure
4.60), bradykinin (lOnM; Figure 4.61) or ATP (30/zM? Figure
4.62) .
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CHAPTER 5
5.1.1 Role of the endothelial cell in the production of 
increased vascular permeability 
Majno and Palade (1961) proposed that the ability of 
histamine to induce increases in vascular permeability 
resulted from active endothelial cell contraction and the 
subsequent formation of inter-endothelial cell gaps.
Several difficulties are associated with evaluating the 
role of the endothelial cell in changes in vascular 
permeability in vivo; these include technical difficulties 
associated with changes in blood flow or hydrostatic
gradients, the interaction of endothelial cells with other 
cell types (for example, white blood cells) and in 
determining experimental drug concentrations precisely. 
Many of these problems may be overcome by the use of an in 
vitro system, in which drug concentrations can be 
accurately controlled and effects on pure homogenous
populations of endothelial cells can be evaluated. Various
in vitro systems, in which endothelial cells are grown on 
membrane filters, have been described previously (Shasby et 
al., 1982, 1985? Rotrosen & Gallin, 1986; Gudgeon & Martin, 
1989). These endothelial cells, grown on membranes, 
maintain a profile of barrier function which is similar to 
that obtained in vivo (Del-Vecchio et al., 1987). It is 
predominantly the endothelial cells of the post-capillary 
venule which are involved in the permeability changes 
occurring during inflammatory oedema (Majno et al., 1961; 
Svensjo et al, 1979). These cells are difficult to isolate
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successfully, but various endothelial cell types with a 
similar profile of responsiveness can be isolated : these 
include human umbilical vein endothelial cells or bovine 
pulmonary artery endothelial cells (Rotrosen & Gallin, 
1986; Casnocha et al., 1989; Lum et al., 1989; Minnear et 
al., 1989).
5.1.2 Agents which inhibit endothelial barrier function ;
4B-phorbol 12-myristate 13-acetate and thrombin 
Previous studies have indicated that, in the absence of 
endothelial cells, transfer of trypan blue-labelled albumin 
(4%) across Transwell polycarbonate membrane filters occurs 
rapidly (Gudgeon & Martin, 1989). The presence of cultured 
endothelial cells restricts this movement (Figure 5.1). In 
this study, BPAEC were found to restrict the movement of 
trypan blue-labelled albumin into the lower chamber. After 
90 min, resting levels (control) of transfer of albumin 
were typically found to be 2-10% (Figures 5.2-5.7) 
(complete equilibration = 100%).
Addition of 4B-phorbol 12-myristate 13-acetate (PMA, 
600nM), an activator of protein kinase C, to BPAEC 
monolayers resulted in a 2-3 fold increase in the transfer 
of albumin across the monolayers after 90 min (Figures 5.2,
5.4 and 5.6). Thrombin (1U ml"1) was also found to induce 
a 1.5—2 fold increase in albumin transfer after a 90 min 
incubation (Figures 5.3, 5.5 and 5.7).
5.2.1 Agents which enhance endothelial barrier function
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Min.
Figure 5.1 Time course showing the passage of trypan 
blue-labelled albumin through Transwell filters in the 
presence (EC) and absence (no EC) of pig aortic endothelial 
cells. HEPES (5mM)-buffered Krebs containing 4% trypan 
blue-labelled albumin was placed in the upper chamber and 
its passage into the lower chamber, which contained only 
HEPES-buffered Krebs, measured at various time points. 
Full equilibration between the upper and lower chambers was 
100%. Modified from Gudgeon and Martin (1989).
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Figure 5.2 Histogram showing the effects of forskolin 
(FOR; 30uM. 90min) on control (C) and 48-phorbol 
12-myristate 13-acetate (PMA; 600nM. 90min) - stimulated 
transfer of trypan blue-labelled albumin across monolayers 
of bovine pulmonary artery endothelial cells. Levels of 
equilibration of albumin are given as the mean of 6 
observations and vertical bars indicate the s.e. mean.
t
**p<0.01 denotes a significant difference from levels of 
albumin transfer across control monolayers. A significant 
difference (p<0.01) exists between groups joined by a 
bracket.
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Figure 5.3 Histogram demonstrating the effects of 
forskolin (FOR; 30/iM, 90min) on control (C) and thrombin 
(THR; 1U ml , 90min) - stimulated transfer of trypan 
blue-labelled albumin across monolayers of bovine pulmonary 
artery endothelial cells. Levels of equilibration of 
albumin are given as the mean of 12 observations and 
vertical bars indicate the s.e. mean. **p<0.01, ***p<0.001 
denotes a significant difference from levels of albumin 
transfer across control monolayers. A significant 
difference (p<0.001) exists between groups joined by a 
bracket.
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Figure 5.4 Histogram demonstrating the effects of 
atriopeptin II (APII; lOOnM, 90min) on basal and 46-phorbol 
12-myristate 13-acetate (PMA; 600nM, 90min) - stimulated 
transfer of trypan blue-labelled albumin across monolayers 
of bovine pulmonary artery endothelial cells. Levels of 
equilibration of albumin are given as the mean of 6 
observations and vertical bars indicate the s.e. mean. 
***p<0.001 denotes a significant difference from levels of 
albumin transfer across control monolayers.
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Figure 5.5 Histogram demonstrating the effects of 
atriopeptin II (APII; lOOnM, 90min) on control (C) and
_ i
thrombin (THR; 1U ml , 90min) - stimulated transfer of 
trypan blue-labelled albumin across monolayers of bovine 
pulmonary artery endothelial cells. Levels of 
equilibration of albumin are given as the mean of 6 
observations and vertical bars indicate the s.e. mean. 
**p<0.01 denotes a significant difference from levels of 
albumin transfer across control monolayers. A significant 
difference (p<0.01) exists between groups joined by a 
bracket.
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Figure 5.6 Histogram illustrating the effects of 8 bromo 
cyclic GMP (8BrcGMP; 30/uM, 90min) on control (C) and 
4B-phorbol 12-myristate 13-acetate (PMA; 600nM, 90min) - 
stimulated transfer of trypan blue-labelled albumin across 
monolayers of bovine pulmonary artery endothelial cells. 
Levels of equilibration of albumin are given as the mean of 
6 observations and vertical bars indicate the s.e. mean. 
*p<0.01 denotes a significant difference from levels of 
albumin transfer across control monolayers.
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Figure 5.7 Histogram illustrating the effects of 8 bromo 
cyclic GMP (8BrcGMP; 30/xM, 90min) on control (C) and
_ i
thrombin (THR; 1U ml , 90min) - stimulated transfer of 
trypan blue-labelled albumin across monolayers of bovine 
pulmonary artery endothelial cells. Levels of 
equilibration of albumin are given as the mean of 5-6 
observations and vertical bars indicate the s.e. mean. 
*p<0.05 denotes a significant difference from levels of 
albumin transfer across control monolayers. A significant 
difference (p<0.01) exists between groups joined by a 
bracket.
Recent studies have demonstrated that elevation of cyclic 
AMP content, but not cyclic GMP content, aids the 
maintenance of epithelial tight junction integrity (Duffey 
et al., 1981). This is in contrast to smooth muscle where 
elevation of cyclic AMP or cyclic GMP content produces 
relaxation (Itoh et al., 1985). In vivo, the ability of 
B-adrenoceptor agonists to inhibit increases in vascular 
permeability induced by inflammatory agents is 
well-documented; this may result from an inhibitory action 
of inter-endothelial gap formation (Marciniak et al., 1978; 
Svensjo & Grega, 1986). This inhibitory action of 
B-adrenoceptor agonists suggests a possible role of cyclic 
AMP in the maintenance of endothelial barrier function. 
Therefore, we wished to determine whether elevation of 
cyclic AMP or cyclic GMP content could enhance the barrier 
function of bovine pulmonary artery endothelial cells.
5.2.2 Efects of forskolin on the ability of BPAEC to
maintain barrier function
Incubation of BPAEC monolayers with forskolin (30juM,
90min), a direct activator of adenylate cyclase, had no
significant effect on control levels of albumin transfer
(Figures 5.2 and 5.3). Co-incubation with forskolin (30juM)
and PMA (600nM) for 90 min abolished the PMA-induced
increase in albumin transfer (Figure 5.2). Co-incubation
-1of forskolin (30/iM) with thrombin (1U ml ) for 90 m m  
abolished the thrombin-induced increase in albumin transfer 
(Figure 5.3), reducing it to slightly below control levels.
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5.2.3 Effects of atriopeptin II on the ability of BPAEC 
to maintain barrier function
The atrial natriuretic factor, atriopeptin II, stimulates 
particulate guanylate cyclase and elevates endothelial 
cyclic GMP levels (Leitman & Murad, 1986? Martin et al.,
1988). Atriopeptin II (lOOnM) had no effect on control 
levels of albumin transfer across BPAEC monolayers 
following a 90 min incubation (Figures 5.4 and 5.5). 
Co-incubation with atriopeptin II (lOOnM) and PMA (600nM) 
for 90 min had no effect on the increase in albumin 
transfer induced by PMA (Figure 5.4). In contrast, 
co-incubation with atriopeptin II (lOOnM) and thrombin (1U 
ml”1) for 90 min abolished the thrombin-induced increase in 
albumin transfer (Figure 5.5).
5.2.4 Effects of 8 bromo cyclic GMP on the ability of 
BPAEC to maintain barrier function
8 bromo cyclic GMP (8BrcGMP; 30/iM), a membrane-permeant 
analogue of cyclic GMP, had no effect on control levels of 
albumin transfer across BPAEC monolayers (Figures 5. € and 
5.7). Co-incubation with 8 bromo cyclic GMP (30/iM) and PMA 
(600nM) for 90 min had no effect on the PMA-induced 
increase in albumin transfer (Figure 5.&). In contrast, 
co-incubation of 8 bromo cyclic GMP (30/iM) with thrombin 
(1U ml-1) for 90 min abolished the increase in albumin 
transfer induced by thrombin (Figure 5."7).
5.3.1 Role of protein kinase C in the regulation of 
rca2+li in BPAEC
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It has been proposed that calcium mobilisation plays an 
important role in the induction of agonist-induced 
increases in endothelial permeability (Rotrosen & Gallin, 
1986? Lum et al., 1989). Supporting the findings of
Gudgeon and Martin (1989), this study has demonstrated that 
activation of protein kinase C, by tumour-promoting phorbol 
esters, results in an increase in endothelial permeability. 
The objects of this part of the study were to determine if 
activation of protein kinase C modulated calcium 
mobilisation in BPAEC and if changes in calcium 
mobilisation correlate with changes in endothelial barrier 
function.
5.3.2 Effects of 4B-phorbol 12-mvristate 13-acetate on
. . . 2+ . thrombin-induced mobilisation of fCa li in BPAEC
In the presence of 1.8mM extracellular calcium, 4J3-phorbol
12-myristate 13-acetate (PMA? lOOnM, 5min) had no effect on
basal levels of [Ca2+]i in BPAEC (Figure 5.8), but reduced
2+ •the magnitude of the initial transient elevation of [Ca ]i 
induced by thrombin (1U ml 1) (Figure 5.8). Addition of 
PMA (lOOnM) during the plateau phase of the increase in 
[Ca2+]i induced by thrombin (1U ml-1) resulted in a fall in 
[Ca2+]i (Figure 5.9).
2+ .5.4.1 Effects of cyclic AMP in the regulation of_LCa li
in BPAEC
In addition to this study, elevation of cyclic AMP content 
has previously been shown to inhibit increases in 
endothelial permeability induced by thrombin (Casnocha et
- 104 -
400 —| -
a
o .
3 0 0 -
200-
100-
0-1 TH'R1Um|-i
t  I
PMA THR
100nM lUml-1
1 min
THROMBIN
500 n
40 0 -
2
c
^  3 0 0 -  
4*(N
200-
BASAL
100 -
C PMA C PMA
Figure 5.8 Individual traces (a) and a histogram (b)
illustrating the effects of pre-treatment with 413-phorbol
12-myristate 13-acetate (PMA; lOOnM, 5min) on basal levels 
2+ •of [Ca ]i and on the magnitude of the initial transient
2+ —1 elevation of [Ca ]i induced by thrombin (THR; 1U ml ) m
bovine pulmonary artery endothelial cells, in the presence
of 1.8mM extracellular calcium. In the histogram, basal
2+ .and thrombin-induced elevations of [Ca ]i m  control cells 
(open columns) and PMA-treated cells (hatched columns) are 
presented as the mean of 7-16 observations and vertical 
bars indicate s.e. mean. ***p<0.001 indicates a 
significant difference between groups joined by a bracket.
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Figure 5.9 Individual traces illustrating the effects of
4B-phorbol 12-myristate 13-acetate (PMA; lOOnM) on the
2+ .plateau phase of the increase m  [Ca ]i induced by 
thrombin (THR; 1U ml*"1; a) in bovine pulmonary artery 
endothelial cells, in the presence of 1.8mM extracellular 
calcium. The trace is representative of 2 separate 
experiments.
al., 1989; Minnear et al., 1989) and histamine (Carson et 
al. , 1989). As a number of studies have proposed that
agonist-induced calcium mobilisation may be the trigger for 
increases in endothelial permeability (Rotrosen & Gallin, 
1986; Lum et al., 1989), an attempt was made to determine 
whether or not cyclic AMP exerted its inhibitory actions on 
permeability via inhibition of endothelial calcium 
mobilisation.
5.4.2 Effects of forskolin on thrombin-induced elevations 
of rca2+l in BPAEC 
In the presence of 1.8mM extracellular calcium,
pre-treatment with forskolin (30/xM, 5min) had no effect on
2+ . . . . .  basal levels of [Ca ]i or the magnitude of the initial
2 +transient elevation of [Ca ]i induced by thrombin (1U
ml”1) (Figure 5.10). Addition of forskolin (30juM) during
2+ .the plateau phase of the increase in [Ca ]i induced by
- 1 . . .  2+ .thrombin (1U ml ) resulted in a rapid increase m  [Ca ]i
of 67±7nM (n=6) (Figure 5.11), which remained relatively
stable for at least 5 min.
2+ .5.5.1 Effects of cyclic GMP on the regulation of [Ca ]jl
in BPAEC
In this study, elevation of cyclic GMP content by 
atriopeptin II and 8 bromo cyclic GMP, has been shown to 
inhibit the thrombin-induced increase in albumin transfer 
across BPAEC monolayers. An attempt was made to determine 
whether or not cyclic GMP enhanced barrier function in 
BPAEC by inhibiting thrombin-induced calcium mobilisation.
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Figure 5.10 Individual traces (a) and a histogram (b)
illustrating the effects of pre-treatment with forskolin
(FOR; 30/iM, 5min) on basal levels of [Ca2+]i and on
2 +the magnitude of the initial transient elevation of [Ca ]i
-1induced by thrombin (THR; 1U ml ) m  bovine pulmonary
artery endothelial cells, in the presence of 1.8mM
extracellular calcium. In the histogram, basal and
2+ .thrombin-induced elevations of [Ca ]i m  control cells 
(open columns) and forskolin-treated cells (hatched 
columns) are presented as the mean of 9-22 observations and 
vertical bars indicate the s.e. mean.
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Figure 5.11 Individual trace illustrating the effects of
forskolin (FOR; 30/zM) on the plateau phase of the increase
2+ • “1 m  [Ca ]i induced by thrombin (THR; 1U ml ) m  bovine
pulmonary artery endothelial cells, in the presence of
1.8mM extracellular calcium. The trace shown is
representative of 6 individual experiments.
5-5.2 Effects of atriopeptin II on thrombin-induced
elevations of rca2+li in BPAEC
In the presence of 1.8mM extracellular calcium,
pre-treatment with atriopeptin II (lOOnM, 5min) had no
effect on basal levels of [Ca2+]i or the magnitude of the
initial transient elevation of [Ca2+]i induced by thrombin
(1U ml ) (Figure 5.12). Addition of atriopeptin II
2+ .(lOOnM) during the plateau phase of the increase in [Ca ]i
_ l
induced by thrombin (1U ml ) resulted in a small elevation
of [Ca2+]i of 10-15nM (n=5; Figure 5.13).
5.5.3 Effects of 8 bromo cyclic GMP on thrombin-induced
elevations of rca2+li in BPAEC
In the presence of 1.8mM extracellular calcium,
pre-treatment with 8 bromo cyclic GMP (30/iM, 5min) had no
effect on basal levels of [Ca2+]i or on the magnitude of
the initial transient elevation of [Ca2+]i induced by
thrombin (Figure 5.14). Addition of 8 bromo cyclic GMP
2+ •(30/iM) during the plateau phase of the increase in [Ca ]i 
induced by thrombin (1U ml )^ resulted in a small elevation
of [Ca2+]i of 10-15nM (n=3? Figure 5.13).
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Figure 5.12 Individual traces (a) and a histogram (b) 
illustrating effects of pre-treatment with atriopeptin II
2+(APII; lOOnM, 5min) on basal levels of [Ca ]i and on the
2+magnitude of the initial transient elevation of [Ca ]i
—1induced by thrombin (THR; 1U ml ) m  bovine pulmonary
artery endothelial cells, in the presence of 1. 8mM
extracellular calcium. In the histogram, basal and 
thrombin-induced elevations of [Ca2+]i in control cells 
(open columns) and atriopeptin II-treated cells (hatched 
columns) are presented as the mean of 6-13 observations and
vertical bars indicate the s.e. mean.
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Figure 5.13 Individual traces illustrating the effects of
atriopeptin II (a; APII; lOOnM) and 8 bromo cyclic GMP (b;
8BrcGMP; 30/iM) on the plateau phase of the increase in
2+ . —1 [Ca ]i induced by thrombin (THR; 1U ml ) m  bovine
pulmonary artery endothelial cells, in the presence of
1.8mM extracellular calcium. Traces (a) and (b) are
representative of 5 and 3 individual experiments,
respectively.
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Figure 5,14 Individual traces (a) and histogram (b) 
illustrating the effects of pre-treatment with 8 bromo 
cyclic GMP (8BrcGMP; 30/xM, 5min) on basal levels of [Ca2+]i
and the magnitude of the initial transient elevation of
2+ . . -1[Ca ]i induced by thrombin (THR; 1U ml ) m  bovine
pulmonary artery endothelial cells, in the presence of
1.8mM extracellular calcium. In the histogram, basal and
2 +thrombin-induced elevations of [Ca ]i in control cells 
(open columns) and SBrcGMP-treated cells (hatched columns) 
are presented as the mean of 4-10 observations and vertical
bars indicate the s.e. mean.
DISCUSSION
CHAPTER 6
Regulation of f Ca2+li in bovine aortic endothelial cells
6.1 Role of intracellular and extracellular pools
In this study, cytosolic calcium ([Ca2+]i) was measured
using the fluorescent dye, fura-2 (Grynkiewicz et al.,
1985). The advantages of this dye over its predecessor,
quin 2, have been discussed in the methods and include
greater resolution at higher calcium concentrations, higher
2+ .quantum yields and the ability to measure [Ca ]i m  ratio 
mode. With fura-2, ratio mode involves the measurement of 
fluorescence, following excitation at two separate 
wavelengths (340nm and 380nm). The ratio of these two 
fluorescence values provides a measure of the intracellular 
calcium concentration which is independent of changes in 
dye concentrations or instrumental variability. Fura-2 
studies were undertaken using endothelial cells grown on 
glass coverslips. This is preferable to using cell 
suspensions as endothelial cells are anchorage-dependent 
and, therefore, this system more closely resembles the in 
situ situation. Furthermore, cells in suspension are more 
susceptible to shear stress, which may lead to partial 
activation of the cells.
In this study, basal levels of [Ca2+]i in bovine aortic 
endothelial cells were approximately lOOnM. This is 
similar to the values of 60-100nM found by other workers in 
endothelial cell studies (Ltickhoff & Biisse, 1986; Hallam &
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Pearson, 1986; Hallam et al., 1988a, b). Bradykinin,
thrombin and adenosine trisphosphate (ATP) each promote the
release of prostacyclin and endothelium-derived relaxing
factor (EDRF) from the endothelium (Weksler et al., 1978;
Pearson et al., 1983; Furchgott, 1984; White & Martin,
1989), and were each found to induce biphasic elevations of 
2+ •[Ca ]i m  bovine aortic endothelial cells, in this study. 
These biphasic elevations of [Ca2+]i consisted of a large, 
transient component, which peaked within 30 seconds,
followed by a lower, well-sustained component (the plateau
2+phase of the increase in [Ca ]i), which was maintained for 
at least 10-15 minutes. These findings are in agreement 
with previous observations made in endothelial cells 
isolated from bovine aorta (Colden-Stanfield et al., 1987; 
Luckhoff et al., 1988b), human umbilical vein (Rotrosen & 
Gallin, 1986; Hallam et al., 1988a, b; Brock & Capasso, 
1988), bovine pulmonary artery (Ryan et al., 1988) and pig 
aorta (Hallam & Pearson, 1986).
Endothelial shape change and release of EDRF are induced by 
platelet activating factor (PAF) and histamine, 
respectively (Grigorian & Ryan, 1987; Furchgott, 1984) and 
these agents have been previously shown to induce calcium 
mobilisation in endothelial cells derived from bovine 
pulmonary artery and bovine aorta, respectively (Brock & 
Gimbrone, 1986; Marsden et al., 1990). In this study, 
these agents had no effect on [Ca2 ]i in bovine aortic 
endothelial cells. However, in the earlier studies, the 
elevations of [Ca2+]i induced by these agents were small in
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magnitude and their reproducibility may depend upon 
variable factors, such as the method of cell isolation or 
culture conditions. Venous endothelium appears to be much 
more responsive to the actions of histamine, which induces 
large elevations of [Ca2+]i in human umbilical vein 
endothelial cells (Rotrosen & Gallin, 1986; Hallam et al., 
1988b).
Although lipopolysaccharide has been previously shown to 
induce release of EDRF (Salvemini et al., 1989), we found 
no evidence that this agent induces calcium mobilisation in 
bovine aortic endothelial cells and, therefore, it may 
promote EDRF release by a calcium-independent mechanism.
Ionomycin, a calcium ionophore (Liu & Hermann, 1978) was
used, during experimental calibrations to promote the entry
of both calcium and manganese. Ionomycin was found to
elevate [Ca2+]i in bovine aortic endothelial cells and, at
2+higher concentrations of this agent, [Ca ]i was elevated 
to a level which saturated the intracellular fura-2. 
Although the major mechanism of action of ionomycin is 
likely to involve the transfer of calcium ions across the
plasma membrane into the cytosol, the ability of this agent
2+to induce a transient elevation of [Ca ]i, in the absence 
of extracellular calcium, suggests that it acts on an 
intracellular calcium pool, which is presumably the 
endoplasmic reticulum.
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The plateau phase of the increases in [Ca2+]i induced by 
bradykinin and ATP, the two agonists which induced the 
greatest elevations of [Ca2+]i, were abolished when bovine 
aortic endothelial cells were placed in nominally 
calcium-free solution containing 0.5mM EGTA, giving an 
extracellular calcium concentration of approximately lOnM. 
This observation has been made in all endothelial cell 
types studied (Hallam & Pearson, 1986; Rotrosen & Gallin, 
1986; Colden-Stanfield et al., 1987). In the presence of
1.8mM extracellular calcium, the plateau phase of the
2+ .increase in [Ca ]i was rapidly terminated by the action of
nickel, which has previously been shown to block calcium
influx into endothelial cells (Hallam et al., 1988b).
Furthermore, this component was not obtained if cells had
been pre-treated with nickel. These observations suggest
2+ .that the plateau phase of the increase m  [Ca ]i is 
dependent on calcium influx, and this is supported by 
studies on 45Ca2+ flux (Bussolino et al., 1985), patch 
clamp analysis (Johns et al., 1987) and the finding that 
agonists can promote entry of another divalent cation, 
manganese, into endothelial cells (Hallam et al., 1988b).
2+  •In this study, the plateau phase of the increase in [Ca ]i 
was found to be sustained and substantially elevated above 
basal [Ca2+]i for several minutes. However, single
endothelial cells rarely display this behaviour and,
2+usually, repetitive oscillations in [Ca ]i are observed
(Jacob et al., 1988). Recent studies undertaken by Carter
2 +  •et al. (1990) suggest that elevations of [Ca ]i obtained
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in single endothelial cells may be heterogenous in nature, 
and this is illustrated in Figure 6.1. Hence, when 
recording from a monolayer population of cells, the fura-2 
fluorescent signal is likely to represent the mean signal 
from thousands of cells and, therefore, if these cells are 
oscillating out of synchrony, then the resulting calcium
signal will be displayed as a sustained elevation of
2+ . 2+[Ca ]i. In this study, oscillations in [Ca ]i were
observed in a small number of experiments with bradykinin
(2 from approximately 400 experiments), but only at the
lowest concentration examined (0.3nM). Oscillations in 
2+ .[Ca ]i, following fluorescence measurement from a large 
population of endothelial cells, have also been observed in 
other studies (Sage et al., 1989? Neylon & Irvine, 1990). 
These calcium oscillations are likely to result from the 
cycling of calcium between the cytosol and intracellular 
calcium stores and are sustained by calcium influx.
Calcium influx is unlikely to occur via voltage-operated 
channels (VOCs) in endothelial cells, as electro- 
physiological studies have failed to show the existence of 
these channels (Colden-Stanfield et al., 1987). In this 
study, depolarisation with potassum chloride had no effect 
on basal [Ca2+]i in bovine aortic endothelial cells, as 
observed previously in pig aortic and bovine pulmonary 
artery endothelial cells (Hallam & Pearson, 1986; 
Colden-Stanfield et al., 1987). The inability of organic 
calcium channel antagonists to block agonist-induced 
elevations of [Ca2+]i (Colden-Stanfield et al., 1987), or
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Figure 6.1 Individual traces representing possible changes 
2+in [Ca ]i observed when recording from single endothelial
2+ .cells. (a) a single, transient elevation of [Ca ]i, (b)
2+  •an initial transient elevation of [Ca ]i, followed by a
sustained plateau phase and (c) an initial transient
2+ . • . 2+ elevation of [Ca ]i, followed by oscillations m  [Ca ]i.
Reproduced from Carter et al. (1990).
endothelium-dependent relaxations (Jayakody et al. , 1987), 
suggests that calcium influx occurs via receptor-operated 
channels (ROCs). However, these ROCs display some membrane 
potential sensitivity as, in this study, it was found that 
the addition of potassium chloride during the plateau phase 
of the increase in [Ca2+]i induced by bradykinin, thrombin 
and ATP resulted in a fall in [Ca2+]i, which was not well 
sustained. Similar inhibition of calcium influx by 
membrane depolarisation has been observed in other studies 
(Laskey et al., 1990? Ltickhoff & Busse, 1990) and may 
result from a reduction in the electrochemical gradient for 
calcium entry through the ROCs. In this study, potassium 
chloride appeared to attenuate calcium influx to a lesser 
extent than that observed in similar studies (Laskey et al, 
1990? Ltickhoff & Busse, 1990). This apparent anomaly may 
result from the lower concentrations of potassium chloride 
used in this study or, alternatively, the use of a slightly 
hypertonic solution, in contrast to the isotonic solutions 
utilised in other studies. The ability of membrane 
depolarisation to reduce calcium influx in the endothelium 
and, subsequently, to reduce EDRF release (Luckhoff & 
Busse, 1990), may explain, in part, why 
acetylcholine-induced EDRF release relaxes
noradrenaline-induced contractions of vascular smooth 
muscle much more easily than potassium chloride- induced 
contractions (Collins et al., 1988).
2+  •The magnitude of the initial transient elevation of [Ca ]i 
induced by bradykinin was also attenuated in the presence
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of high concentrations of potassium chloride, although this 
concentration had no effect on basal [Ca2+]i. The 
mechanism of this inhibition is not clear, although it may 
result from the hyperosmolarity of the final potassium- 
containing solution.
The mechanism of calcium entry through ROCs, in the 
endothelium, is not known. It may involve direct coupling 
between the receptor and the ion channel, as observed in 
response to ATP in vascular smooth muscle (Benham & Tsien,
1987). Alternatively, inositol (1,3,4,5) tetrakisphosphate 
has been implicated in the control of calcium influx 
(Irvine & Moor, 1986, 1987), although this
tetrakisphosphate isomer may not be present in the 
endothelium (Pollock et al., 1988). Another possibility is 
that calcium entry may occur via a mechanism related to the 
capacitative model (Putney, 1990), which proposes that 
calcium influx is promoted subsequent to the inositol 
(1,4,5) trisphosphate-mediated discharge of calcium stores. 
This model is operational in parotid acinar cells, where 
the inositol phosphate-mediated discharge of intracellular 
calcium stores results in calcium influx (Bird et al., 
1991).
As we wished to determined whether the intracellular 
calcium stores were in equilibrium with extracellular 
calcium, we examined the effects of removal of 
extracellular calcium. When bovine aortic endothelial 
cells were bathed in nominally calcium-free solution
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containing 0.5mM EGTA, the magnitude of the initial 
transient elevations of [Ca2+]i was significantly reduced 
with all concentrations of bradykinin and ATP examined. 
This observation is consistent with the findings of 
Colden-Stanfield et al. (1987) and Schilling et al. (1988). 
In a separate study, in which no statistical validation was 
presented (Liickhoff et al., 1988b), no reduction in the 
magnitude of this component was observed in bovine aortic 
endothelial cells. Under similar, nominally calcium-free 
conditions, variable reductions in the magnitude of the 
initial transient component have been observed in human 
umbilical vein endothelial cells, in response to histamine 
or thrombin (Hallam et al., 1988a; Brock & Capasso, 1988). 
In contrast, in a study in which the older, less sensitive
probe, quin 2, was used, no reduction in the magnitude of
2 +the transient elevation of [Ca ]i was reported (Rotrosen &
Gallin, 1986). In pig aortic endothelial cells, the
initial transient component induced by ATP was also reduced
slightly in calcium-free conditions (Hallam & Pearson,
1986). In conclusion, in statistically-validated studies
using the more sensitive probe, fura-2, there appears to be
general agreement that the magnitude of the initial
2+  •agonist-induced transient elevations of [Ca ]i is reduced 
in calcium-free solutions.
From our studies performed in nominally calcium-free 
solutions, it was not possible to determine whether the 
reduced magnitude of the bradykinin-induced initial 
transient elevation of [Ca2+]i was due to an impaired
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ability to release intracellular calcium, to the depletion 
of an intracellular store or to loss of a transient calcium 
influx component. Discharge of calcium from intracellular 
stores is mediated via Ins(l,4,5)P3 (Streb et al., 1983). 
However, as bradykinin-induced hydrolysis of 
phosphoinositides is not inhibited when bovine aortic 
endothelial cells are placed in calcium-free solution, it 
is unlikely that reduced production of Ins(l,4,5)P3
accounts for the reduction in the initial transient
2+elevation of [Ca ]i. Loss of a calcium influx component
is also unlikely since, in the presence of extracellular
calcium, treatment with nickel, which blocks calcium influx
(Hallam et al., 1988b), had no effect on the magnitude on
the bradykinin-induced initial transient elevation of 
2+ .[Ca ]i m  this study, although the plateau phase was
abolished. Lanthanum, another inhibitor of calcium influx,
was similarly found to have little effect on the magnitude
2+ .of the initial transient elevation of [Ca ]i, despite 
blocking the sustained component (Colden-Stanfield et al.,
1987). Our novel observation that the ability of caffeine 
to release intracellular calcium (Weber & Herz, 1968), and 
elevate [Ca2+]i in bovine aortic endothelial cells, was 
blocked in the absence of extracellular calcium, is 
consistent with the depletion of intracellular stores. The 
small magnitude of the elevation of [Ca2+]i induced, 
however, shows that the caffeine-sensitive calcium pool is 
a small proportion of the total intracellular content. It 
is likely, therefore, that the bradykinin-induced initial 
transient elevation of [Ca2+]i is completely dependent upon
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release of calcium from an intracellular store and that 
exposure to calcium-free solution leads to depletion of 
this store.
The reduction of this initial, transient elevation of 
2+ .[Ca ]i, m  the absence of extracellular calcium, has been 
correlated with functional changes. For example, release 
of prostacyclin from the endothelium is closely correlated 
to the initial transient elevation of [Ca2+]i (Hallam et 
al., 1988a). In pig aortic endothelial cells, removal of 
extracellular calcium has little effect on prostacyclin 
release or on the magnitude of the initial transient 
elevation of [Ca2+]i (Hallam & Pearson, 1986; White & 
Martin, 1989). In contrast, in this study, in bovine 
aortic endothelial cells, removal of extracellular calcium 
significantly reduced the initial calcium transient and 
this corresponds to a significant reduction in prostacyclin 
production in these cells, as observed by Ltickhoff and 
co-workers (1988a).
In a separate series of experiments, an attempt was made to
examine the kinetics of the loss of the bradykinin-induced
initial transient elevation of [Ca2+]i in calcium-free
solution, in bovine aortic endothelial cells. In these
experiments, cells were bathed in ImM extracellular calcium
and then exposed to EGTA, a calcium chelator, for different
times and at different concentrations. Exposure to EGTA
(2mM), for only 1 minute, reduced the magnitude of the
2+  •bradykinin-induced transient elevation of [Ca ]i by 50%.
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However, increasing the concentration of EGTA or the time 
of exposure resulted in no further reduction in the 
bradykinin-induced initial transient elevation of [Ca2+]i. 
These novel observations suggest the possible existence of 
two intracellular calcium pools; one which is rapidly 
depleted in the presence of low extracellular calcium and a 
second which is resistant even to prolonged removal of 
extracellular calcium. The rapidly deleted store appears 
to contribute more to responses obtained to sub-maximal
stimuli since, in the presence of EGTA, the initial
2+ .transient elevation of [Ca ]i is blocked to a greater 
degree when the concentration of bradykinin is low. Freay 
et al. (1989) have described the existence of two, 
non-mitochondrial calcium pools in bovine pulmonary artery 
endothelial cells, only one of which is sensitive to the 
actions of Ins(l,4,5)P3. Ghosh et al. (1989) have 
described the presence of separate guanosine 
triphosphate(GTP)-sensitive and Ins (1,4,5)P3-sensitive 
pools in smooth muscle cells. Whether these calcium pools 
are equivalent to the two pools suggested by our findings 
remains to be determined, although Freay et al. (1989) 
found that GTP does not modulate Ins(1,4,5)P3-induced 
release of calcium from intracellular stores in bovine 
pulmonary artery endothelial cells.
When bovine aortic endothelial cells were bathed in 
nominally calcium-free solution in the presence of 0.5mM 
EGTA, the bradykinin - or ATP-induced transient elevation 
of [Ca2+]i was complete within 90s. In a separate series
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of experiments, we found that subsequent re-addition of 
extracellular calcium, to achieve a free concentration of 
around 1.8mM, resulted in a biphasic elevation of [Ca2+]i, 
consisting of a large, initial transient component, 
followed by a smaller, well-maintained component. It is 
likely that the latter is analogous to the plateau phase of 
the increase in [Ca2+]i induced by bradykinin or ATP in the 
presence of extracellular calcium. However, the nature of 
the initial transient component is less clear, and may 
derive from calcium influx, further intracellular release 
of calcium or calcium-induced calcium release. It was 
certainly agonist-dependent as it was not observed when 
calcium was re-added to cells bathed in calcium-free medium 
in the absence of agonist. Procaine has been shown to 
abolish calcium-induced calcium release (Weber & Herz, 
1968? Saida & van Breemen, 1984). However, in this study, 
the initial component appeared largely unchanged in the
presence of procaine, although it was impossible to
2 +precisely measure [Ca ]i, m  the presence of procaine as 
this compound absorbs fura-2 fluorescence. It is, 
therefore, unlikely that this transient component results 
from calcium-induced calcium release and it may simply 
derive from the reloading and subsequent discharge of 
intracellular calcium stores, upon re-addition of 
extracellular calcium.
The ability of TMB-8, a putative inhibitor of intracellular 
calcium release (Malagodi & Chiou, 1974), to inhibit
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agonist-induced prostacyclin production by endothelial 
cells (Seid et al., 1983; Ltickhoff et al., 1988a? White & 
Martin, 1989) appears consistent with the belief that 
prostacyclin production is more dependent upon release of 
calcium from intracellular stores than from calcium influx 
(Seid et al., 1983? Ltickhoff et al., 1988a, Hallam et al., 
1988a? White & Martin, 1989). However, in this study, 
treatment with TMB-8 for up to 15 minutes had no effect on 
the bradykinin-induced transient elevation of [Ca2+]i. 
This indicates that TMB-8 is unable to inhibit release of 
calcium from intracellular stores in bovine aortic 
endothelial cells. This finding is supported by the 
observation that TMB-8 does not inhibit Ins(1,4,5)P3~ 
induced calcium release in NG108-15 neuroblastoma x glioma
cells (Campbell et al., 1990). TMB-8 did induce a small
2+elevation of [Ca ]i by itself, which was dependent upon 
the presence of extracellular calcium, although the precise 
mechanism by which it produces this is not known. It, 
therefore, appears unlikely that TMB-8 inhibits the release 
of prostacyclin by inhibiting release of calcium from 
intracellular stores.
6.2 Protein kinase C and [Ca2+]i
As described in section 6.1., agonist-induced elevations of 
[Ca2+]i in bovine aortic endothelial cells consist of an 
initial transient component, which is largely due to the 
release of calcium from intracellular stores, and a plateau
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phase, which is due to calcium influx from the 
extracellular space. The tumour-promoting phorbol esters 
are known activators of protein kinase C (Castagna et al., 
1982) and are useful tools for activating this pathway in 
cells. Pre-treatment of bovine aortic endothelial cells 
with phorbol myristate acetate (PMA), an active phorbol 
ester, had no effect on basal [Ca2+]i but reduced the 
magnitude of the initial transient elevation of [Ca2+]i 
induced by maximal concentrations of thrombin and low
concentrations of bradykinin or ATP. In contrast, the
2 +initial transient elevation of [Ca ]i induced by maximal 
and near maximal concentrations of bradykinin and ATP were 
unaffected. These findings in bovine aortic endothelial 
cells contrast with the ability of phorbol esters to 
inhibit intracellular release of calcium induced by maximal 
concentrations of thrombin, bradykinin and ATP in human 
umbilical vein endothelial cells (Brock & Capasso, 1988; 
Carter et al., 1989), and may highlight a species or site 
difference. The ability of PMA to inhibit this initial 
transient elevation of [Ca2+]i is likely to result from its 
ability to activate protein kinase C. In support of this, 
staurosporine, an inhibitor of protein kinase C (Tamaoki et 
al., 1986? Davis et al., 1989), blocked the inhibitory 
effect of PMA and, secondly, the inactive phorbol ester, 4o( 
-phorbol, 12,13-didecanoate, lacked the activity of PMA.
2+  •The initial transient elevation of [Ca ]i in many cell 
types is likely to result from Ins(l,4,5)P3-induced release 
of calcium from intracellular stores (Berridge, 1984). A
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number of agents, including bradykinin, ATP, histamine and
thrombin, induce hydrolysis of phosphoinositides and
production of Ins(l,4,5)P3 in the endothelial cell (Derian
& Moskowitz, 1986; Pirotton et al. , 1987; Pollock et al.,
1988; Brock & Capasso, 1988). Therefore, the ability of
phorbol esters to inhibit production of Ins(l,4,5)P3 in the
endothelium (Brock & Capasso, 1988; Halldorsson et al.,
1988; Carter et al., 1989) is likely to account for the
ability of these compounds to inhibit the initial transient
2+elevation of [Ca ]i. However, in bovine aortic 
endothelial cells, PMA differentially inhibits release of 
intracellular calcium induced by different agonists and 
this may reflect the extent to which receptor-mediated 
Ins(l,4,5)P3 production may be inhibited by protein kinase 
C. Alternatively, at low agonist concentrations, where 
Ins(l,4,5)P3 generation may be limited, other mechanisms 
may contribute to the inhibitory actions of PMA: for
example, activation of protein kinase C may promote 
breakdown of Ins(l,4,5)P3 (Connolly et al., 1986) or raise 
the threshold for activation of the Ins(l,4,5)P3 receptor 
(Willems et al., 1989).
As described in section 6.1, the sustained plateau phase of
2+  •the agonist-induced increase in [Ca ]i results from
calcium influx through receptor-operated channels. In this
2+  •study, it was found that PMA induces a fall in [Ca ]i when
2+ .added during the plateau phase of the increase in [Ca ]i 
induced by maximal or submaximal concentrations of 
thrombin, bradykinin or ATP. Hence, this component of the
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biphasic response is much more sensitive to the actions of 
PMA than is the large, transient intracellular release 
component. This is in contrast to platelets and 
submandibular duct cells, where the calcium influx 
component is less sensitive to the actions of the phorbol 
esters (Valone et al., 1987? He et al., 1988). EDRF 
production is calcium-dependent (Singer & Peach, 1982; Long 
& Stone, 1985) and this is likely to result from the 
calcium-dependence of nitric oxide synthase (Meyer et al, 
1989). As nitrovasodilator-induced relaxations are 
unaffected by phorbol esters (Lewis & Henderson, 1987), it 
is likely that the phorbol esters inhibit the production of 
EDRF. Furthermore, the inability of phorbol esters to 
inhibit endothelium-dependent relaxations induced by the 
calcium ionophore, A23187 (Weinheimer et al., 1986? Lewis & 
Henderson, 1987; Cherry & Gillis, 1988), suggests that 
these agents inhibit EDRF release via the inhibition of 
receptor-mediated calcium mobilisation. However, receptor- 
mediated agonists are not all equally sensitive to 
inhibition: for example, Smith and Lang (1990) have shown 
that substance P - and ATP-induced production of EDRF in 
pig aortic endothelial cells, is inhibited by phorbol 
esters, although that induced by bradykinin is unaffected. 
This differential sensitivity may be explained by our 
finding that bradykinin-induced calcium mobilisation, both 
from intracellular and extracellular pools, in bovine 
aortic endothelial cells, is less sensitive to the 
inhibitory actions of phorbol esters than that induced by 
other agonists.
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The mechanism of action of PMA was examined in greater 
detail to determine whether or not it inhibits the 
agonist-induced plateau phase of [Ca2+]i via promotion of 
calcium efflux, inhibition of calcium influx, or a 
combination of these mechanisms. By making use of the 
ability of manganese to quench fura-2 fluorescence, Hallam 
et al. (1988b) showed that agonists promote entry of
manganese into the endothelial cell by a similar route to 
that used by calcium. Hence, agonist-induced quenching of 
cytosolic fura-2 by manganese can be taken as indirect 
evidence of the opening of channels that permit calcium 
influx. In this study, thrombin increased the rate at 
which manganese quenched fura-2 fluorescence, indicating 
that it promoted calcium influx. PMA inhibited the ability 
of thrombin to increase the quenching of fura-2 
fluorescence, but the inactive phorbol ester, 4 -PDD did 
not. It is likely, therefore, that activation of protein 
kinase C by PMA inhibits calcium influx.
In a number of cell types, for example, neutrophils, 
platelets and smooth muscle, phorbol esters activate the 
plasma membrane Ca2+ATPase and, therefore, promote calcium 
efflux (Lagast et al., 1984; Rink & Sage, 1987; Rashatwar 
et al, 1987). Experimentally, this action may be 
demonstrated by the ability of phorbol esters to reduce the 
sustained elevation of [Ca2+]i induced by a low 
concentration of a calcium ionophore, as observed in
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neutrophils (MacCarthy et al., 1989). However, in this
study, PMA had no effect on ionomycin-induced elevations of
2+ .[Ca ]i, suggesting that activation of protein kinase C 
does not stimulate calcium extrusion in bovine aortic 
endothelial cells.
Although the site of action of protein kinase C is not 
known, possible substrates for phosphorylation include 
membrane receptors, G-proteins, phosphoinositidase C or 
calcium channels. A number of studies have demonstrated 
the inhibition of G-protein function by protein kinase C 
(Smith et al., 1987; Orellana et al., 1987; Bochakov et 
al., 1990), which may subsequently result in reduced 
phosphoinositide hydrolysis and calcium mobilisation. It 
is possible that membrane receptors may be coupled to 
calcium mobilisation via distinct G proteins which differ 
in their susceptibility to inhibition by protein kinase C. 
This is supported by the work of Voyno - Yasenetskaya et 
al. (1989b) who showed the ability of pertussis toxin to 
inhibit histamine, but not bradykinin-induced 
phosphoinositide hydrolysis in human umbilical vein 
endothelial cells. This may provide an explanation for the 
differential agonist sensitivity to the phorbol esters, 
demonstrated in this study and that of Smith and Lang 
(1990). The finding of this study that agonist-induced 
influx of calcium is more sensitive to inhibition by PMA, 
than is intracellular calcium release, requires an 
explanation. Theoretically, an alteration in the
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proportion of functional G proteins, relative to the 
appropriate cellular effector, could underly this 
differential sensitivity. According to this scheme, it is 
possible that intracellular release of calcium (via 
Ins(l,4,5)P3) and calcium influx are both functionally 
coupled to G proteins. In untreated cells, functional G 
proteins may be greatly in excess of both the cellular 
effector systems (Figure 6.2a). However, in PMA-treated 
cells, the number of functional G proteins may fall to 
levels which are insufficient to promote maximal activation 
of the calcium influx channel, but which still allow 
maximal activation of phosphoinositidase C and, therefore, 
maximal release of calcium from intracellular stores via 
Ins(l,4,5)P3 (Figure 6.2b). However, if the number of 
functional G-proteins falls further, then intracellular 
release of calcium will also be inhibited (Figure 6.2c).
The finding of this study that staurosporine increases the
2+  •magnitude of the plateau phase of the increase in [Ca ]i 
induced by bradykinin and thrombin is likely to reflect the 
ability of these agonists to activate protein kinase C 
themselves, and so inhibit their own actions by a negative 
feedback loop. These agonists may activate protein kinase 
C by inducing hydrolysis of phosphoinositides (Derian & 
Moskowitz, 1986; Halldorsson et al., 1988) or, 
alternatively, phosphatidylcholine (Michaelis & Martin,
1988). In contrast, staurosporine induced a fall in the 
plateau phase of the increase in [Ca2+]i induced by ATP. 
This may result from the ability of staurosporine to
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Figure 6.2 A diagrammatic representation of a theory which 
may explain the changes in cellular messenger systems which 
underlie the greater sensitivity of intracellular release of 
calcium, in comparison to calcium influx, to the actions of 
the phorbol esters. In this scheme, the processes 
controlling intracellular release of calcium and calcium 
influx are coupled to membrane-bound receptors via 
regulatory G-proteins (Figure 6.2a). The numbers 
associated with each receptor, G-protein and effector 
indicate the proportional number of each protein associated 
with the system. Treatment with phorbol esters may lower 
the number of functional G proteins in the cell (Figure 
6.2b). However, this number of G-proteins may still be 
sufficient to fully activate phosphoinositidase C (PIC) 
and, therefore, maximally activate intracellular release of 
calcium. However, following further treatment with phorbol 
esters, if the number of functional G-proteins falls below 
the level required for maximal activation of PIC, then 
intracellular release of calcium will also be inhibited 
(Figure 6.2c). (As discussed with Dr. Andrew Newby.)
interact with the ATP binding sites in proteins (Davis et 
al., 1989).
6.3 Cyclic AMP and [Ca2+]i
Little is known about how cyclic AMP regulates endothelial
cell function. Initial studies suggested that elevation of 
cyclic AMP content may inhibit prostacyclin production by a 
negative feedback mechanism (Adams Brotherton & Hoak, 
1982), although this was later ascribed to the cyclic
AMP-independent, inhibitory actions of the
phosphodiesterase inhibitor, 3-isobutyl-l-methyl xanthine 
which was used in these studies (Adams Brotherton et al., 
1982).
Elevation of cyclic AMP via prostacyclin, forskolin,
calcitonin gene-related peptide and B-adrenoceptor agonists
has been also proposed to augment EDRF release (Shimokawa
et al., 1988; Gray & Marshall, 1991a, b; Gardiner et al.,
1991). This may be explained by our observation that both
forskolin and isoprenaline induced biphasic elevations of 
2+ .[Ca ]i when added during the plateau phase of the increase
2+ . . .m  [Ca ]i induced by thrombin, bradykinin and ATP, as EDRF
production is calcium-dependent (Singer & Peach, 1982; Long 
& Stone, 1985). In contrast to the afore-mentioned 
studies, Kuhn et al. (1991) found that elevation of cyclic 
AMP had no effect on bradykinin-induced EDRF release from 
bovine aortic endothelial cells. However, in this latter
study, the concentration of bradykinin used was maximal
and, therefore, it is possible that the elevation of
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2+ .[Ca ]i was sufficient to fully activate nitric oxide
synthase, making an additional augmentation of enzyme
2+ .activity, m  response to a further increase in [Ca ]i, 
impossible.
The biphasic elevations of [Ca2+]i observed, in this study,
when forskolin or isoprenaline was added during the
2+ .agonist-induced elevation of [Ca ]i, in bovine aortic 
endothelial cells, consisted of a large, initial transient 
elevation, followed by a lower, more sustained plateau
phase. As neither forskolin nor isoprenaline had any
2+ . . . .  . effect on basal [Ca ]i, it is likely that their actions
result only from the facilitation of agonist-induced
calcium mobilisation. This is in contrast to the ability
of cyclic AMP to independently release an intracellular
calcium pool in T lymphocytes (Kelley et al., 1990). The
initial transient and sustained phases of the increases in
2+[Ca ]i, induced by forskolin and isoprenaline, are likely 
to result from intracellular release and calcium influx, 
respectively, since only the latter was abolished in the 
presence of the calcium entry blocker, nickel. 
Furthermore, although it has been proposed that 
staurosporine is a non-selective protein kinase inhibitor 
(Davis et al., 1989), it had no effect on the forskolin- 
induced augmentation of calcium mobilisation, suggesting 
that its actions in the endothelium are selective for 
protein kinase C.
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The above explanation of the cyclic AMP-mediated
enhancement of calcium mobilisation may be somewhat
simplistic. As discussed in section 6.1, the
2+ .agonist-induced plateau phase of the increase in [Ca ]i,
obtained from a population of cells, may simply result from
the mean signal from thousands of cells which are
undergoing calcium oscillations out of synchrony. These
calcium oscillations are likely to derive from the constant
cycling of calcium between intracellular pools and the
cytosol and are ultimately dependent upon calcium influx.
2+ •It xs likely that the biphasic augmentation of [Ca ]i 
observed in this study, in populations of bovine aortic 
endothelial cells, may simply represent an enhanced 
frequency and amplitude of calcium oscillations at the 
single cell level, as observed in hepatocytes (Schofl et
al., 1991). The mechanism by which cyclic AMP enhances
2+  •agonist-induced oscillations in [Ca ]i may involve 
facilitation of calcium influx, as observed in hepatocytes 
(Poggioli et al., 1986) and cardiac myocytes (Cachelin et 
al., 1983). An additional mechanism of action of cyclic 
AMP may involve modification of the properties of the 
intracellular calcium stores: for example, enhanced uptake 
into intracellular stores may occur, as observed in cardiac 
myocytes (Fabiato & Fabiato, 1975; Mueller & van Breemen, 
1979) or in smooth muscle (Itoh et al., 1985). If this 
occurs in the endothelial cell, it will result in the 
increased cycling of calcium between Ins(1,4,5)P3-sensitive 
calcium stores and the cytosol.
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In addition to a direct effect on cellular calcium
mobilisation, it is possible that cyclic AMP could augment 
2+ .[Ca ]i indirectly. As discussed in section 6.2, 
activation of protein kinase C inhibits agonist-induced 
elevations of [Ca2+]i in bovine aortic endothelial cells. 
Furthermore, elevation of cyclic AMP content inhibits the 
actions of protein kinase C in the endothelium (Gudgeon & 
Martin, 1989), at least when considering endothelial 
barrier function. It is unlikely that forskolin enhances 
calcium mobilisation in bovine aortic endothelial cells by 
inhibiting ongoing protein kinase C activity, as it was 
found that forskolin was unable to attenuate the ability of
PMA to inhibit the plateau phase of the agonist-induced
2+ .increase m  [Ca ]i.
This study has demonstrated that elevating the
intracellular cyclic AMP content, during the
2+ .agonist-induced plateau phase of the increase m  [Ca ]i,
clearly augments intracellular relase of calcium. However,
this study using bovine aortic endothelial cells, and that
of Carson et al. (1989), using human umbilical vein
endothelial cells, both show that agents which elevate
endothelial cyclic AMP content have no effect on the
magnitude of the agonist-induced initial transient
2+ .elevation of [Ca ]i. The observation of an augmentation 
of intracellular release during the plateau phase, but not 
the initial transient elevation is likely to result from 
the small magnitude of this augmentation, relative to the
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magnitude of the discharge that normally underlies the 
initial transient.
It is possible that the enhanced release of calcium from
intracellular stores, observed during the plateau phase,
may be dependent upon enhanced uptake into the agonist-
sensitive pool, either from other intracellular stores or
from the extracellular pool. Therefore, if cells are
treated, before agonist addition, with a cyclic
AMP-elevating agent, the intracellular calcium stores may
often be at full capacity and, therefore, unable to be
further loaded. Subseguently, upon agonist addition, the
2+ .magnitude of the initial transient elevation of [Ca ]i 
would be identical in both control cells and treated cells. 
In one study, elevating cyclic AMP content has been
reported to augment slightly the ATP-induced initial
24-transient elevation of [Ca ]i in bovine aortic endothelial 
cells (Brock et al., 1988). All of these findings, 
demonstrating either no effect on calcium mobilisation, or 
augmentation of calcium mobilisation, clearly conflict with 
those of Luckhoff et al. (1990), who reported that 
elevating cyclic AMP content inhibits endothelial calcium 
mobilisation in bovine aortic endothelial cells. Why the 
results of this latter group differ so markedly from all 
other published reports is not clear.
6.4 Cyclic GMP and [Ca2+]i
Endothelial cyclic GMP content is elevated by atrial 
natriuretic factors (Leitman & Murad, 1986; Martin et al.,
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1988) or by agents which induce production of EDRF (Martin 
et al., 1988). It has been proposed that EDRF regulates 
its own production via a negative feedback mechanism 
involving cyclic GMP (Evans et al., 1988? Hogan et al.,
1989). Cyclic GMP has also been reported to modulate other 
endothelial functions; for example, it inhibits production 
of thromboxane A2 and endothelin (Worthington & Fuller, 
1983? Saijonmaa et al., 1990; Boulanger & Liischer, 1990). 
Cyclic GMP has been demonstrated to inhibit production of 
Ins(l,4,5)P3 in pig aortic endothelial cells (Lang & Lewis, 
1991a), but in this study, in bovine aortic endothelial
cells, elevation of cyclic GMP content did not modulate
2+ 2+ . either basal [Ca ]i or elevations of [Ca ]i induced by
thrombin, bradykinin or ATP. Ryan et al. (1988) similarly
demonstrated the inability of 8 bromo cyclic GMP to inhibit
2+ .the histamine-induced transient elevation of [Ca ]i m  
human umbilical vein endothelial cells.
As bradykinin, thrombin and ATP are known to increase EDRF
production (Furchgott, 1984) and, therefore, increase
endothelial cyclic GMP content, the possibility was
considered that endogenously generated cyclic GMP was
capable of inhibiting endothelial calcium mobilisation,
making further inhibition impossible. N -nitro-L-arginine,
an inhibitor of EDRF production (Moore et al, 1990) did
2+ .not, however, modulate basal [Ca ]i, the magnitude of the
2+ .initial transient elevation of [Ca ]i or the plateau phase 
of the increase in [Ca2+]i induced by bradykinin, ATP or 
thrombin. Therefore, this data suggests that cyclic GMP
- 131 -
does not modulate calcium mobilisation in bovine aortic 
endothelial cells. In support of these findings, a 
functional study has demonstrated a lack of effect of 
cyclic GMP on EDRF release from bovine aortic endothelial 
cells (Kuhn et al., 1991).
It is not entirely clear why cyclic GMP has no effect on 
calcium mobilisation or EDRF production in bovine aortic 
endothelial cells, but inhibits EDRF release from rabbit 
aorta and Ins(l,4,5)P3 production in pig aortic endothelial 
cells. The results of one functional study in pig aortic 
endothelial cells are consistent with the inability of 
cyclic GMP to modulate bradykinin-induced calcium 
mobilisation in pig aortic endothelial cells (White & 
Martin, 1989). Here, bradykinin-induced production of 
prostacyclin was unaffected following elevation of cyclic 
GMP content (Martin et al., 1989), despite production being 
dependent upon the release of calcium from intracellular 
stores (Seid et al., 1983; Ltickhoff et al., 1988a; Hallam 
et al., 1988a; White & Martin, 1989). In contrast to these 
findings in pig aortic endothelial cells, nitric oxide 
inhibited prostacyclin production in bovine aortic 
endothelial cells by an apparently cyclic GMP-dependent 
mechanism (Doni et al., 1988) and this clearly contrasts 
with our findings demonstrating the inability of cyclic GMP 
to inhibit calcium mobilisation in bovine aortic 
endothelial cells.
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These observed differences may result from differing 
agonist sensitivities to the actions of cyclic GMP: for
example, in rabbit aorta, EDRF release induced by either 
substance P or muscarinic agonists is inhibited by 
elevating cyclic GMP content, but that induced by ATP is 
not. Species differences may play their part, as 
thrombin-induced Ins(l,4,5)P3 production is inhibited by 
elevation of cyclic GMP content in pig aortic endothelial 
cells (Lang & Lewis, 1991a), while thrombin-induced calcium 
mobilisation in bovine aortic endothelial cells (this 
study) and thrombin-induced prostacyclin production in 
human umbilical vein endothelial cells (Adams Brotherton, 
1986) were unaffected by elevation of cyclic GMP content.
High phosphodiesterase activity and extrusion of cyclic GMP 
may contribute to the lack of elevation of cyclic GMP 
content, in response to nitrovasodilators, observed in 
bovine aortic endothelial cells (Schini et al., 1989) and
these findings may explain the lack of effect of sodium
2+ .nitroprusside on [Ca ]i m  this study. However, 8 bromo 
cyclic GMP, a stable analogue of cyclic GMP, presumably 
exerts a direct effect on cellular function and its actions 
are unlikely to be attenuated in the presence of high 
phosphodiesterase activity.
The lack of effect of cyclic GMP on calcium mobilisation in 
bovine aortic endothelial cells may result from a lack of 
cyclic GMP-dependent protein kinase in these cells, as 
proposed by Mackie et al. (1986). However, these workers
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used endothelial cells which had been passaged as many as 
five times, in contrast to this study, where the cells were 
passaged only on a single occasion. It is possible that 
endothelial cell characteristics may be altered following 
repeated passaging and the changes may include loss of 
certain protein kinase activities. Atrial natriuretic 
factor (ANF) inhibits thrombin-induced increases in 
vascular permeability (Baron et al., 1989) and inhibits 
Na-K-Cl transport (O'Donnell, 1989) in bovine aortic 
endothelial cells. This latter function is likely to be 
cyclic GMP-mediated, as the effects of ANF were mimicked by 
8 bromo cyclic GMP (O'Donnell, 1989). Furthermore, 
oxyhaemoglobin has been shown to enhance endothelin release 
from bovine aortic endothelial cells, suggesting that EDRF, 
presumably through cyclic GMP, inhibits endothelin 
production in these cells (Cocks et al., 1991). Although 
these findings provide indirect evidence for the presence 
of cyclic GMP-dependent protein kinase in endothelial 
cells, it is possible that cyclic GMP-mediated responses 
occur independently of protein kinase activation, as 
observed in the retina (Haynes et al., 1986).
2+ .6.5 G proteins and [Ca ]i
Bradykinin, thrombin and ATP have each been shown to induce 
hydrolysis of phosphoinositides in the endothelium (Derian 
& Moskowitz, 1986; Jaffe et al. , 1987; Pirroton et al.,
1987; Lang & Lewis, 1991a). Receptor-mediated activation 
of the inositol lipid pathway is thought to be regulated 
via G proteins, some of which are inhibited by pertussis
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toxin (Cockcroft & Stutchfield, 1988). As it is apparent
that agonist-induced phosphoinositide hydrolysis in the
endothelium is guanine nucleotide-dependent (Brock et al.,
1988; Voyno-Yasenetskaya et al., 1989a), suggesting G
protein involvement, sensitivity of agonist-induced calcium
mobilisation to pertussis toxin was examined in bovine
aortic endothelial cells. Following bradykinin treatment
with pertussis toxin, thrombin and ATP-induced elevations 
24-of [Ca ]i were completely unaffected. It is unlikely that 
the lack of effect of pertussis toxin results from the 
inability of the toxin to enter the endothelial cell as 
pertussis toxin substrates have been found in endothelial 
cells isolated from pig aorta, bovine pulmonary artery and 
human umbilical vein (Lambert et al., 1986; 
Voyno-Yasenetskaya et al., 1989a, b) . Our findings are 
consistent with the lack of effect of pertussis toxin 
treatment on bradykinin-induced hydrolysis of 
phosphoinositides in endothelial cells derived from the 
above three sites (Lambert et al., 1986; Voyno-Yasenetskaya 
et al., 1989a, b) , but contrast with the pertussis toxin 
sensitivity of the thrombin-activated G protein in human 
umbilical vein endothelial cells (Lampugnani et al., 1990). 
A small inhibition of ATP-induced inositol phosphate 
production in bovine aortic endothelial cells has been 
previously found, following treatment with pertussis toxin 
(Pirotton et al., 1987). It is not entirely clear why no 
inhibition of the ATP-induced initial transient elevation 
of [Ca2+]i was observed in this study, although our 
findings agree with those of Flavahan et al. (1989) who
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found that ADP-induced endothelium-dependent relaxation was 
unaffected by pertussis toxin treatment.
Not all endothelial agonists are insensitive to the actions 
of pertussis toxin: for example, EDRF production induced by 
0(2-adrenoceptor agonists, serotonin, histamine and 
endothelin-3 is regulated by a pertussis toxin-sensitive 
pathway, as is endothelin-3-induced calcium mobilisation 
and histamine-induced phosphoinositide hydrolysis
(Weinheimer & Osswald, 1989; Flavahan et al., 1989; 
Voyno-Yasenetskaya et al., 1989b; Emori et al., 1991). 
Clearly, control of endothelial function may be regulated 
by at least two different groups of G proteins, only one of 
which is sensitive to the actions of pertussis toxin.
6.6 Conclusion
In conclusion, this study has demonstrated the ability of a
2+ .number of agonists to induce biphasic elevations of [Ca ]i
in bovine aortic endothelial cells. These elevations of
7+  2+  ■[Ca ]i are dependent upon mobilisation of [Ca ]i from
both intracellular and extracellular calcium pools. The
intracellular pool consists of two pools - one which is
rapidly depleted upon removal of extracellular calcium and
a second which is highly resistant to such depletion.
Whether these pools are related to the distinct
intracellular calcium pools, described by other workers,
requires further investigation.
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Activation of protein kinase C, by the tumour-promoting 
phorbol esters, inhibits agonist-induced calcium 
mobilisation in bovine aortic endothelial cells and this is 
likely to be the mechanism by which these compounds inhibit 
EDRF release. However, differential agonist sensitivity to 
the actions of the phorbol esters was observed and this may 
account for the ability of these compounds to inhibit 
agonist-induced EDRF release to varying degrees. As 
agonists which induce calcium mobilisation were also found
to activate protein kinase C, as shown by the ability of
2+staurosporine to increase [Ca ]i when added during the
2+ .plateau phase of the increase in [Ca ]i, this enzyme may 
activate a negative feedback pathway which is involved in 
the regulation of endothelial calcium mobilisation.
Elevation of endothelial cyclic AMP content was found to 
augment agonist-induced calcium mobilisation, from both 
intracellular and extracellular calcium pools. Hence, this 
cyclic nucleotide may enhance the activation of 
calcium-dependent processes, such as EDRF production, in 
the endothelium. In contrast to cyclic AMP, elevation of 
cyclic GMP levels had no effect on endothelial calcium 
mobilisation. This suggests that cyclic GMP does not 
modulate endothelial cell function via the inhibition of 
calcium mobilisation, at least in bovine aortic endothelial 
cells.
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CHAPTER 7
Role of calcium mobilisation in the regulation of 
endothelial barr-i m- function 
7.1 Agents which inhibit endothelial barrier function
The production of vascular leakage and oedema by 
inflammatory mediators, such as histamine and bradykinin 
results mainly from the actions of these agents on the 
endothelium of the post-capillary venule (Majno et al., 
1961; Svensjo et al, 1979) and may result from the ability 
of these agents to induce endothelial cell contraction and 
inter-endothelial gap formation (Majno et al., 1969). 
Alternatively, vascular leakage may be promoted by the 
actions of activated neutrophils, which release oxygen- 
derived free radicals and proteolytic enzymes, resulting in 
endothelial cell injury (Wedmore & Williams, 1981). 
However, evaluation of endothelial barrier function in vivo 
is complicated by the actions of other cell types, 
difficulties in precisely evaluating drug concentrations 
and haemodynamic effects. Ideally, endothelial cells of 
the post-capillary venule would be the cells of choice if 
establishing an in vitro endothelial cell culture model to 
investigate the changes in barrier function occurring 
during inflammation. However, isolation of endothelial 
cells from such small vessels is technically difficult and 
is also likely to result in a small cell yield. Therefore, 
in a number of studies, including this one, endothelial 
cells from umbilical vein and pulmonary artery have been
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used to assess barrier function as these cells respond, in 
a similar manner to post capillary venule endothelium, to a 
number of inflammatory mediators (Killackey et al., 1986; 
Rotrosen & Gallin, 1986; Carson et al., 1989; Casnocha et 
al., 1989; Lum et al., 1989; Minnear et al., 1989).
In this study, endothelial barrier function was evaluated 
by assessing the passage of an inert, high molecular weight 
marker (trypan blue-labelled albumin) across monolayers of 
bovine pulmonary artery endothelial cells, cultured on 
polycarbonate membrane filters. The basal trans- 
endothelial transfer of this marker was enhanced by 
thrombin, a receptor-mediated agonist, and by 4B-phorbol 
12-myristate 13-acetate (PMA), an activator of protein 
kinase C. The observation that thrombin increases vascular 
leakage and, therefore, macromolecular transfer across the 
endothelial barrier is supported by a number of in vitro 
and in vivo studies (Killackey et al., 1986; Minnear et 
al., 1986, 1989; Lum et al., 1989; Casnocha et al. , 1989;
Lynch et al., 1990).
Phorbol ester-induced increases in macromolecular transport 
across pig aortic and bovine pulmonary artery endothelial 
monolayers have also been previously described in in vitro 
studies (Gudgeon & Martin, 1989; Lynch et al., 1990). The 
effects of phorbol esters in the endothelium are thought to 
be mediated via the activation of protein kinase C, as they 
are mimicked by synthetic diacylglycerols (Lynch et al.,
1990), not mimicked by inactive phorbol esters (Gudgeon &
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Martin, 1989; Lynch et al., 1990) and inhibited by H7, an 
inhibitor of protein kinase C (Lynch et al., 1990). In 
contrast to these studies, PMA inhibited albumin transfer 
across monolayers of human umbilical vein endothelial cells 
(Yamada et al., 1990). The reason for this anomaly is not 
clear, although protein kinase C may exist as different 
isoenzymes (Kikkawa et al., 1989) which may mediate 
different cellular functions in different cells. 
Therefore, if the distribution of these isoforms differs 
between endothelial cell types, then the responsiveness of 
these cells to phorbol esters may vary.
Inflammatory mediators may increase macromolecular 
transport as a result of endothelial contraction and 
inter-endothelial gap formation in vivo (Majno & Palade, 
1961; Majno et al., 1969). In this study, thrombin and PMA 
enhanced albumin transport across endothelial monolayers 
and this is likely to correspond with the ability of those 
agents to induce a number of morphological changes,
including shape change, cell contraction and 
inter-endothelial gap formation (Laposata et al., 1983; 
Antonov et al., 1986; Garcia et al., 1986; Killackey et
al., 1986; Minnear et al., 1989). These morphological
changes may result from the redistribution of endothelial 
contractile proteins - actin, myosin, vinculin and 
-actinin have all been found in the endothelium (Becker & 
Nachmann, 1973; Herman et al., 1982; Drenckhahn, 1983; 
Franke et al., 1988). It is likely that actin distribution 
is a key factor involved in the regulation of the
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endothelial barrier as the maintenance of inter-endothelial 
cell junctions is associated with filamentous actin fibres 
(F-actin) in sub-plasmalemmal regions and at inter- 
endothelial junctions (Simionescu et al., 1978? Drenckhahn, 
1983; Morel et al., 1990; Schnittler et al., 1990). 
Inhibition of endothelial barrier function may be 
associated with alterations in the cellular actin pool? for 
example, via depolymerisation of F-actin to G-actin (the 
monomeric form of actin), and the centralisation of actin 
stress fibres (Rotrosen & Gallin, 1986? Garcia et al, 1986? 
Minnear et al., 1989). As in vascular smooth muscle, 
development of endothelial cell contraction may occur via 
an interaction between actin and myosin (Schnittler et al, 
1990). Although these morphological changes may account 
for enhanced endothelial albumin transfer, other mechanisms 
cannot be eliminated. Albumin transport may occur via 
vesicular transcytosis (Ghitescu et al., 1986? Milici et 
al., 1987), although whether or not this pathway is 
activated by thrombin or PMA remains to be determined.
Inhibition of endothelial barrier function by intracellular
messengers may involve elevation of cytosolic calcium 
2+([Ca ]i) and activation of protein kinase C. An important 
role for calcium has been suggested by a number of studies. 
For example, increased vascular permeability, endothelial 
shape change and endothelial cell contraction are inhibited 
by removal of extracellular calcium, blockade of calcium 
influx or buffering of cytosolic calcium (Liddell et al., 
1981; Shasby et al., 1985; Lum et al., 1989? Morel et al.,
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1989), but promoted by calcium ionophores (Shasby et al., 
1985; Olesen, 1987; Gudgeon & Martin, 1989; Morel et al. , 
1990; Yamada et al., 1990). However, ionophore-induced 
vascular leakage may simply result from endothelial cell 
detachment from the substratum (Gudgeon & Martin, 1989). 
Release of calcium from intracellular stores may contribute 
to vascular leakage, as discharge of these stores via 
"caged” Ins(l,4,5)P3, induces endothelial cell contraction 
by a mechanism that is sensitive to calmodulin antagonists 
(Morel et al., 1990).
Calcium may exert its actions by modulating cytoskeletal 
proteins. A possible site of action is promotion of 
actin-myosin induced contractions (Schnittler et al., 1990) 
via activation of myosin light-chain kinase (Wysolmerski et 
al., 1990). Calcium-dependent activation of gelsolin (Yin 
& Stossel, 1979) may promote dissolution of F-actin fibres 
which, as described above, play a key role in the 
maintenance of cell shape.
Inhibition of endothelial barrier function can, however,
2+ .occur in the absence of changes in [Ca ]i. For example,
in this study, the phorbol ester, PMA, enhanced albumin
transfer, but did not elevate [Ca2+]i. Furthermore, PMA
was found to inhibit thrombin-induced elevations of 
7+[Ca ]i, demonstrating that protein kinase C acts as a 
bidirectional regulator of cell function. This enhanced 
albumin transfer may result from endothelial cell 
contraction and changes in cell shape which have been
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previously reported, following exposure to phorbol esters 
(Antonov et al., 1986; Gudgeon & Martin, 1989). 
Inflammatory mediators, such as thrombin, histamine and 
bradykinin may activate protein kinase C via hydrolysis of 
phosphatidylinositol and its related metabolites (Derian & 
Moskowitz, 1986; Brock & Capasso, 1988; Pollock et al., 
1988) or, alternatively, via hydrolysis of 
phosphatidylcholine (Martin & Michaelis, 1988). In support 
of this proposal, recent studies have demonstrated that 
thrombin induces activation of protein kinase C in bovine 
pulmonary artery endothelial cells (Lynch et al., 1990).
Protein kinase C enhances the calcium-sensitivity of smooth 
muscle contractile filaments to calcium (Itoh et al., 
1988), although it is not known whether a similar mechanism 
regulates endothelial cell contraction. Thrombin-induced 
alterations in endothelial F-actin distribution and content 
(Garcia et al., 1986; Minnear et al., 1989) may result from 
increased protein kinase C activation, as phorbol esters 
have been found to induce actin reorganisation in a kidney 
epithelial cell line (Schliva et al., 1984). A number of 
other cytoskeletal proteins (talin, vinculin, vimentin) may 
also serve as substrates for protein kinase C (Werth et 
al., 1983; Litchfield & Ball, 1986; Huang et al., 1988b), 
although it remains to be determined whether protein kinase 
C acts via these proteins in the endothelium.
7.2 Agents which enhance endothelial barrier function
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7.2.1 Cyclic AMP
6-adrenoceptor agonists are known to inhibit vascular 
leakage induced by inflammatory mediators, at the 
post-capillary venule (Svensjo et al., 1977, 1979?
Marciniak et al., 1978), by a mechanism which may involve 
direct enhancement of the endothelial barrier. As these 
agonists elevate endothelial cyclic AMP levels (Hopkins St 
Gorman, 1981), this cyclic nucleotide was thought to be 
involved in the regulation of barrier function.
Forskolin, which directly activates the catalytic subunit 
of adenylate cyclase (Seamon et al., 1981) is known to 
elevate cyclic AMP content in the endothelium (Adams 
Brotherton et al., 1982). In this study, it was 
demonstrated that forskolin enhances the barrier function 
of bovine pulmonary artery endothelial cells. Elevation of 
cyclic AMP tended to reduce basal albumin transfer across 
BPAEC monolayers, although not significantly. Elevated 
levels of cyclic AMP have been reported to reduce control 
vascular permeability in a number of studies (Casnocha et 
al., 1989? Carson et al., 1989), although not in others 
(Kempski et al., 1987). These differences may simply 
reflect variable degrees of "leakiness” in different 
endothelial experimental systems. In this study, elevation 
of cyclic AMP by forskolin abolished thrombin - and 
PMA-induced albumin transfer across monolayers of bovine 
pulmonary artery endothelial cells. These observations are 
supported by other studies demonstrating the ability of 
cyclic AMP to inhibit macromolecular transport induced by
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histamine, thrombin and PMA across endothelial monolayers 
(Killackey et al., 1986? Gudgeon & Martin, 1989? Carson et 
al., 1989? Casnocha et al, 1989). Elevation of cyclic AMP 
also attenuates thrombin-induced vascular leakage in the 
lung circulation during in vivo and ex vivo studies 
(Minnear et al., 1986? Horgan et al., 1987). In contrast 
to the above studies, Antonov and co-workers (1986) 
observed increased shape change in human umbilical vein 
endothelial cells exposed to forskolin, although why the 
findings of this study differ from all other studies is not 
clear.
Cyclic AMP-mediated enhancement of endothelial barrier 
function is associated with a number of morphological 
changes including a reduced number of endothelial gaps, and 
the relaxation and flattening of cells (Laposata et al., 
1983? Bensch et al. , 1983? Minnear et al., 1989? Oliver,
1990). The precise mechanism by which cyclic AMP acts is 
not entirely clear, although a direct cytoskeletal effect 
may be involved as its actions are associated with 
increased F-actin, especially in plasmalammal regions 
(Minnear et al., 1989? Stelzner et al., 1989). Inhibition 
of shape change by cyclic AMP may result from 
phosphorylation, and reduced calcium sensitivity, of myosin 
light chain kinase (Conti & Adelstein, 1981? Hathaway et 
al., 1985), an enzyme implicated in the induction of
endothelial cell contraction (Wysolmerski et al., 1990).
2+ .As described earlier, a change in [Ca ]i may be an 
important trigger for alterations in endothelial barrier
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function. Therefore, an examination of whether or not 
elevation of cyclic AMP content inhibited thrombin-induced 
calcium mobilisation in BPAEC was undertaken. However, in
this study, forskolin-induced elevation of cyclic AMP
24-content had no effect on basal [Ca ]i or on the magnitude
of the thrombin-induced initial transient elevation of 
24- .[Ca ]i but enhanced the plateau phase of the increase of 
24- .[Ca ]i, as described in section 6.3. Hence, m  contrast 
to smooth muscle and platelets, where elevated cyclic AMP 
content inhibits calcium mobilisation (Meisheri & van 
Breemen, 1982; MacIntyre et al., 1985b), in the endothelial 
cell cyclic AMP enhances calcium mobilisation. The ability 
of cyclic AMP to augment calcium mobilisation has been 
previously observed in hepatocytes and cardiac cells 
(Cachelin et al., 1983; Poggioli et al., 1986). The 
findings of ths study, coupled with the inability of cyclic 
AMP to inhibit histamine-induced intracellular release of 
calcium in human umbilical vein endothelial cells (Carson 
et al., 1989), suggests that calcium may not be the primary 
intracellular stimulus for increased vascular permeability. 
As both thrombin and PMA increase protein kinase C activity 
in the endothelium (Lynch et al., 1990), activation of this 
pathway may be the major pathway for inhibition of 
endothelial barrier function. Cyclic AMP may exert its 
actions by antagonising the actions of protein kinase C, 
although the precise cellular location of its actions is 
not clear.
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7.2.2 Cyclic GMP
EDRF, which mediates vascular relaxation via increased 
cyclic GMP levels (Rapoport & Murad, 1983), has been 
proposed to enhance vascular leakage (Chander et al., 1988? 
Hughes et al., 1990). This local hormone effect of EDRF 
probably results from its vasodilatory actions increasing 
hydrostatic pressure in vascular beds. However, it is 
possible that cyclic GMP could modulate endothelial barrier 
function directly as has been observed with cyclic AMP, as 
both cyclic nucleotides relax vascular smooth muscle (Itoh 
et al., 1985).
In this study, endothelial cyclic GMP content was elevated 
by atriopeptin II, a known stimulant of particulate 
guanylate cyclase (Leitman & Murad, 1986; Martin et al., 
1988) and, additionally, by the membrane-permeant analogue 
of cyclic GMP, 8 bromo cyclic GMP. However, elevation of 
cyclic GMP content had no effect on basal or PMA-induced 
transfer of albumin across monolayers of bovine pulmonary 
artery endothelial cells, but abolished that induced by 
thrombin. In support of these observations, elevation of 
cyclic GMP content inhibited thrombin-induced transfer of 
albumin across bovine aortic endothelial cell monolayers 
(Baron et al., 1989), but had no effect on PMA-induced 
albumin transfer in pig aortic endothelial cells (Gudgeon & 
Martin, 1989). The inhibitory action of cyclic GMP is 
associated with the maintenance of inter-endothelial cell 
junctions and peripheral cytoskeletal filaments (Baron et 
al., 1989), and with endothelial cell relaxation (Morel et
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al., 1989). Atriopeptin II is unlikely to mediate its 
actions on barrier function via a cyclic GMP-independent 
mechanism, as its effects were mimicked by 8 bromo cyclic 
GMP.
The cyclic GMP-mediated relaxation of vascular smooth
muscle and inhibition of platelet aggregation, results from
inhibition of phosphatidylinositol - (4,5)-bisphosphate
(PtdIns(4,5)P2) breakdown and the subsequent calcium
mobilisation in these systems (Takai et al., 1981;
MacIntyre et al., 1985b; Collins et al., 1986).
Furthermore, elevation of smooth muscle cyclic GMP content
may result in inhibition of calcium influx through both
VOCs and ROCs (Collins et al., 1988). As described in
section 7.1, calcium may be an important stimulus for
increased vascular permeability. However, cyclic GMP does
not inhibit thrombin-induced albumin transfer in bovine
pulmonary artery endothelial cells by inhibiting calcium
mobilisation, as neither atriopeptin II not 8 bromo cyclic
2+ .GMP inhibited thrombin-induced increases m  [Ca ]i. Both
2+ .agents induced a small, delayed elevation of [Ca ]i when
2+ .added during the plateau phase of the increase of [Ca ]i 
induced by thrombin. The mechanism involved is not known, 
although it may involve the inhibition of thrombin- induced 
protein kinase C activity. Hence, although we cannot 
eliminate the possibility that cyclic GMP enhances barrier 
function by inhibition of a calcium-dependent process, it 
is more likely to exert its actions by inhibiting the 
protein kinase C signalling pathway. As cyclic GMP had no
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effect on PMA-induced albumin transfer, it is clear that it 
does not inhibit the actions of protein kinase C and, 
therefore, may block the pathway linking the thrombin
finding that endothelin-l-mediated activation of protein 
kinase C is inhibited in rat aorta by elevation of cyclic 
GMP (Lang & Lewis, 1991b). The inability of cyclic GMP to 
inhibit calcium mobilisation in bovine pulmonary artery 
endothelial cells suggests that diacylglycerol (DAG) 
production from PtdIns(4,5)P2 is unaffected, although Lang 
and Lewis (1991a) have observed a cyclic GMP-mediated 
inhibition of Ptdlns(4,5)P2 hydrolysis in pig aortic 
endothelial cells. Phosphatidylcholine may be an 
alternative source of DAG in the endothelial cell (Martin & 
Michaelis, 1988) and its hydrolysis may be important for 
sustained production of this metabolite. Therefore, if 
hydrolysis of Ptdlns(4,5)P2 and phosphatidylcholine are 
regulated by different coupling mechanisms (for example, 
different G proteins), then selective inhibition could 
occur.
7.3 Conclusions
In conclusion, this study has demonstrated that the barrier 
function of bovine pulmonary artery endothelial cells is 
inhibited by thrombin, a receptor-mediated agonist,and PMA,
a direct activator of protein kinase C. PMA enhances
2+  •albumin transfer m  the absence of changes m  [Ca ]i, 
suggesting that protein kinase C may have a key role in the 
regulation of endothelial barrier function and that
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receptor to protein kinase C.
2+elevation of [Ca ]i is not a pre-requisite for enhanced
macromolecular transfer. Thrombin-induced macromolecular
2+transfer may result from its ability to elevate [Ca ji,
activate protein kinase C, or from a synergistic
interaction between the two messenger systems, as observed
in platelets (Rink et al., 1983). As protein kinase C
activation also inhibits agonist-induced elevations of 
2+ .[Ca ]i, this enzyme acts as a bidirectional regulator of 
endothelial cell function - promoting cell activation while 
simultaneously inhibiting initiation of subsequent cellular 
responses.
Elevation of cyclic AMP content inhibits thrombin - and 
PMA-induced albumin transfer. However, elevation of cyclic 
AMP content does not inhibit the thrombin-induced increase 
in vascular permeability via the inhibition of calcium 
mobilisation and, in fact, enhances calcium mobilisation. 
Therefore, cyclic AMP may enhance barrier function by 
inhibiting the intracellular actions of protein kinase C, 
although we cannot eliminate the possibility that cyclic 
AMP inhibits the actions of thrombin by inhibiting a 
calcium-dependent pathway.
Elevation of cyclic GMP content does not inhibit 
PMA-induced albumin transfer and, therefore, does not 
inhibit the endothelial actions of protein kinase C. 
Elevation of cyclic GMP content does inhibit 
thrombin-induced albumin transfer, but not via inhibition 
of calcium mobilisation and, therefore, cyclic GMP may
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inhibit either a step subsequent to calcium mobilisation 
or, alternatively, the coupling of the thrombin receptor to 
activation of protein kinase C.
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